Cyanocyclobutyl compounds for the inhibition of Cbl-b and their uses

Cbl-b inhibitors enhance the efficacy of cancer vaccines and oncolytic viruses by modulating the immune system, addressing the limitations of current treatments and improving tumor recognition and removal.

JP7587528B2Active Publication Date: 2024-11-20NURIX THERAPEUTICS INC
View PDF 2 Cites 0 Cited by

Patent Information

Application Number
JP2021568427
Authority / Receiving Office
JP · JP
Patent Type
Patents
Current Assignee / Owner
Priority Date
2019-08-19
Filing Date
2020-05-15
Publication Date
2024-11-20
Estimated Expiration
2040-05-15

AI Technical Summary

Technical Problem

Current cancer vaccines and oncolytic viruses have limited effectiveness in treating cancer, with low response rates and no significant improvement in overall survival for patients with visceral metastases, highlighting the need for improved therapeutic methods to enhance immune response against tumors.

Method used

Development of compounds and compositions that inhibit the Cbl-b enzyme, which can be administered alone or in combination with cancer vaccines and oncolytic viruses to modulate the immune system, enhance T cell activation, and increase the efficacy of cancer treatments.

Benefits of technology

The Cbl-b inhibitors enhance T cell activation and immune response, potentially improving the effectiveness of cancer vaccines and oncolytic viruses, leading to better tumor recognition and removal by the immune system.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure 0007587528000001
    Figure 0007587528000001
  • Figure 0007587528000002
    Figure 0007587528000002
  • Figure 0007587528000003
    Figure 0007587528000003
Patent Text Reader

Abstract

Disclosed are compounds, compositions, and methods for use in inhibiting the E3 enzyme Cbl-b of the ubiquitin-proteasome pathway. The compounds, compositions, and methods can be used to modulate the immune system, treat diseases amenable to immune system modulation, and treat cells in vivo, in vitro, or ex vivo. Also disclosed are pharmaceutical compositions comprising a Cbl-b inhibitor and a cancer vaccine, and methods for treating cancer using the Cbl-b inhibitor and the cancer vaccine; and pharmaceutical compositions comprising a Cbl-b inhibitor and an oncolytic virus, and methods for treating cancer using the Cbl-b inhibitor and the oncolytic virus. [Formula 1] TIFF2022532247000187.tif40170
Need to check novelty before this filing date? Find Prior Art

Description

[Technical field]

[0001] CROSS-REFERENCE TO RELATED APPLICATIONS

[0001] This application claims the benefit under 35 U.S.C. §119 of U.S. Provisional Patent Application Nos. 62 / 849,722, filed May 17, 2019; 62 / 880,437, filed July 30, 2019; 62 / 888,845, filed August 19, 2019; and 62 / 888,870, filed August 19, 2019, the contents of each of which are incorporated by reference in their entirety herein.

[0002] Field

[0002] Provided herein are compounds and compositions for inhibiting the Cbl-b enzyme and methods of use thereof in regulating the immune system, treating disease, and in vivo, in vitro, or ex vivo treatment of cells. Also provided herein are pharmaceutical compositions, kits, and methods of treating cancer, including combinations of inhibitors of the Cbl-b enzyme and cancer vaccines; and pharmaceutical compositions, kits, and methods of treating cancer, including combinations of inhibitors of the Cbl-b enzyme and oncolytic viruses. [Background technology]

[0003] background

[0003] The ubiquitin proteasome pathway is a complex system involved in the control of protein function and catabolism. Eukaryotic proteins conjugate ubiquitin, a 76 amino acid, 8.5 kilodalton protein. This conjugation, known as ubiquitination, results in functional changes or degradation of the target protein. Ubiquitination of a target protein occurs through a combination of a series of reactions involving ubiquitin and a set of enzymes known as E1, E2, and E3 enzymes. Ubiquitin is activated by a ubiquitin-activating enzyme, or E1 enzyme. Ubiquitin is then transferred to a ubiquitin-conjugating enzyme, or E2 enzyme. Finally, a ubiquitin ligase, or E3 enzyme, facilitates the transfer of ubiquitin from the E2 enzyme to the target protein. Polyubiquitination of a target protein serves as a primary signal leading to proteasomal degradation of the ubiquitin-conjugated protein, where it undergoes proteolysis. Ubiquitination by E3 ligases can also alter protein activity, interaction, or localization, and it regulates diverse biological processes, including cell division, DNA repair, and cell signaling.

[0004]

[0004] Protein synthesis and degradation in cells are critical for cell cycle control, cell proliferation, apoptosis, and many other cellular processes. Therefore, the ability to regulate the ubiquitin-proteasome pathway provides ample opportunities for intervention in disease processes. Intervention mechanisms may include enhancing the degradation of oncogene products, reducing the degradation of tumor suppressor proteins, modulating immune cell responses, and modulating antitumor immune responses.

[0005] Numerous clinical trials have evaluated therapeutic cancer vaccines. However, only two therapeutic cancer vaccines have been approved for use in the United States. In particular, the Bacillus Calmette-Guerin strain of Mycobacterium bovis has been approved for the treatment of bladder cancer, and an ex vivo activated autologous cell vaccine has been approved for the treatment of prostate cancer. Nevertheless, the response rate and overall survival of patients treated with cancer vaccines are significantly less than ideal. Thus, there is a need in the art for a method to improve the efficacy of cancer vaccines.

[0006]

[0006] Although there are many clinical trials using oncolytic viruses for the treatment of cancer, only one oncolytic virus has been approved for use in the United States and Europe. In particular, talimogene laherparepvec is a genetically modified herpes simplex virus approved for the treatment of melanoma. However, even talimogene laherparepvec has not shown any improvement in overall survival or benefit to patients with visceral metastases. Therefore, there is a need in the art for a method to improve the efficacy of oncolytic virus therapy.

[0007]

[0007] The human genome encodes approximately 35 E2 enzymes and over 500 E3 enzymes. Casitas B lineage lymphoma oncogene b (Cbl-b) is an E3 ubiquitin ligase that negatively regulates T cell activation (Wallner et al., Clin Dev Immunol, 2012: 692639). Thus, the discovery of drugs that modulate E2 or E3 enzymes offers the potential for treatment against disease processes involving specific E2 or E3 enzymes. This patent application relates to drugs that inhibit one such E3 enzyme, Casitas B lineage lymphoma oncogene b (Cbl-b); drugs that inhibit Cbl-b for use in combination with cancer vaccines, and pharmaceutical compositions comprising a Cbl-b inhibitor and a cancer vaccine; and drugs that inhibit Cbl-b for use in combination with oncolytic viruses, and pharmaceutical compositions comprising a Cbl-b inhibitor and an oncolytic virus. Summary of the Invention [Means for solving the problem]

[0008] overview

[0008] Disclosed herein are compounds and compositions for inhibiting Cbl-b enzymes and methods of using them in regulating the immune system, treating disease, and in vivo, in vitro, or ex vivo treatment of cells. Also disclosed herein are methods of using Cbl-b inhibitors in the treatment of cancer. Briefly, Cbl-b inhibitors are administered to individuals with cancer either alone or as part of a combination treatment, together with one or more of immune checkpoint inhibitors, anti-neoplastic agents, and radiation therapy. In addition, cells treated in vivo and / or in vitro with compounds or compositions as disclosed herein may be used in adoptive cell therapy to treat cancer.

[0009]

[0009] The present specification provides a compound of formula (I) [ka] or a tautomer, a stereoisomer, or a pharma- ceutically acceptable salt thereof, [ka] teeth, [ka] and; Z 1 is CH or nitrogen; Z 2 is CH or nitrogen; R 1 is hydrogen, C 1 ~C 6 Alkyl or C 1 ~C 6 is haloalkyl; R 2 is hydrogen, C 1 ~C 6Alkyl, C 1 ~C 6 Haloalkyl or C 3 ~C 6 is cycloalkyl; R 3 -CF 3 or cyclopropyl; R 4 -CF 3 or cyclopropyl; X is hydrogen, C 1 ~C 6 Alkyl, C 1 ~C 6 Haloalkyl, or [ka] and; R 5 is hydrogen, C 1 ~C 6 Alkyl, C 1 ~C 6 Haloalkyl, C 1 ~C 6 Alkyl-OH or C 1 ~C 6 Alkyl-CN; R 6 is a monocyclic C 3 ~C 6 Cycloalkyl, fused bicyclic C 4 ~C 8 Cycloalkyl, Bridged Bicyclic C 4 ~C 8 Cycloalkyl, spiro bicyclic C 5 ~C 8 cycloalkyl, or 5- or 6-membered heterocyclyl, each of which is selected from 1 to 5 R 7 is optionally substituted by groups; or R 5 and R 6together with the nitrogen atom to which they are attached form a 5-10 membered monocyclic, fused bicyclic, or bridged heterocyclyl, or a 5-10 membered monocyclic or bicyclic heteroaryl, each of which optionally contains 1-2 additional heteroatoms selected from the group consisting of nitrogen and oxygen, and each of which optionally contains 1-5 R 8 optionally substituted by groups; Each R 7 are independently, halo, C 1 ~C 6 Alkyl, C 1 ~C 6 Haloalkyl, C 1 ~C 6 Alkyl-OH or C 1 ~C 6 Alkyl-CN; Each R 8 are independently 1 ~C 6 Alkyl, C 1 ~C 6 Haloalkyl, C 1 ~C 6 Alkyl-OH, -CN, C 1 ~C 6 Alkyl-CN, -(C 1 ~C 6 alkylene)-O-(C 1 ~C 6 alkyl), hydroxy, or halo; or two R attached to the same carbon atom 8 The groups, together with the carbon atoms to which they are attached, form spiro C 3 ~C 6 Forms a cycloalkyl or spiro 5-6 membered heterocyclyl; Each R 9 are independently hydrogen, C 1 ~C 6 Alkyl, C 1 ~C 6 Haloalkyl or C 1 ~C 6 alkyl-OH; and n is 0 or 1.

[0010]

[0010] In some embodiments, [ka] teeth, [ka] In some embodiments, Z 1 is CH. In some embodiments, Z 1 is N.

[0011]

[0011] In some embodiments, [ka] teeth, [ka] It is.

[0012] In some embodiments, [ka] teeth, [ka] In some embodiments, Z 2 is CH. In some embodiments, Z 2 is N.

[0013] In some embodiments, [ka] teeth, [ka] It is.

[0014] In some embodiments, R 1 , H, C 1 ~C 3 Alkyl or C 1 ~C 3 In some embodiments, R 1 -H, -CH 3 , or -CF 3 It is.

[0015] In some embodiments, R 2 , H, C 1 ~C 3 Alkyl, C 1 ~C 3 Haloalkyl or C 3 ~C 4 In some embodiments, R 2 -H, -CH 3 , -CF 3 , -CHF 2 , -CH 2 F, or cyclopropyl.

[0016] In some embodiments, n is 0. In some embodiments, n is 1.

[0017] In some embodiments, X is H. In some embodiments, X is C 1 ~C 3 Alkyl or C 1 ~C 3 In some embodiments, X is -CH 3 or -CF 3 It is.

[0018] In some embodiments, X is [ka] It is.

[0019] In some embodiments, R 5 , H, C 1 ~C 3 Alkyl or C 1 ~C 3 In some embodiments, R 5 -H, -CH 3 , -CF 3 , -CH 2 CN or -CH 2 It is OH.

[0020] In some embodiments, R 6 is a monocyclic C 3 ~C 6 Cycloalkyl, fused bicyclic C 4 ~C 8 Cycloalkyl, Bridged Bicyclic C 4 ~C 8 Cycloalkyl, spiro bicyclic C 5 ~C 8 cycloalkyl, or 5- or 6-membered heterocyclyl, each of which is selected from 1 to 5 R 7 In some embodiments, R 6 teeth, [ka] is selected from the group consisting of:

[0021] In some embodiments, each R 7 are, when present, independently: halo, C 1 ~C 3 Alkyl, C 1 ~C 3 Haloalkyl, C 1 ~C 3 Alkyl-OH or C 1 ~C 3 In some embodiments, each R 7 -, if present, independently represents fluoro, -CH 3 , -CF 3 , -CH2 OH or -CH 2 It is CN.

[0022] In some embodiments, R 5 and R 6 together with the nitrogen atom to which they are attached form a 5-10 membered monocyclic, fused bicyclic, or bridged heterocyclyl, or a 5-10 membered monocyclic or bicyclic heteroaryl, each of which optionally contains 1-2 additional heteroatoms selected from the group consisting of N and O, and each of which optionally contains 1-5 R 8 In some embodiments, R 5 and R 6 together with the nitrogen atom to which they are attached, [ka] The moiety is selected from the group consisting of:

[0023] In some embodiments, each R 8 are, if present, independently, C 1 ~C 3 Alkyl, C 1 ~C 3 Haloalkyl, C 1 ~C 3 Alkyl-OH, -CN, C 1 ~C 3 Alkyl-CN, -(C 1 ~C 3 alkylene)-O-(C 1 ~C 3 alkyl), hydroxy, or halo, or two R 8 The groups, together with the carbon atoms to which they are attached, form spiro C 3 ~C 4 In some embodiments, each R 8 each independently, if present, is -CH 3, -CH 2 CH 3 , -CF 3 , -CH 2 OH, -CN, -CH 2 CN, -CH 2 -O-CH 3 , hydroxy, or F, or two R 8 The groups together with the carbon atom to which they are attached form a spirocyclopropyl.

[0024] In some embodiments, each R 9 are independently H, C 1 ~C 3 Alkyl, C 1 ~C 3 Haloalkyl or C 1 ~C 3 In some embodiments, each R 9 are independently H, -CH 3 , -CF 3 , or -CH 2 It is OH.

[0025]

[0025] Also disclosed herein is a compound selected from the compounds in Table 1, or a tautomer thereof, or a pharma- ceutically acceptable salt thereof. Also disclosed herein is a compound selected from any of the compounds described above or disclosed herein, or a tautomer thereof, or a pharma- ceutically acceptable salt thereof, and a pharma- ceutically acceptable excipient.

[0026]

[0026] Also disclosed herein is a method for regulating the activity of an immune cell, comprising contacting an immune cell with an effective amount of any compound described above or disclosed herein, or a tautomer thereof, or a pharma- ceutically acceptable salt thereof.

[0027]

[0027] Also disclosed herein is a method for treating a cancer responsive to inhibition of Cbl-b activity in an individual in need thereof, comprising administering to the individual an effective amount of any compound described above or disclosed herein, or a tautomer thereof, or a pharma- ceutically acceptable salt thereof.

[0028]

[0028] Also disclosed herein is a method for inhibiting Cbl-b activity in an individual in need thereof, comprising administering to the individual an effective amount of any compound described above or disclosed herein, or a tautomer thereof, or a pharma- ceutically acceptable salt thereof.

[0029]

[0029] Also disclosed herein is a method for treating or preventing a disease or condition associated with Cbl-b activity in an individual in need thereof, comprising administering to the individual any compound described above or disclosed herein, or a tautomer thereof, or a pharma- ceutically acceptable salt thereof.

[0030]

[0030] Also disclosed herein is a method for producing modified immune cells, the method comprising culturing a cell population containing immune cells in the presence of an effective amount of any compound described above or disclosed herein, or a tautomer thereof, or a pharma- ceutically acceptable salt thereof.

[0031]

[0031] Also disclosed herein are modified immune cells comprising a Cbl-b inhibitor, wherein the Cbl-b inhibitor is any compound described above or disclosed herein, or a tautomer thereof, or a pharma-ceutically acceptable salt thereof.

[0032]

[0032] Also disclosed herein is an isolated modified immune cell, wherein the immune cell has been contacted or is in contact with any compound described above or disclosed herein, or a tautomer thereof, or a pharma- ceutically acceptable salt thereof.

[0033]

[0033] Also disclosed herein is a composition comprising a cell population containing isolated modified immune cells, wherein the immune cells have been contacted or are in contact with any compound described above or disclosed herein, or a tautomer thereof, or a pharma- ceutically acceptable salt thereof.

[0034]

[0034] Also disclosed herein is a method of inhibiting abnormal cell proliferation comprising administering to an individual in need thereof an effective amount of isolated modified immune cells, wherein the immune cells have been contacted or are in contact with any compound described above or disclosed herein, or a tautomer thereof, or a pharma-ceutically acceptable salt thereof.

[0035]

[0035] Also disclosed herein is a method of inhibiting abnormal cell proliferation comprising administering to an individual in need thereof a composition comprising a cell population containing isolated modified immune cells, wherein the immune cells have been contacted or are in contact with any compound described above or disclosed herein, or a tautomer thereof, or a pharma-ceutically acceptable salt thereof.

[0036]

[0036] Also disclosed herein is a method for inhibiting abnormal cell proliferation, comprising administering an effective amount of any compound described above or disclosed herein, or a tautomer thereof, or a pharma- ceutically acceptable salt thereof.

[0037]

[0037] Also disclosed herein is a cell culture composition comprising a cell population containing immune cells and a Cbl-b inhibitor, wherein the Cbl-b inhibitor is any compound described above or disclosed herein, or a tautomer thereof, or a pharma-ceutically acceptable salt thereof.

[0038]

[0038] Also disclosed herein is a pharmaceutical composition comprising a Cbl-b inhibitor and one or both of an adjuvant and an antigen, wherein the Cbl-b inhibitor is any compound described above or disclosed herein, or a tautomer thereof, or a pharma-ceutically acceptable salt thereof.

[0039]

[0039] Also disclosed herein is an article of manufacture comprising any modified immune cell as disclosed herein, any composition comprising a cell population as disclosed herein, any cell culture composition as disclosed herein, or any pharmaceutical composition as disclosed herein.

[0040]

[0040] Also disclosed herein is a kit comprising any composition comprising any modified immune cell as disclosed herein or a cell population as disclosed herein.

[0041]

[0041] Also disclosed herein is the use of a Cbl-b inhibitor in the manufacture of a medicament for the treatment or prevention of a disease or condition associated with Cbl-b activity, wherein the Cbl-b inhibitor is any compound described above or disclosed herein, or a tautomer thereof, or a pharma-ceutically acceptable salt thereof.

[0042] In any of the embodiments disclosed herein, the Cbl-b protein can be a mammalian Cbl-b, or a human Cbl-b.

[0043] Also disclosed herein are Cbl-b inhibitor compounds, vaccines, and compositions comprising Cbl-b inhibitors and vaccines, and methods of use thereof in the treatment of cancer. The Cbl-b inhibitors and cancer vaccines can be administered to individuals with cancer.

[0044] Also disclosed herein are Cbl-b inhibitor compounds, oncolytic viruses, and compositions comprising a Cbl-b inhibitor and an oncolytic virus, and methods of use thereof in the treatment of cancer. The Cbl-b inhibitor and the oncolytic virus can be administered to an individual with cancer.

[0045]

[0045] Provided herein is a method of immunization comprising administering to an individual in need thereof an effective amount of a small molecule Cbl-b inhibitor and administering to the individual an effective amount of a vaccine.

[0046]

[0046] Provided herein is a method for treating cancer, comprising administering to an individual having cancer an effective amount of a small molecule Cbl-b inhibitor and administering to the individual an effective amount of an oncolytic virus.

[0047]

[0047] Provided herein is a method of treating cancer comprising administering to an individual having cancer an effective amount of an agent capable of lowering the activation threshold of an immune cell, and administering to the individual an effective amount of a therapeutic cancer vaccine; or administering to the individual an effective amount of an oncolytic virus.

[0048] Provided herein is a pharmaceutical composition comprising a cancer vaccine and a small molecule Cbl-b inhibitor, optionally further comprising a pharma ceutically acceptable excipient.

[0049]

[0049] Provided herein is a kit for treating cancer comprising: (a) a small molecule Cbl-b inhibitor; (b) a therapeutic cancer vaccine; and (c) instructions for administering effective amounts of the Cbl-b inhibitor and the therapeutic cancer vaccine to treat cancer in an individual.

[0050]

[0050] Provided herein is a kit for treating cancer comprising: (a) a pharmaceutical composition comprising a small molecule Cbl-b inhibitor and a therapeutic cancer vaccine; and (b) instructions for administering an effective amount of the pharmaceutical composition comprising a Cbl-b inhibitor and a therapeutic cancer vaccine to treat cancer in an individual.

[0051] Provided herein is a pharmaceutical composition comprising an oncolytic virus and a small molecule Cbl-b inhibitor, optionally further comprising a pharma ceutically acceptable excipient.

[0052]

[0052] Provided herein is a kit for treating cancer comprising: (a) a small molecule Cbl-b inhibitor; (b) an oncolytic virus; and (c) instructions for administering effective amounts of the Cbl-b inhibitor and the oncolytic virus to treat cancer in an individual.

[0053]

[0053] Also provided herein is a kit for treating cancer comprising: (a) a pharmaceutical composition comprising a small molecule Cbl-b inhibitor and an oncolytic virus; and (b) instructions for administering an effective amount of the pharmaceutical composition comprising the small molecule Cbl-b inhibitor and an oncolytic virus to treat cancer in an individual. DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS

[0054] Detailed Description

[0054] Provided herein are compounds and pharmaceutical compositions that inhibit the Cbl-b enzyme, as well as methods of treatment using such compounds and pharmaceutical compositions. The compounds and compositions can be used in methods of regulating the immune system, treating diseases, and treating cells in vivo, in vitro, or ex vivo. Also provided herein are pharmaceutical compositions comprising a cancer vaccine and a compound that inhibits the Cbl-b enzyme, as well as methods of treatment using such compounds, cancer vaccines, and pharmaceutical compositions. Also provided herein are pharmaceutical compositions comprising an oncolytic virus and a compound that inhibits the Cbl-b enzyme, as well as methods of treatment using such compounds, oncolytic viruses, and pharmaceutical compositions.

[0055]

[0055] T cell activation and T cell tolerance are tightly controlled processes that control immune responses to tumors while preventing autoimmunity. Tolerance prevents the immune system from attacking cells expressing "self" antigens. In peripheral tolerance, T cells that recognize "self" antigens (i.e., autoreactive T cells) become functionally unresponsive or are eliminated after encountering "self" antigens outside the thymus. Thus, the peripheral tolerance process is important in preventing autoimmune diseases. Normally, cancer cells are eliminated by activated T cells that recognize tumor antigens expressed on the surface of the cancer cells. However, in cancer, the tumor microenvironment can support T cell tolerance to cancer cells, allowing them to avoid recognition and elimination by the immune system. The ability of cancer cells to evade tumor immune surveillance can contribute to unchecked tumor growth. Thus, T cell tolerance can be a type of T cell dysfunction. The general principles of T cell dysfunction are well known in the art (see Schietinger et al., Trends Immunol., 35: 51-60, 2014). Another type of T cell dysfunction that can contribute to uncontrolled tumor growth is T cell exhaustion, T cell senescence, and / or T cell anergy. Therefore, treating T cell dysfunction, for example, by increasing T cell activation, increasing T cell proliferation, decreasing T cell tolerance, and / or decreasing T cell exhaustion, is beneficial for preventing or treating cancer. Additional cells of the immune system are important for the recognition and elimination of cancer cells in immune surveillance. For example, natural killer (NK) cells are lymphocytes of the innate immune system that can identify and kill cancer cells (see Martinez-Losato et al., Clin Cancer Res., 21: 5048-5056, 2015). Recent studies have also shown that B cell subsets with distinct phenotypes and functions exhibit diverse roles in anti-tumor responses (see Saravaria et al., Cell Mol Immunol., 14: 662-674, 2017). Due to their role in tumor surveillance, NK cells and B cells may also be suitable therapeutic targets for the prevention or treatment of cancer.

[0056] Cbl-b is a RING-type E3 ligase that plays an important role in the immune system due to its function as a negative regulator of immune activation. Cbl-b plays an essential role in reducing T cell activation, thus promoting T cell tolerance. Studies have shown that cbl-b-deficient T cells exhibit a reduced threshold for activation by antigen recognition receptors and costimulatory molecules (e.g., CD28). For example, loss of Cbl-b in T cells abrogates the requirement for CD28 costimulation during T cell activation and proliferation (see Bachmaier et al., Nature, 403: 211-216, 2000). Such cbl-b- / - T cells are largely resistant to T cell anergy, a tolerance mechanism in which T cells are functionally inactivated and T cell proliferation is severely impaired (see Jeon et al., Immunity, 21: 167-177, 2004; and Schwartz et al., Annu Rev Immunol., 21: 305-34, 2003). In support of this, loss of Cbl-b in cbl-b knockout mice impaired the induction of T cell tolerance and exacerbated autoimmunity (see Jeon et al., Immunity, 21: 167-177, 2004). Importantly, loss of Cbl-b in mice also resulted in robust antitumor responses that were primarily dependent on cytotoxic T cells. One study showed that cbl-b- / - CD8+ T cells were resistant to regulatory T cell-mediated suppression and exhibited enhanced activation and tumor infiltration. Therapeutic transfer of naive cbl-b- / - CD8+ T cells was sufficient to mediate rejection of established tumors (see Loeser et al., J Exp Med., 204: 879-891, 2007). Recent studies have shown that Cbl-b also plays a role in NK cell activation. Genetic deletion of Cbl-b or targeted inactivation of its E3 ligase activity enabled NK cells to spontaneously reject metastatic tumors in mouse models (see Paolino et al., Nature, 507: 508-512, 2014).

[0057] Provided herein are compounds and compositions that are potent inhibitors of Cbl-b and can be used in novel approaches to treat diseases such as cancer. In some embodiments, the compounds and compositions provided herein can be used in methods to modulate the immune system, such as increasing the activation of T cells, NK cells, and B cells, as well as in vivo, in vitro, or ex vivo treatment of such cells.

[0058] I. Definition

[0058] An "effective amount" of an agent disclosed herein is an amount sufficient to carry out a specifically described purpose. An "effective amount" may be determined empirically and routinely in relation to the described purpose. An "effective amount" or a "sufficient amount" of an agent is an amount appropriate to produce a desired biological effect, such as a beneficial outcome, including a beneficial clinical outcome. In some embodiments, the term "effective amount" refers to an amount of an agent effective to "treat" a disease or disorder in an individual (e.g., a mammal such as a human).

[0059]

[0059] The term "Cbl-b" as used herein refers to Cbl-b protein. The term also includes naturally occurring variants of Cbl-b, including splice variants or allelic variants. The term also includes non-naturally occurring variants of Cbl-b, such as recombinant Cbl-b proteins or truncated variants thereof, which generally maintain the binding ability (e.g., ability to bind E2 enzyme) of naturally occurring Cbl-b or naturally occurring Cbl-b variants.

[0060]

[0060] The terms "pharmaceutical formulation" and "pharmaceutical composition" refer to a preparation in a form that allows the biological activity of the active ingredient to be effective and that does not contain additional ingredients that are unacceptably toxic to the individual to whom the formulation or composition will be administered. Such a formulation or composition may be sterile. Such a formulation or composition may be sterile, provided that an oncolytic virus may be included.

[0061]

[0061] "Excipient" as used herein includes a pharma- ceutically acceptable excipient, carrier, vehicle, or stabilizer that is non-toxic to cells or mammals exposed thereto at the dosages and concentrations used. Often the physiologically acceptable excipient is an aqueous pH buffered solution.

[0062]

[0062] A reference to a compound as described in a pharmaceutical composition, or to a compound as described in a claim to a pharmaceutical composition, refers to the compound described by the described formula in the pharmaceutical composition, without the other elements of the pharmaceutical composition, i.e., without carriers, excipients, etc.

[0063] The term "treating" or "treatment" of a disease refers to carrying out a protocol, which may include administering one or more therapeutic agents to an individual (human or otherwise) in an attempt to achieve beneficial or desired results, including clinical results, in the individual. Beneficial or desired clinical results include, but are not limited to, alleviation or amelioration of one or more symptoms, reduction in the extent of the disease, a stabilized (i.e., not worsening) state of the disease, prevention of the spread of the disease, delay or slowing of the progression of the disease, improvement or palliation of the disease state, and remission (whether partial or complete). "Treatment" may also mean extending survival compared to the expected survival of an individual not receiving treatment. Furthermore, "treating" and "treatment" may occur by administration of a dose of one or more therapeutic agents, or may occur upon administration of a series of doses of one or more therapeutic agents. "Treating" or "treatment" does not require complete alleviation of signs or symptoms, and does not require a cure. "Treatment" may also refer to clinical interventions such as administering one or more therapeutic agents to an individual designed to alter the natural course of the individual or cells under treatment (i.e., designed to alter the course of the individual or cells that would occur in the absence of that clinical intervention). The term "therapeutic agent" may refer to a Cbl-b inhibitor, modified immune cells, or compositions thereof.

[0064]

[0064] As used herein, an "individual" or "subject" is a mammal. For purposes of treatment, "mammals" include humans; non-human primates; domestic and farm animals; and zoo, sport, or pet animals, such as dogs, horses, rabbits, cows, pigs, hamsters, gerbils, mice, ferrets, rats, and cats. In some embodiments, the individual or subject is a human.

[0065]

[0065] As used herein, the term "T cell dysfunction" refers to a state of reduced immune responsiveness to antigen stimulation. The term "T cell dysfunction" includes elements common to both T cell exhaustion and / or T cell anergy, in which antigen recognition can occur but the subsequent immune response is insufficient to suppress tumor growth. The term "T cell dysfunction" also includes recalcitrance or unresponsiveness to antigen recognition, such as impaired ability to couple antigen recognition to downstream T cell effector functions, such as proliferation, cytokine production, and / or target cell killing.

[0066]

[0066] The term "T cell anergy" refers to a state in which the cells do not respond to antigenic stimulation due to defective or insufficient signals delivered through the T cell receptor. "T cell anergy" can also occur when there is no costimulation upon stimulation with an antigen, resulting in the cells becoming unresponsive to subsequent activation by the antigen, even in the context of costimulation.

[0067] The term "T cell exhaustion" refers to a state of T cell dysfunction caused by persistent TCR signaling, which can occur in cancer. It is distinct from anergy in that it occurs by persistent signaling, rather than through defective or faulty signaling. It is defined by defective effector function, persistent expression of inhibitory receptors, and a transcriptional state that differs from functional effector or memory T cells.

[0068]

[0068] A "T cell dysfunction disorder" is a disorder or condition characterized by reduced responsiveness of T cells to antigenic stimulation. Reduced responsiveness can result in ineffective tumor suppression. In some embodiments, the term "T cell dysfunction disorder" encompasses cancer, such as hematological or non-hematological cancers. In some embodiments, a "T cell dysfunction disorder" is one in which T cells are anergic or have a reduced ability to secrete cytokines, proliferate, or carry out cytolytic activity.

[0069]

[0069] "Enhancing T cell function" means inducing, inducing, or stimulating T cells to exhibit sustained or amplified biological function, or to regenerate or reactivate exhausted or inactive T cells. Examples of enhanced T cell function include increased T cell activation (e.g., increased cytokine production, increased expression of T cell activation markers, etc.), increased T cell proliferation, decreased T cell exhaustion, and / or decreased T cell tolerance compared to the state of the T cells before treatment with a Cbl-b inhibitor. Methods for measuring enhanced T cell function are known in the art.

[0070] "Proliferation" is used herein to refer to the proliferation of cells. An increase in proliferation includes the production of a greater number of cells compared to a baseline value. A decrease in proliferation includes the production of a decreased number of cells compared to a baseline value. In some embodiments, the cells are immune cells, such as T cells, and an increase in proliferation is desired. In some embodiments, the cells are cancer cells, and a decrease in proliferation is desired.

[0071]

[0071] "Alkyl," as used herein, refers to a saturated linear (i.e., unbranched) or branched monovalent hydrocarbon chain or combinations thereof. Particular alkyl groups are those having a specified number of carbon atoms, such as alkyl groups having 1 to 20 carbon atoms ("C 1 ~C 20 alkyl) and alkyl groups having 1 to 10 carbon atoms ("C 1 ~C 10" alkyl), alkyl groups having 1 to 8 carbon atoms ("C 1 ~C 8 alkyl) and alkyl groups having 1 to 6 carbon atoms ("C 1 ~C 6 alkyl) and alkyl groups having 2 to 6 carbon atoms ("C 2 ~C 6 alkyl) or an alkyl group having 1 to 4 carbon atoms ("C 1 ~C 4 Examples of alkyl groups include, but are not limited to, methyl, ethyl, n-propyl, isopropyl, n-butyl, t-butyl, isobutyl, sec-butyl, and the like, homologs and isomers thereof, e.g., n-pentyl, n-hexyl, n-heptyl, n-octyl.

[0072] "Alkenyl," as used herein, refers to an unsaturated linear (i.e., unbranched) or branched monovalent hydrocarbon chain, or combinations thereof, having at least one site of olefinic unsaturation (i.e., having at least one moiety of the formula C=C). Particular alkenyl groups are those having a specified number of carbon atoms, such as alkenyl groups having 2 to 20 carbon atoms ("C 2 ~C 20 alkenyl) having 2 to 10 carbon atoms ("C 2 ~C 10 " alkenyl), alkenyl groups having 2 to 8 carbon atoms ("C 2 ~C 8 alkenyl) and alkenyl groups having 2 to 6 carbon atoms ("C 2 ~C 6alkenyl groups having 2 to 4 carbon atoms ("C2-C4 alkenyl"). Alkenyl groups can be in the "cis" or "trans" configuration, or alternatively, in the "E" or "Z" configuration. Examples of alkenyl groups include, but are not limited to, groups such as ethenyl (or vinyl), prop-1-enyl, prop-2-enyl (or allyl), 2-methylprop-1-enyl, but-1-enyl, but-2-enyl, but-3-enyl, buta-1,3-dienyl, 2-methylbuta-1,3-dienyl, homologs, and isomers thereof.

[0073]

[0073] "Alkynyl," as used herein, refers to an unsaturated linear (i.e., unbranched) or branched monovalent hydrocarbon chain, or combinations thereof, having at least one site of acetylenic unsaturation (i.e., having at least one moiety of the formula C≡C). Particular alkynyl groups are those having the specified number of carbon atoms, such as alkynyl groups having 2 to 20 carbon atoms ("C 2 ~C 20 alkynyl groups having 2 to 10 carbon atoms ("C 2 ~C 10 alkynyl groups having 2 to 8 carbon atoms ("C 2 ~C 8 alkynyl groups having 2 to 6 carbon atoms ("C 2 ~C 6 alkynyl) or an alkynyl group having 2 to 4 carbon atoms ("C 2 ~C 4 Examples of alkynyl groups include, but are not limited to, groups such as ethynyl (or acetylenyl), prop-1-ynyl, prop-2-ynyl (or propargyl), but-1-ynyl, but-2-ynyl, but-3-ynyl, homologs, and isomers thereof.

[0074]

[0074] "Alkylene," as used herein, refers to a residue equivalent to alkyl, but exhibiting a divalent value. Particular alkylene groups are those having 1 to 6 carbon atoms ("C 1 ~C6 alkylene) with 1 to 5 carbon atoms ("C 1 ~C 5 alkylene"), 1 to 4 carbon atoms ("C 1 ~C 4 alkylene) or 1 to 3 carbon atoms ("C 1 ~C 3 Examples of alkylene groups include, but are not limited to, methylene (-CH 2 -), ethylene (-CH 2 CH 2 -), propylene (-CH 2 CH 2 CH 2 -), butylene (-CH 2 CH 2 CH 2 CH 2 -) and other groups.

[0075]

[0075] "Cycloalkyl" as used herein refers to a non-aromatic saturated or unsaturated cyclic monovalent hydrocarbon structure. Particular cycloalkyl groups are those having a specified number of cyclic carbon atoms (i.e., ring carbon atoms), such as cycloalkyl groups having 3 to 12 cyclic carbon atoms ("C 3 ~C 12 Particular cycloalkyls are cyclic hydrocarbons having 3 to 8 ring carbon atoms ("C 3 ~C 8 Cycloalkyl) or cyclic hydrocarbons having 3 to 6 cyclic carbon atoms ("C 3 ~C 6 Cycloalkyl groups include, but are not limited to, cyclohexyl, cycloalkyl groups, and the like. Cycloalkyls can consist of one ring, such as cyclohexyl, or multiple rings, such as adamantyl, but are intended to exclude aromatic (e.g., aryl) groups. Cycloalkyls containing more than one ring can be fused, spiro, or bridged, or combinations thereof. Examples of cycloalkyl groups include, but are not limited to, cyclopropyl ... [ka] , cyclobutyl [ka] , cyclopentyl [ka] , cyclohexyl [ka] , 1-cyclohexenyl, 3-cyclohexenyl, cycloheptyl [ka] , norbornyl, etc.

[0076]

[0076] "Cycloalkylene," as used herein, refers to a residue identical to cycloalkyl, but which is divalent (i.e., as opposed to monovalent). Particular cycloalkylene groups are those having 3 to 12 cyclic carbon atoms ("C 3 ~C 12 Cycloalkylene"), those with 3 to 8 cyclic carbon atoms ("C 3 ~C 8 cycloalkylene"), or those having 3 to 6 cyclic carbon atoms ("C 3 ~C 6 Examples of cycloalkylene groups include, but are not limited to, cyclopropylene. [ka] , cyclobutylene [ka] , cyclopentylene [ka] , cyclohexylene [ka] , 1,2-cyclohexenylene, 1,3-cyclohexenylene, 1,4-cyclohexenylene, cycloheptylene [ka] , norbornylene, and the like.

[0077] "Aryl," as used herein, refers to an aromatic carbocyclic group having a single ring (e.g., phenyl) or multiple condensed rings (e.g., naphthyl or anthryl), one or more of which may be non-aromatic. Particular aryl groups are those having 6 to 14 annular carbon atoms (i.e., ring carbon atoms) ("C 6 ~C 14 Aryl groups are groups that are either aromatic or non-aromatic. Aryl groups having two or more rings, where at least one ring is non-aromatic, can be attached to the parent structure at either an aromatic or non-aromatic ring position. In one variation, aryl groups having two or more rings, where at least one ring is non-aromatic, are attached to the parent structure at an aromatic ring position. Examples of aryl include, but are not limited to, phenyl, naphthyl, 1-naphthyl, 2-naphthyl, 1,2,3,4-tetrahydronaphthalene-6- ... [ka] Examples of such groups include:

[0078]

[0078] "Carbocyclyl" or "carbocyclic" refers to an aromatic or non-aromatic monovalent cyclic group in which all ring members are carbon atoms, such as cyclohexyl, phenyl, and 1,2-dihydronaphthyl.

[0079]

[0079] "Arylene," as used herein, refers to a radical similar to aryl, but exhibiting divalency. Particular arylene groups are those having 6 to 14 cyclic carbon atoms ("C 6~C 14 Examples of arylene include, but are not limited to, groups such as phenylene, o-phenylene (i.e., 1,2-phenylene), m-phenylene (i.e., 1,3-phenylene), p-phenylene (i.e., 1,4-phenylene), naphthylene, 1,2-naphthylene, 1,3-naphthylene, 1,4-naphthylene, 2,7-naphthylene, 2,6-naphthylene, and the like.

[0080]

[0080] "Heteroaryl," as used herein, refers to an unsaturated aromatic cyclic group having 1 to 14 ring carbon atoms and at least one ring heteroatom, including, but not limited to, heteroatoms such as nitrogen, oxygen, and sulfur. Heteroaryl groups can have a single ring (e.g., pyridyl or imidazolyl) or multiple condensed rings (e.g., indolizinyl, indolyl, or quinolinyl), at least one of which is aromatic. Particular heteroaryl groups are a 5-14 membered ring having 1-12 ring carbon atoms and 1-6 ring heteroatoms independently selected from the group consisting of nitrogen (N), oxygen (O), and sulfur (S) ("5-14 membered heteroaryl"); a 5-10 membered ring having 1-8 ring carbon atoms and 1-4 ring heteroatoms independently selected from the group consisting of nitrogen, oxygen, and sulfur ("5-10 membered heteroaryl"); or a 5-, 6-, or 7 membered ring having 1-5 ring carbon atoms and 1-4 ring heteroatoms independently selected from the group consisting of nitrogen, oxygen, and sulfur ("5-7 membered heteroaryl"). In one variation, heteroaryl includes a monocyclic aromatic 5-, 6-, or 7 membered ring having 1-6 ring carbon atoms and 1-4 ring heteroatoms independently selected from the group consisting of nitrogen, oxygen, and sulfur. In another variation, heteroaryl includes polycyclic aromatic rings having 1-12 ring carbon atoms and 1-6 ring heteroatoms independently selected from the group consisting of nitrogen, oxygen, and sulfur. Heteroaryl groups having two or more rings, where at least one ring is non-aromatic, can be attached to the parent structure at either an aromatic or non-aromatic ring position. Examples of heteroaryl include, but are not limited to, groups such as pyridyl, benzimidazolyl, benzotriazolyl, benzo[b]thienyl, quinolinyl, indolyl, and benzothiazolyl. "Heteroaryl" also includes: [ka] (2,4-dihydro-3H-1,2,4-triazol-3-on-2-yl), and the like, [ka] (1H-1,2,4-triazol-5-ol-1-yl).

[0081]

[0081] "Heterocyclyl" and "heterocyclic group", as used herein, refer to a non-aromatic saturated or partially unsaturated cyclic group having the number of atoms and heteroatoms as specified, or, if the number of atoms or heteroatoms is not specified, having at least three ring atoms, 1 to 14 ring carbon atoms, and at least one ring heteroatom, including, but not limited to, nitrogen, oxygen, and sulfur heteroatoms. Heterocyclic groups can have a single ring (e.g., tetrahydrothiophenyl, oxazolidinyl) or multiple condensed rings (e.g., decahydroquinolinyl, octahydrobenzo[d]oxazolyl). Multiple condensed rings include, but are not limited to, bicyclic, tricyclic, and tetracyclic rings, as well as bridged or spirocyclic ring systems. Examples of heterocyclic groups include, but are not limited to, aziridinyl, azetidinyl, pyrrolidinyl, piperidinyl, oxiranyl, oxetanyl, tetrahydrofuranyl, tetrahydropyranyl, oxazolidinyl, piperazinyl, morpholinyl, dioxanyl, 3,6-dihydro-2H-pyranyl, 2,3-dihydro-1H-imidazolyl, and the like.

[0082]

[0082] "Heteroarylene" as used herein refers to a moiety equivalent to heteroaryl, but which is divalent. Particular heteroarylene groups are 5-14 membered rings having 1-12 ring carbon atoms and 1-6 ring heteroatoms independently selected from the group consisting of nitrogen, oxygen, and sulfur ("5-14 membered heteroarylene"); 5-10 membered rings having 1-8 ring carbon atoms and 1-4 ring heteroatoms independently selected from the group consisting of nitrogen, oxygen, and sulfur ("5-10 membered heteroarylene"); or 5-, 6-, or 7-membered rings having 1-5 ring carbon atoms and 1-4 ring heteroatoms independently selected from the group consisting of nitrogen, oxygen, and sulfur ("5-7 membered heteroarylene"). Examples of heteroarylene include, but are not limited to, groups such as pyridylene, benzimidazolylene, benzotriazolylene, benzo[b]thienylene, quinolinylene, indolylene, and benzothiazolylene.

[0083]

[0083] "Halo" or "halogen" refers to elements in Group 17 of the element having atomic number 9 through 85. Halo groups include fluoro (F), chloro (Cl), bromo (Br), and iodo (I).

[0084]

[0084] "Haloalkyl", "haloalkylene", "haloaryl", "haloarylene", "haloheteroaryl", and similar terms refer to a moiety substituted with at least one halo group. When a haloalkyl moiety or other halo-substituted moiety is substituted with more than one halogen, it may be expressed using a prefix corresponding to the number of halogen moieties attached. For example, dihaloaryl, dihaloalkyl, trihaloaryl, trihaloalkyl, etc. refer to aryl and alkyl substituted with two ("di") or three ("tri") halo groups, which may, but need not, be the same halo; thus, for example, the haloaryl group 4-chloro-3-fluorophenyl is within the scope of dihaloaryl. Some haloalkyl groups, in which each hydrogen (H) of the alkyl group is replaced with a halo group, are referred to as "perhaloalkyl". Particular perhaloalkyl groups include trifluoroalkyl (-CF 3Similarly, "perhaloalkoxy" refers to an alkoxy group in which a halogen replaces each hydrogen (H) in the hydrocarbon that makes up the alkyl portion of the alkoxy group. An example of a perhaloalkoxy group is trifluoromethoxy (-OCF 3 ) "Haloalkyl" includes monohaloalkyl, dihaloalkyl, trihaloalkyl, perhaloalkyl, and any other number of halo substituents possible on the alkyl group; and similarly for other groups such as haloalkylene, haloaryl, haloarylene, haloheteroaryl, etc.

[0085] "Amino" refers to the group -NH 2 Refers to...

[0086]

[0086] "Oxo" refers to the group =O, ie, an oxygen atom that is double bonded to carbon or another chemical element.

[0087]

[0087] "Optionally substituted" means that a group is unsubstituted or substituted with one or more (e.g., 1, 2, 3, 4, or 5) of the substituents listed for that group (where the substituents can be the same or different). In one embodiment, an optionally substituted group is unsubstituted. In one embodiment, an optionally substituted group has one substituent. In another embodiment, an optionally substituted group has two substituents. In another embodiment, an optionally substituted group has three substituents. In another embodiment, an optionally substituted group has four substituents. In some embodiments, an optionally substituted group has 1-2, 1-3, 1-4, or 1-5 substituents. When multiple substituents are present, each substituent is independently selected unless otherwise indicated. For example, the group -N(C 1 ~C 4 Alkyl)(C 1 ~C 4 Alkyl) 1 ~C 4 The alkyl) substituent is -N(CH 3 )(CH2 CH 3 ) may be selected independently of the other to yield groups such as:

[0088]

[0088] In addition to the disclosures herein, the term "substituted" when used to modify a designated group or radical can also mean that one or more hydrogen atoms (H) of the designated group or radical are each, independently of one another, replaced with the same or different substituents as defined herein. In some embodiments, a substituted group has 1, 2, 3, or 4 substituents, 1, 2, or 3 substituents, 1 or 2 substituents, or 1 substituent.

[0089]

[0089] Substituents may be attached at any chemically possible position on the designated group or radical, unless otherwise specified. Thus, for example, in one embodiment, -C 1 ~C 8 Alkyl-OH includes, for example, -CH 2 CH 2 OH and -CH(OH)-CH 3 , and -CH 2 C(OH)(CH 3 ) 2 As a further example, in one embodiment, -C 1 ~C 6 Alkyl-OH includes, for example, -CH 2 CH 2 OH and -CH(OH)-CH 3 , and -CH 2 C(OH)(CH 3 ) 2 As a further example, in one embodiment, -C 1 ~C 6 Alkyl-CN includes, for example, -CH 2 CH 2 CN and -CH(CN)-CH 3 , and -CH 2 C(CN)(CH 3 ) 2 etc.

[0090]

[0090] Unless a specific isotope of an element is indicated in the formula, the present disclosure encompasses any isotopologue of the compounds disclosed herein, such as, for example, deuterated derivatives of the compounds (where H can be 2H, i.e., deuterium (D)). Deuterated compounds can provide favorable changes in pharmacokinetic (ADME) properties. Isotopologues can have isotopic substitutions at any and all positions in the structure, or can have atoms present at natural abundance at any and all positions in the structure.

[0091]

[0091] "Small molecule," as used herein, refers to a compound with a molecular weight below 1,000 daltons.

[0092]

[0092] Hydrogen atoms may also be replaced by closely related bioisosteres, such as fluorine, provided that such replacement results in a stable compound.

[0093]

[0093] The present disclosure also encompasses any and all stereochemical forms, including any enantiomeric or diastereomeric forms, and cis / trans or E / Z isomers, of the compounds described herein. Unless stereochemistry is explicitly indicated in a chemical structure or chemical name, the structure or chemical name is intended to encompass any possible stereoisomers of the compound depicted. In addition, when a specific stereochemical form is depicted, it is understood that any ratio mixture of the disclosed compounds, including any ratio mixture of two or more stereochemical forms of the disclosed compounds, is also described and encompassed by the present disclosure, such that all other stereochemical forms, as well as general non-stereospecific forms and racemic, non-racemic, enantioenriched, and scameric mixtures of the compounds are encompassed. Compositions including the disclosed compounds, such as compositions of substantially pure compounds, including specific stereochemical forms, are also contemplated. Compositions comprising mixtures of any ratio of the disclosed compounds, including compositions comprising mixtures of any ratio of two or more stereochemical forms of the disclosed compounds, are also encompassed by the present disclosure, just as racemic, non-racemic, enantioenriched, and scalaminic mixtures of the compounds are encompassed by the present disclosure. When stereochemistry is explicitly indicated for one or more portions of a molecule, but not for one or more other portions of the molecule, the structure is intended to encompass all possible stereoisomers of the portion or portions where stereochemistry is not explicitly indicated. The present disclosure also encompasses any and all tautomeric forms of the compounds described herein.

[0094]

[0094] The present disclosure is intended to encompass all salts of the compounds described herein, as well as methods of using such salts of the compounds. In one embodiment, the salts of the compounds include pharma- ceutically acceptable salts. A pharma- ceutically acceptable salt is one that can be administered to humans and / or animals as a drug or medicine and that, upon administration, retains at least a portion of the biological activity of the free compound (neutral or non-salt compound). The desired salts of basic compounds can be prepared by treating the compound with an acid, by methods known to those skilled in the art. Examples of inorganic acids include, but are not limited to, hydrochloric acid, hydrobromic acid, sulfuric acid, nitric acid, and phosphoric acid. Examples of organic acids include, but are not limited to, formic acid, acetic acid, propionic acid, glycolic acid, pyruvic acid, oxalic acid, maleic acid, malonic acid, succinic acid, fumaric acid, tartaric acid, citric acid, benzoic acid, cinnamic acid, mandelic acid, sulfonic acid, and salicylic acid. Salts of basic compounds with amino acids, such as aspartic acid and glutamic acid, can also be prepared. The desired salt of an acidic compound can be prepared by treating the compound with a base by methods known to those skilled in the art. Examples of inorganic salts of acidic compounds include, but are not limited to, alkali metal and alkaline earth salts, such as sodium, potassium, magnesium, and calcium salts; ammonium salts; and aluminum salts. Examples of organic salts of acidic compounds include, but are not limited to, procaine salts, dibenzylamine salts, N-ethylpiperidine salts, N,N'-dibenzylethylenediamine salts, and triethylamine salts. Salts of acidic compounds with amino acids, such as lysine salts, can also be prepared. For a list of pharma-ceutically acceptable salts, see, for example, PH Stahl and CG Wermuth (eds.) "Handbook of Pharmaceutical Salts, Properties, Selection and Use" Wiley-VCH, 2011 (ISBN: 978-3-90639-051-2). Some pharma- ceutically acceptable salts are also disclosed in Berge, J. Pharm. Sci. 66:1 (1977).

[0095] IC for Cbl-b inhibition as described in Biological Examples 1, 8, and / or 12 50 The Cbl-b activity assay (Cbl-b inhibition assay) used to measure the IC value uses a mixture containing N-terminally biotinylated Avi-tagged Cbl-b, a fluorescently labeled inhibitor probe with a BODIPY FL tag (Example 59), and an assay buffer. In one embodiment, the IC value for inhibition of Cbl-b is 50 In the Cbl-b activity assay (Cbl-b inhibition assay) used to measure the IC for inhibition of Cbl-b, the conditions described in Biological Examples 1, 8, and / or 12 are used with 0.5 nM Cbl-b ("high" final concentration). 50 In the Cbl-b activity assays used to measure Cbl-b (Cbl-b inhibition assays), the conditions described in Biological Examples 1, 8, and / or 12 are used with 0.125 nM Cbl-b ("low" final concentration).

[0096]

[0096] For clarity, it is understood that certain features disclosed herein that are described in the context of separate embodiments may also be provided in combination as a single embodiment. Conversely, for brevity, various features disclosed herein that are described in the context of a single embodiment may also be provided individually or in any suitable subcombination. All combinations of the embodiments with respect to the chemical groups represented by the variables are specifically included in the present disclosure and are disclosed herein as if each and every combination were individually and explicitly disclosed, so long as each and every combination includes a compound that is a stable compound (i.e., a compound that can be isolated, characterized, and tested for biological activity). In addition, all subcombinations of the chemical groups listed in the embodiments describing such variables are also specifically included in the present disclosure and are disclosed herein as if each and every such subcombination of the chemical groups were individually and explicitly disclosed herein.

[0097]

[0097] Aspects and embodiments described in this specification as "comprising" are understood to include embodiments "consisting of" and "consisting essentially of."

[0098] As used in this specification and the appended claims, the singular forms "a," "an," and "the" include plural referents unless specifically indicated otherwise or clear from the context. For example, "a" excipient includes one or more excipients.

[0099]

[0099] The expression "about" a value includes 90% to 110% of that value. For example, about 50 billion cells refers to 45 to 55 billion cells, including 50 billion cells. For example, a temperature of "about 100 degrees" refers to a temperature of about 90 degrees to about 110 degrees.

[0100]

[0100] When a numerical range of compounds is given, all compounds falling within the numerical limits are included, including any indicated "a" and "b", unless expressly excluded. For example, the expression "compounds 41-43" refers to compounds 41, 42, and 43.

[0101] II. Compounds In one embodiment, a compound of formula (I) [ka] or a tautomer thereof, a stereoisomer thereof, or a pharma- ceutically acceptable salt thereof, wherein: [ka] teeth, [ka] and; Z1 is CH or N; Z 2 is CH or N; R 1 , H, C 1 ~C 6 Alkyl or C 1 ~C 6 is haloalkyl; R 2 , H, C 1 ~C 6 Alkyl, C 1 ~C 6 Haloalkyl or C 3 ~C 6 is cycloalkyl; R 3 -CF 3 or cyclopropyl; R 4 -CF 3 or cyclopropyl; n is 0 or 1; X is H, C 1 ~C 6 Alkyl, C 1 ~C 6 haloalkyl, or [ka] and; R 5 , H, C 1 ~C 6 Alkyl, C 1 ~C 6 Haloalkyl, C 1 ~C 6 Alkyl-OH or C 1 ~C 6 Alkyl-CN; R 6 is a monocyclic C 3 ~C 6 Cycloalkyl, fused bicyclic C 4 ~C 8 Cycloalkyl, Bridged Bicyclic C 4 ~C 8 Cycloalkyl, spiro bicyclic C 5 ~C 8cycloalkyl, or 5- or 6-membered heterocyclyl, each of which is selected from 1 to 5 R 7 is optionally substituted by groups; or R 5 and R 6 together with the nitrogen atom to which they are attached form a 5-10 membered monocyclic, fused bicyclic, or bridged heterocyclyl, or a 5-10 membered monocyclic or bicyclic heteroaryl, each of which optionally contains 1-2 additional heteroatoms selected from the group consisting of N and O, and each of which optionally contains 1-5 R 8 optionally substituted by groups; Each R 7 are independently, halo, C 1 ~C 6 Alkyl, C 1 ~C 6 Haloalkyl, C 1 ~C 6 Alkyl-OH or C 1 ~C 6 Alkyl-CN; Each R 8 are independently 1 ~C 6 Alkyl, C 1 ~C 6 Haloalkyl, C 1 ~C 6 Alkyl-OH, -CN, C 1 ~C 6 Alkyl-CN, -(C 1 ~C 6 alkylene)-O-(C 1 ~C 6 alkyl), hydroxy, or halo; or two R attached to the same carbon atom 8 The groups, together with the carbon atoms to which they are attached, form spiro C 3 ~C 6 forming a cycloalkyl or spiro 5-6 membered heterocyclyl; and Each R 9 are independently H, C 1 ~C 6 Alkyl, C 1 ~C6 Haloalkyl or C 1 ~C 6 wherein R is alkyl-OH.

[0102]

[0102] In some embodiments, [ka] (i.e., the ring A portion) is [ka] In some embodiments, Z 1 is CH. In another embodiment, Z 1 is N. In some embodiments, R 3 -CF 3 In another embodiment, R 3 is cyclopropyl. In some embodiments, the Ring A moiety is [ka] In some embodiments, Z 2 is CH. In another embodiment, Z 2 is N. In some embodiments, R 4 -CF 3 In another embodiment, R 4 is cyclopropyl. In some embodiments, the Ring A moiety is [ka] In some embodiments, the Ring A moiety is selected from the group consisting of: [ka] In some embodiments, the Ring A moiety is [ka] In some embodiments, the Ring A moiety is [ka] In some embodiments, the Ring A moiety is [ka] In some embodiments, the Ring A moiety is [ka] In some embodiments, the Ring A moiety is [ka] In some embodiments, the Ring A moiety is [ka] In some embodiments, the Ring A moiety is [ka] It is.

[0103] In some embodiments, R 1 , H, C 1 ~C 6 Alkyl or C 1 ~C 6 In some embodiments, R 1 , H, C 1 ~C 3 Alkyl or C 1 ~C 3 In some embodiments, R 1 -H, -CH 3 , or -CF 3 In some embodiments, R 1is H.

[0104] In some embodiments, R 1 is C 1 ~C 6 In some embodiments, R 1 is C 1 ~C 3 In some embodiments, R 1 is methyl, ethyl, n-propyl, or isopropyl. 1 -CH 3 It is.

[0105] In some embodiments, R 1 is C 1 ~C 6 In some embodiments, R 1 is a C containing 1 to 13 halogen atoms 1 ~C 6 In some embodiments, R 1 is a C containing 1 to 7 halogen atoms 1 ~C 6 In some embodiments, R 1 is C 1 ~C 3 In some embodiments, R 1 is a C containing 1 to 7 halogen atoms 1 ~C 3 In some embodiments, R 1 C containing 1 to 5 halogen atoms 1 ~C 2 In some embodiments, the halogen atoms are independently selected from the group consisting of chloro, bromo, and fluoro atoms. In some embodiments, the halogen atoms are independently selected from the group consisting of chloro and fluoro atoms. In some embodiments, the halogen atoms are all fluoro atoms. In some embodiments, the halogen atoms are a combination of chloro and fluoro atoms. In some embodiments, R 1-CF 3 , -CCl 3 , -CF 2 Cl, -CFCl 2 , -CHF 2 , -CH 2 F, -CHCl 2 , -CH 2 F, or -CHFCl. In some embodiments, R 1 -CF 3 It is.

[0106] In some embodiments, R 2 , H, C 1 ~C 6 Alkyl, C 1 ~C 6 Haloalkyl or C 3 ~C 6 In some embodiments, R 2 , H, C 1 ~C 3 Alkyl, C 1 ~C 3 Haloalkyl or C 3 ~C 4 In some embodiments, R 2 -H, -CH 3 , -CF 3 , -CHF 2 , -CH 2 F, or cyclopropyl.

[0107] In some embodiments, R 2 is H.

[0108] In some embodiments, R 2 is C 1 ~C 6 In some embodiments, R 2 is C 1 ~C 3 In some embodiments, R 2 is methyl, ethyl, n-propyl, or isopropyl. 2 -CH3 It is.

[0109] In some embodiments, R 2 is C 1 ~C 6 In some embodiments, R 2 is a C containing 1 to 7 halogen atoms 1 ~C 6 In some embodiments, R 2 is C 1 ~C 3 In some embodiments, R 2 is a C containing 1 to 7 halogen atoms 1 ~C 3 In some embodiments, R 2 C containing 1 to 5 halogen atoms 1 ~C 2 In some embodiments, the halogen atoms are independently selected from the group consisting of chloro, bromo, and fluoro atoms. In some embodiments, the halogen atoms are independently selected from the group consisting of chloro and fluoro atoms. In some embodiments, the halogen atoms are all fluoro atoms. In some embodiments, the halogen atoms are a combination of chloro and fluoro atoms. In some embodiments, R 2 -CF 3 , -CCl 3 , -CF 2 Cl, -CFCl 2 , -CHF 2 , -CH 2 F, -CHCl 2 , -CH 2 F, or -CHFCl. In some embodiments, R 2 -CF 3 , -CHF 2 , or -CH 2 It's F.

[0110] In some embodiments, R 2 is C 3 ~C 6In some embodiments, R 2 is C 3 ~C 5 In some embodiments, R 2 is C 3 ~C 4 In some embodiments, R 2 is cyclopropyl, cyclobutyl, or cyclopentyl. 2 is cyclopropyl.

[0111] In some embodiments, n is 1. In some embodiments, n is 0.

[0112] In some embodiments, X is H, C 1 ~C 6 Alkyl, C 1 ~C 6 haloalkyl, or [ka] In some embodiments, X is H. In some embodiments, X is C 1 ~C 3 Alkyl or C 1 ~C 3 In some embodiments, X is -CH 3 or -CF 3 It is.

[0113] In some embodiments, X is C 1 ~C 6 In some embodiments, X is C 1 ~C 3 In some embodiments, X is methyl, ethyl, n-propyl, or isopropyl. In some embodiments, X is -CH 3 It is.

[0114] In some embodiments, X is C1 ~C 6 In some embodiments, X is a C alkyl group containing 1 to 7 halogen atoms. 1 ~C 6 In some embodiments, X is C 1 ~C 3 In some embodiments, X is a C alkyl group containing 1 to 7 halogen atoms. 1 ~C 3 In some embodiments, X is a C alkyl group containing 1 to 5 halogen atoms. 1 ~C 2 In some embodiments, the halogen atoms are independently selected from the group consisting of chloro, bromo, and fluoro atoms. In some embodiments, the halogen atoms are independently selected from the group consisting of chloro and fluoro atoms. In some embodiments, the halogen atoms are all fluoro atoms. In some embodiments, the halogen atoms are a combination of chloro and fluoro atoms. In some embodiments, X is -CF 3 , -CCl 3 , -CF 2 Cl, -CFCl 2 , -CHF 2 , -CH 2 F, -CHCl 2 , -CH 2 F, or -CHFCl. In some embodiments, X is -CF 3 It is.

[0115] In some embodiments, X is [ka] It is.

[0116] In some embodiments, R 5 , H, C 1 ~C 6 Alkyl, C 1 ~C 6 Haloalkyl, C 1 ~C6 Alkyl-OH or C 1 ~C 6 In some embodiments, R 5 , H, C 1 ~C 3 Alkyl or C 1 ~C 3 In some embodiments, R 5 -H, -CH 3 , -CF 3 , -CH 2 CN or -CH 2 In some embodiments, R 5 is H.

[0117] In some embodiments, R 5 is C 1 ~C 6 In some embodiments, R 5 is C 1 ~C 3 In some embodiments, R 5 is methyl, ethyl, n-propyl, or isopropyl. 5 -CH 3 It is.

[0118] In some embodiments, R 5 is C 1 ~C 6 In some embodiments, R 5 is a C containing 1 to 7 halogen atoms 1 ~C 6 In some embodiments, R 5 is C 1 ~C 3 In some embodiments, R 5 is a C containing 1 to 7 halogen atoms 1 ~C 3 In some embodiments, R 5 C containing 1 to 5 halogen atoms 1 ~C2 In some embodiments, the halogen atoms are independently selected from the group consisting of chloro, bromo, and fluoro atoms. In some embodiments, the halogen atoms are independently selected from the group consisting of chloro and fluoro atoms. In some embodiments, the halogen atoms are all fluoro atoms. In some embodiments, the halogen atoms are a combination of chloro and fluoro atoms. In some embodiments, R 5 -CF 3 , -CCl 3 , -CF 2 Cl, -CFCl 2 , -CHF 2 , -CH 2 F, -CHCl 2 , -CH 2 F, or -CHFCl. In some embodiments, R 5 -CF 3 It is.

[0119] In some embodiments, R 5 is C 1 ~C 6 In some embodiments, R 5 is C 1 ~C 3 In some embodiments, R 5 -CH 2 OH, -CH 2 CH 2 -OH, -CH 2 CH 2 CH 2 -OH or -C(CH 3 ) 2 In some embodiments, R 5 -CH 2 It is OH.

[0120] In some embodiments, R 5 is C 1 ~C 6 In some embodiments, R 5 is C 1 ~C3 In some embodiments, R 5 -CH 2 CN, -CH 2 CH 2 -CN, -CH 2 CH 2 CH 2 -CN or -C(CH 3 ) 2 In some embodiments, R 5 -CH 2 It is CN.

[0121] In some embodiments, R 6 is a monocyclic C 3 ~C 6 Cycloalkyl, fused bicyclic C 4 ~C 8 Cycloalkyl, Bridged Bicyclic C 4 ~C 8 Cycloalkyl, spiro bicyclic C 5 ~C 8 cycloalkyl, or 5- or 6-membered heterocyclyl, each of which is selected from 1 to 5 R 7 is optionally substituted by a group.

[0122] In some embodiments, R 6 is 1 to 5 R 7 Monocyclic C optionally substituted with a group 3 ~C 6 In some embodiments, R 6 is 1 to 5 R 7 Monocyclic C optionally substituted with a group 3 ~C 5 In some embodiments, R 6 is 1 to 5 R 7 Monocyclic C optionally substituted with a group 4 ~C 5 In some embodiments, R 6 is cyclopropyl, cyclobutyl, or cyclopentyl, each of which is selected from 1 to 5 R 7In some embodiments, R 6 is cyclobutyl or cyclopentyl, each of which is selected from 1 to 5 R 7 In some embodiments, R 6 is 1 to 5 R 7 Monocyclic C substituted by a group 3 ~C 6 In some embodiments, R 6 is one R 7 Monocyclic C substituted by a group 3 ~C 6 In some embodiments, R 6 is two R 7 Monocyclic C substituted by a group 3 ~C 6 In some embodiments, R 6 is 3 R 7 Monocyclic C substituted by a group 3 ~C 6 In some embodiments, R 6 is 4 R 7 Monocyclic C substituted by a group 3 ~C 6 In some embodiments, R 6 is 5 R 7 Monocyclic C substituted by a group 3 ~C 6 In some embodiments, R 6 is an unsubstituted monocyclic C 3 ~C 6 It is cycloalkyl.

[0123] In some embodiments, R 6 is 1 to 5 R 7 A fused bicyclic C optionally substituted with a group 4 ~C 8 In some embodiments, R 6 is 1 to 5 R 7A fused bicyclic C optionally substituted with a group 4 ~C 7 In some embodiments, R 6 is 1 to 5 R 7 A fused bicyclic C optionally substituted with a group 5 ~C 8 In some embodiments, R 6 is 1 to 5 R 7 A fused bicyclic ring C substituted with a group 4 ~C 8 In some embodiments, R 6 is one R 7 A fused bicyclic ring C substituted with a group 4 ~C 8 In some embodiments, R 6 is two R 7 A fused bicyclic ring C substituted with a group 4 ~C 8 In some embodiments, R 6 is 3 R 7 A fused bicyclic ring C substituted with a group 4 ~C 8 In some embodiments, R 6 is 4 R 7 A fused bicyclic ring C substituted with a group 4 ~C 8 In some embodiments, R 6 is 5 R 7 A fused bicyclic ring C substituted with a group 4 ~C 8 In some embodiments, R 6 is an unsubstituted fused bicyclic C 4 ~C 8 In some embodiments, R 6 teeth, [ka] [In the formula, -(R 7 )0-5 represents optional substitution of either one of the two rings constituting the fused bicyclic ring system. In some embodiments, both rings of the fused bicyclic ring system are substituted. In some embodiments, one of the two rings of the fused bicyclic ring system is substituted, and the other ring is unsubstituted. In some embodiments, both rings of the fused bicyclic ring system are unsubstituted.

[0124] In some embodiments, R 6 is 1 to 5 R 7 A bridged bicyclic C optionally substituted with a group 4 ~C 8 In some embodiments, R 6 is 1 to 5 R 7 A bridged bicyclic C optionally substituted with a group 5 ~C 8 In some embodiments, R 6 is 1 to 5 R 7 Bridged bicyclic C substituted with a group 4 ~C 8 In some embodiments, R 6 is one R 7 Bridged bicyclic C substituted with a group 4 ~C 8 In some embodiments, R 6 is two R 7 Bridged bicyclic C substituted with a group 4 ~C 8 In some embodiments, R 6 is 3 R 7 Bridged bicyclic C substituted with a group 4 ~C 8 In some embodiments, R 6 is 4 R 7 Bridged bicyclic C substituted with a group 4 ~C 8 In some embodiments, R 6 is 5 R 7Bridged bicyclic C substituted with a group 4 ~C 8 In some embodiments, R 6 is an unsubstituted bridged bicyclic C 4 ~C 8 In some embodiments, R 6 teeth, [ka] [In the formula, -(R 7 ) 0-5 represents optional substitution at any of the carbon atoms that make up the bridged bicyclic ring system. 4 ~C 8 The bridging portion of the cycloalkyl is C 1 ~C 3 In some embodiments, the bridged bicyclic C 4 ~C 8 The bridging portion of the cycloalkyl is -CH 2 -or-CH 2 CH 2 In some embodiments, the bridged bicyclic C 4 ~C 8 The bridging portion of the cycloalkyl is -CH 2 -It is.

[0125] In some embodiments, R 6 is 1 to 5 R 7 spiro bicyclic C optionally substituted with a group 5 ~C 8 In some embodiments, R 6 is 1 to 5 R 7 spiro bicyclic C optionally substituted with a group 6 ~C 8 In some embodiments, R 6 is 1 to 5 R 7 spiro bicyclic C optionally substituted with a group 5 ~C 7 In some embodiments, R6 is 1 to 5 R 7 Spiro bicyclic C substituted by groups 5 ~C 8 In some embodiments, R 6 is one R 7 Spiro bicyclic C substituted by groups 5 ~C 8 In some embodiments, R 6 is two R 7 Spiro bicyclic C substituted by groups 5 ~C 8 In some embodiments, R 6 is 3 R 7 Spiro bicyclic C substituted by groups 5 ~C 8 In some embodiments, R 6 is 4 R 7 Spiro bicyclic C substituted by groups 5 ~C 8 In some embodiments, R 6 is 5 R 7 Spiro bicyclic C substituted by groups 5 ~C 8 In some embodiments, R 6 is an unsubstituted spiro bicyclic C 5 ~C 8 In some embodiments, R 6 teeth, [ka] [In the formula, -(R 7 ) 0-5 represents optional substitution of either one of the two rings constituting the spiro-bicyclic ring system. In some embodiments, both rings of the spiro-bicyclic ring system are substituted. In some embodiments, one of the two rings of the spiro-bicyclic ring system is substituted and the other ring is unsubstituted. In some embodiments, both rings of the spiro-bicyclic ring system are unsubstituted.

[0126] In some embodiments, R 6 is 1 to 5 R 7 In some embodiments, R is a 5-6 membered heterocyclyl optionally substituted by a group. 6 is 1 to 5 R 7 In some embodiments, R is a 5-6 membered heterocyclyl substituted by a group. 6 is one R 7 In some embodiments, R is a 5-6 membered heterocyclyl substituted by a group. 6 is two R 7 In some embodiments, R is a 5-6 membered heterocyclyl substituted by a group. 6 is 3 R 7 In some embodiments, R is a 5-6 membered heterocyclyl substituted by a group. 6 is 4 R 7 In some embodiments, R is a 5-6 membered heterocyclyl substituted by a group. 6 is 5 R 7 In some embodiments, R is a 5-6 membered heterocyclyl substituted by a group. 6 is an unsubstituted 5-6 membered heterocyclyl. In some embodiments, the 5-6 membered heterocyclyl contains 1 to 3 heteroatoms selected from the group consisting of nitrogen, oxygen, and sulfur. In some embodiments, the 5-6 membered heterocyclyl contains 1 nitrogen atom. In some embodiments, the 5-6 membered heterocyclyl contains 2 nitrogen atoms. In some embodiments, the 5-6 membered heterocyclyl contains 1 oxygen atom. In some embodiments, the 5-6 membered heterocyclyl contains 2 oxygen atoms. In some embodiments, the 5-6 membered heterocyclyl contains 1 oxygen atom and 1 nitrogen atom. In some embodiments, the 5-6 membered heterocyclyl contains 1 sulfur atom. In some embodiments, the 5-6 membered heterocyclyl contains 1 nitrogen atom and 1 sulfur atom. In some embodiments, the 5-6 membered heterocyclyl contains 1 nitrogen atom and 1 sulfur atom. In some embodiments, R 6is tetrahydrofuranyl, dioxolanyl, pyrrolidinyl, pyrazolidinyl, piperidinyl, isoxazolidinyl, or tetrahydropyranyl, each of which is selected from 1 to 5 R 7 In some embodiments, R 6 teeth, [ka] It is.

[0127] In some embodiments, R 6 teeth, [ka] In some embodiments, R 6 teeth, [ka] In some embodiments, R 6 teeth, [ka] In some embodiments, R 6 teeth, [ka] In some embodiments, R 6 teeth, [ka] In some embodiments, R 6 teeth, [ka] It is.

[0128] In some embodiments, each R 7 are independently, halo, C 1 ~C 6 Alkyl, C 1 ~C 6 Haloalkyl, C 1 ~C 6 Alkyl-OH or C 1 ~C 6 In some embodiments, each R 7 are independently, halo, C 1 ~C 3 Alkyl, C 1 ~C 3 Haloalkyl, C 1 ~C 3 Alkyl-OH or C 1 ~C 3 In some embodiments, each R 7 are independently fluoro, -CH 3 , -CF 3 , -CH 2 OH or -CH 2 It is CN.

[0129] In some embodiments, R 7 is halo. In some embodiments, R 7 is chloro, fluoro, or bromo. 7 is chloro or fluoro. In some embodiments, R 7 is fluoro.

[0130] In some embodiments, R 7 is C 1 ~C 6 In some embodiments, R 7 is C 1 ~C 3 In some embodiments, R 7 is methyl, ethyl, n-propyl, or isopropyl. 7 -CH 3 It is.

[0131] In some embodiments, R 7 is C 1 ~C 6 In some embodiments, R 7 is a C containing 1 to 7 halogen atoms 1 ~C 6 In some embodiments, R 7 is C 1 ~C 3 In some embodiments, R 7 is a C containing 1 to 7 halogen atoms 1 ~C 3 In some embodiments, R 7 C containing 1 to 5 halogen atoms 1 ~C 2 In some embodiments, the halogen atoms are independently selected from the group consisting of chloro, bromo, and fluoro atoms. In some embodiments, the halogen atoms are independently selected from the group consisting of chloro and fluoro atoms. In some embodiments, the halogen atoms are all fluoro atoms. In some embodiments, the halogen atoms are a combination of chloro and fluoro atoms. In some embodiments, R 7 -CF 3 , -CCl 3 , -CF 2 Cl, -CFCl 2 , -CHF 2 , -CH 2 F, -CHCl 2 , -CH 2 F, or -CHFCl. In some embodiments, R 7 -CF 3 It is.

[0132] In some embodiments, R 7 is C 1 ~C 6 In some embodiments, R 7 is C 1 ~C 3In some embodiments, R 7 -CH 2 OH, -CH 2 CH 2 -OH, -CH 2 CH 2 CH 2 -OH or -C(CH 3 ) 2 In some embodiments, R 7 -CH 2 It is OH.

[0133] In some embodiments, R 7 is C 1 ~C 6 In some embodiments, R 7 is C 1 ~C 3 In some embodiments, R 7 -CH 2 CN, -CH 2 CH 2 -CN, -CH 2 CH 2 CH 2 -CN or -C(CH 3 ) 2 In some embodiments, R 7 -CH 2 It is CN.

[0134] In some embodiments, R 5 and R 6 together with the nitrogen atom to which they are attached form a 5-10 membered monocyclic, fused bicyclic, or bridged heterocyclyl, or a 5-10 membered monocyclic or bicyclic heteroaryl, each of which optionally contains 1-2 additional heteroatoms selected from the group consisting of N and O, and each of which optionally contains 1-5 R 8 is optionally substituted by a group.

[0135] In some embodiments, R5 and R 6 Together with the nitrogen atom to which they are attached, they are one to five R 8 In some embodiments, R 5 and R 6 Together with the nitrogen atom to which they are attached, they are one to five R 8 In some embodiments, R 5 and R 6 Together with the nitrogen atom to which they are attached, they are one to five R 8 In some embodiments, the 5- to 10-membered monocyclic heterocyclyl is optionally substituted by 1 to 5 R 8 In some embodiments, the 5-10 membered monocyclic heterocyclyl is substituted by one R 8 In some embodiments, the 5-10 membered monocyclic heterocyclyl is substituted by two R 8 In some embodiments, the 5-10 membered monocyclic heterocyclyl is substituted with three R 8 In some embodiments, the 5-10 membered monocyclic heterocyclyl is substituted by 4 R 8 In some embodiments, the 5-10 membered monocyclic heterocyclyl is substituted with 5 R 8 In some embodiments, the 5-10 membered monocyclic heterocyclyl is unsubstituted. In some embodiments, the 5-10 membered monocyclic heterocyclyl optionally contains 1 to 2 additional heteroatoms selected from the group consisting of N and O. In some embodiments, the 5-10 membered monocyclic heterocyclyl contains 1 nitrogen atom. In some embodiments, the 5-10 membered monocyclic heterocyclyl contains 1 nitrogen atom and 1 oxygen atom. In some embodiments, the 5-10 membered monocyclic heterocyclyl contains 2 nitrogen atoms.

[0136] In some embodiments, R 5 and R 6 Together with the nitrogen atom to which they are attached, they are one to five R 8 In some embodiments, R 5 and R 6 Together with the nitrogen atom to which they are attached, they are one to five R 8 In some embodiments, the 5- to 10-membered fused bicylic heterocyclyl is optionally substituted by 1 to 5 R 8 In some embodiments, the 5-10 membered fused bicylic heterocyclyl is substituted with one R 8 In some embodiments, the 5-10 membered fused bicylic heterocyclyl is substituted with two R 8 In some embodiments, the 5-10 membered fused bicylic heterocyclyl is substituted with three R 8 In some embodiments, the 5-10 membered fused bicylic heterocyclyl is substituted with four R 8 In some embodiments, the 5- to 10-membered fused bicylic heterocyclyl is substituted with 5 R 8In some embodiments, the 5-10 membered fused bicylic heterocyclyl is unsubstituted. In some embodiments, the 5-10 membered fused bicylic heterocyclyl optionally contains 1-2 additional heteroatoms selected from the group consisting of N and O. In some embodiments, the 5-10 membered fused bicylic heterocyclyl contains 1 nitrogen atom. In some embodiments, the 5-10 membered fused bicylic heterocyclyl contains 1 nitrogen atom and 1 oxygen atom. In some embodiments, the 5-10 membered fused bicylic heterocyclyl contains 2 nitrogen atoms. In some embodiments, the 5-10 membered fused bicylic heterocyclyl contains 1 saturated ring fused with a partially unsaturated ring. In some embodiments, a 5-10 membered fused bicylic heterocyclyl contains one saturated ring fused to a second saturated ring. In some embodiments, a 5-10 membered fused bicylic heterocyclyl contains one partially unsaturated ring fused to a second partially unsaturated ring.

[0137] In some embodiments, R 5 and R 6 Together with the nitrogen atom to which they are attached, they are one to five R 8 In some embodiments, R 5 and R 6 Together with the nitrogen atom to which they are attached, they are one to five R 8 In some embodiments, R 5 and R 6 Together with the nitrogen atom to which they are attached, they are one to five R 8 In some embodiments, the 5- to 10-membered bridged heterocyclyl is optionally substituted with 1 to 5 R 8In some embodiments, the 5- to 10-membered bridged heterocyclyl is substituted with one R 8 In some embodiments, the 5- to 10-membered bridged heterocyclyl is substituted with two R 8 In some embodiments, the 5- to 10-membered bridged heterocyclyl is substituted with three R 8 In some embodiments, the 5- to 10-membered bridged heterocyclyl is substituted with four R 8 In some embodiments, the 5- to 10-membered bridged heterocyclyl is substituted with 5 R 8 In some embodiments, the 5- to 10-membered bridged heterocyclyl is unsubstituted. In some embodiments, the 5- to 10-membered bridged heterocyclyl optionally contains 1 to 2 additional heteroatoms selected from the group consisting of N and O. In some embodiments, the 5- to 10-membered bridged heterocyclyl contains 1 nitrogen atom. In some embodiments, the 5- to 10-membered bridged heterocyclyl contains 1 nitrogen atom and 1 oxygen atom. In some embodiments, the 5- to 10-membered bridged heterocyclyl contains 2 nitrogen atoms. In some embodiments, the bridging portion of the 5- to 10-membered bridged heterocyclyl is C 1 ~C 3 In some embodiments, the bridge portion of the 5- to 10-membered bridged heterocyclyl is -CH 2 In some embodiments, the bridge portion of the 5- to 10-membered bridged heterocyclyl is -CH 2 CH 2 -It is.

[0138] In some embodiments, R 5 and R 6 Together with the nitrogen atom to which they are attached, they are one to five R 8 In some embodiments, R 5 and R 6 Together with the nitrogen atom to which they are attached, they are one to five R 8In some embodiments, R 5 and R 6 Together with the nitrogen atom to which they are attached, they are one to five R 8 In some embodiments, the 5- to 10-membered monocyclic heteroaryl is optionally substituted with 1 to 5 R 8 In some embodiments, the 5-10 membered monocyclic heteroaryl is substituted with one R 8 In some embodiments, the 5-10 membered monocyclic heteroaryl is substituted with two R 8 In some embodiments, the 5-10 membered monocyclic heteroaryl is substituted with three R 8 In some embodiments, the 5-10 membered monocyclic heteroaryl is substituted with 4 R 8 In some embodiments, the 5-10 membered monocyclic heteroaryl is substituted with 5 R 8 In some embodiments, the 5-10 membered monocyclic heteroaryl is unsubstituted. In some embodiments, the 5-10 membered monocyclic heteroaryl optionally contains 1 to 2 additional heteroatoms selected from the group consisting of N and O. In some embodiments, the 5-10 membered monocyclic heteroaryl contains 1 nitrogen atom. In some embodiments, the 5-10 membered monocyclic heteroaryl contains 1 nitrogen atom and 1 oxygen atom. In some embodiments, the 5-10 membered monocyclic heteroaryl contains 2 nitrogen atoms.

[0139] In some embodiments, R 5 and R 6 Together with the nitrogen atom to which they are attached, they are one to five R 8 In some embodiments, R 5 and R 6Together with the nitrogen atom to which they are attached, they are one to five R 8 In some embodiments, the 5-10 membered bicyclic heteroaryl is optionally substituted with 1-5 R 8 In some embodiments, the 5-10 membered bicyclic heteroaryl is substituted with one R 8 In some embodiments, the 5-10 membered bicyclic heteroaryl is substituted with two R 8 In some embodiments, the 5-10 membered bicyclic heteroaryl is substituted with three R 8 In some embodiments, the 5-10 membered bicyclic heteroaryl is substituted with 4 R 8 In some embodiments, the 5-10 membered bicyclic heteroaryl is substituted with 5 R 8 In some embodiments, the 5-10 membered bicyclic heteroaryl is unsubstituted. In some embodiments, the 5-10 membered bicyclic heteroaryl optionally contains 1-2 additional heteroatoms selected from the group consisting of N and O. In some embodiments, the 5-10 membered bicyclic heteroaryl contains 1 nitrogen atom. In some embodiments, the 5-10 membered bicyclic heteroaryl contains 1 nitrogen atom and 1 oxygen atom. In some embodiments, the 5-10 membered bicyclic heteroaryl contains 2 nitrogen atoms. In some embodiments, the 5-10 membered bicyclic heteroaryl contains 1 aromatic ring fused to a saturated ring. In some embodiments, the 5-10 membered bicyclic heteroaryl contains 1 aromatic ring fused to a second aromatic ring. In some embodiments, the 5-10 membered bicyclic heteroaryl contains 1 aromatic ring fused to a partially unsaturated ring.

[0140] In some embodiments, R 5 and R 6 together with the nitrogen atom to which they are attached, [ka] [In the formula, -(R 8 ) 0-5 represents an optional substitution of either of the two rings constituting a fused or bridged bicyclic ring system, or any carbon atom of a monocyclic ring system. In some embodiments, both rings of a fused or bridged bicyclic ring system are substituted. In some embodiments, one of the two rings of a fused or bridged bicyclic ring system is substituted and the other ring is unsubstituted. In some embodiments, both rings of a fused or bridged bicyclic ring system are unsubstituted.

[0141] In some embodiments, R 5 and R 6 together with the nitrogen atom to which they are attached, [ka] In some embodiments, R 5 and R 6 together with the nitrogen atom to which they are attached, [ka] In some embodiments, R 5 and R 6 together with the nitrogen atom to which they are attached, [ka] In some embodiments, R 5 and R 6 together with the nitrogen atom to which they are attached, [ka] In some embodiments, R 5 and R 6together with the nitrogen atom to which they are attached, [ka] In some embodiments, R 5 and R 6 together with the nitrogen atom to which they are attached, [ka] In some embodiments, R 5 and R 6 together with the nitrogen atom to which they are attached, [ka] In some embodiments, R 5 and R 6 together with the nitrogen atom to which they are attached, [ka] In some embodiments, R 5 and R 6 together with the nitrogen atom to which they are attached, [ka] In some embodiments, R 5 and R 6 together with the nitrogen atom to which they are attached, [ka] Form.

[0142] In some embodiments, each R 8 are independently 1 ~C 6 Alkyl, C 1~C 6 Haloalkyl, C 1 ~C 6 Alkyl-OH, -CN, C 1 ~C 6 Alkyl-CN, -(C 1 ~C 6 alkylene)-O-(C 1 ~C 6 alkyl), hydroxy, or halo. 8 are independently 1 ~C 3 Alkyl, C 1 ~C 3 Haloalkyl, C 1 ~C 3 Alkyl-OH, -CN, C 1 ~C 3 Alkyl-CN, -(C 1 ~C 3 alkylene)-O-(C 1 ~C 3 alkyl), hydroxy, or halo. 8 are independently -CH 3 , -CH 2 CH 3 , -CF 3 , -CH 2 OH, -CN, -CH 2 CN, -CH 2 -O-CH 3 , hydroxy, or F.

[0143] In some embodiments, R 8 is C 1 ~C 6 In some embodiments, R 8 is C 1 ~C 3 In some embodiments, R 8 is methyl, ethyl, n-propyl, or isopropyl. 8 -CH 3 or -CH 2 CH 3 It is.

[0144] In some embodiments, R 8 is C 1 ~C 6 In some embodiments, R 8 is a C containing 1 to 7 halogen atoms 1 ~C 6 In some embodiments, R 8 is C 1 ~C 3 In some embodiments, R 8 is a C containing 1 to 7 halogen atoms 1 ~C 3 In some embodiments, R 8 C containing 1 to 5 halogen atoms 1 ~C 2 In some embodiments, the halogen atoms are independently selected from the group consisting of chloro, bromo, and fluoro atoms. In some embodiments, the halogen atoms are independently selected from the group consisting of chloro and fluoro atoms. In some embodiments, the halogen atoms are all fluoro atoms. In some embodiments, the halogen atoms are a combination of chloro and fluoro atoms. In some embodiments, R 8 -CF 3 , -CCl 3 , -CF 2 Cl, -CFCl 2 , -CHF 2 , -CH 2 F, -CHCl 2 , -CH 2 F, or -CHFCl. In some embodiments, R 8 -CF 3 It is.

[0145] In some embodiments, R 8 is C 1 ~C 6 In some embodiments, R 8 is C 1 ~C 3 In some embodiments, R8 -CH 2 OH, -CH 2 CH 2 -OH, -CH 2 CH 2 CH 2 -OH or -C(CH 3 ) 2 In some embodiments, R 8 -CH 2 It is OH.

[0146] In some embodiments, R 8 In some embodiments, R 8 is C 1 ~C 6 In some embodiments, R 8 is C 1 ~C 3 In some embodiments, R 8 -CH 2 CN, -CH 2 CH 2 -CN, -CH 2 CH 2 CH 2 -CN or -C(CH 3 ) 2 In some embodiments, R 8 -CH 2 It is CN.

[0147] In some embodiments, R 8 is -(C 1 ~C 6 alkylene)-O-(C 1 ~C 6 In some embodiments, R 8 is -(C 1 ~C 3 alkylene)-O-(C 1 ~C 3 In some embodiments, R 8 is -(C 1 ~C 2 alkylene)-O-(C 1 ~C2 In some embodiments, R 8 -CH 2 -O-CH 3 , -CH 2 -O-CH 2 CH 3 , -CH 2 CH 2 -O-CH 2 CH 3 , or -CH 2 CH 2 -O-CH 3 In some embodiments, R 8 -CH 2 -O-CH 3 It is.

[0148] In some embodiments, R 8 is hydroxy.

[0149] In some embodiments, R 8 is halo. In some embodiments, R 8 is chloro, fluoro, or bromo. 8 is chloro or fluoro. In some embodiments, R 8 is fluoro.

[0150] In some embodiments, two R 8 The groups, together with the carbon atoms to which they are attached, form spiro C 3 ~C 6 In some embodiments, two R 8 The groups, together with the carbon atoms to which they are attached, form spiro C 3 ~C 4 In some embodiments, two R 8 The groups together with the carbon atom to which they are attached form a spirocyclopropyl.

[0151] In some embodiments, two R 8 The groups, together with the carbon atoms to which they are attached, form spiro C 3 ~C 6 In some embodiments, two R attached to the same carbon atom form a cycloalkyl. 8 The groups, together with the carbon atoms to which they are attached, form spiro C 3 ~C 5 In some embodiments, two R attached to the same carbon atom form a cycloalkyl. 8 In some embodiments, the R groups taken together with the carbon atom to which they are attached form a spirocyclopropyl, cyclobutyl, or cyclopentyl. 8 The groups together with the carbon atom to which they are attached form a spirocyclopropyl.

[0152] In some embodiments, two R 8 The groups together with the carbon atom to which they are attached form a spiro 5-6 membered heterocyclyl. In some embodiments, the spiro 5-6 membered heterocyclyl contains 1 to 3 heteroatoms selected from the group consisting of nitrogen, oxygen, and sulfur. In some embodiments, the spiro 5-6 membered heterocyclyl contains 1 nitrogen atom. In some embodiments, the spiro 5-6 membered heterocyclyl contains 2 nitrogen atoms. In some embodiments, the spiro 5-6 membered heterocyclyl contains 1 oxygen atom. In some embodiments, the spiro 5-6 membered heterocyclyl contains 2 oxygen atoms. In some embodiments, the spiro 5-6 membered heterocyclyl contains 1 nitrogen atom and 1 oxygen atom. In some embodiments, the spiro 5-6 membered heterocyclyl is pyrrolidinyl, tetrahydrofuranyl, piperidinyl, tetrahydropyranyl, or thiolanyl.

[0153] In some embodiments, each R9 are independently H, C 1 ~C 6 Alkyl, C 1 ~C 6 Haloalkyl or C 1 ~C 6 In some embodiments, each R 9 are independently H, C 1 ~C 3 Alkyl, C 1 ~C 3 Haloalkyl or C 1 ~C 3 In some embodiments, each R 9 are independently H, -CH 3 , -CF 3 , or -CH 2 It is OH.

[0154] In some embodiments, R 9 is H. In some embodiments, at least one R 9 is H. In some embodiments, one R 9 is H, and the other R 9 is C 1 ~C 6 Alkyl, C 1 ~C 6 Haloalkyl or C 1 ~C 6 In some embodiments, one R 9 is H, and the other R 9 is C 1 ~C 6 In some embodiments, one R 9 is H, and the other R 9 is C 1 ~C 6 In some embodiments, one R 9 is H, and the other R 9 Ha-CH 3 In some embodiments, R 9 Both groups are H.

[0155] In some embodiments, R 9 is C 1 ~C 6 In some embodiments, R 9 is C 1 ~C 3 In some embodiments, R 9 is methyl, ethyl, n-propyl, or isopropyl. 9 -CH 3 In some embodiments, R 9 Both groups are independently C 1 ~C 6 In some embodiments, R 9 Both groups are independently C 1 ~C 3 In some embodiments, R 9 Both groups are -CH 3 It is.

[0156] In some embodiments, R 9 is C 1 ~C 6 In some embodiments, R 9 is a C containing 1 to 7 halogen atoms 1 ~C 6 In some embodiments, R 9 is C 1 ~C 3 In some embodiments, R 9 is a C containing 1 to 7 halogen atoms 1 ~C 3 In some embodiments, R 9 C containing 1 to 5 halogen atoms 1 ~C 2In some embodiments, the halogen atoms are independently selected from the group consisting of chloro, bromo, and fluoro atoms. In some embodiments, the halogen atoms are independently selected from the group consisting of chloro and fluoro atoms. In some embodiments, the halogen atoms are all fluoro atoms. In some embodiments, the halogen atoms are a combination of chloro and fluoro atoms. In some embodiments, R 9 -CF 3 , -CCl 3 , -CF 2 Cl, -CFCl 2 , -CHF 2 , -CH 2 F, -CHCl 2 , -CH 2 F, or -CHFCl. In some embodiments, R 9 -CF 3 It is.

[0157] In some embodiments, R 9 is C 1 ~C 6 In some embodiments, R 9 is C 1 ~C 3 In some embodiments, R 9 -CH 2 OH, -CH 2 CH 2 -OH, -CH 2 CH 2 CH 2 -OH or -C(CH 3 ) 2 In some embodiments, R 9 -CH 2 It is OH.

[0158]

[0158] In some embodiments, a compound of formula (I), or any variation or aspect thereof, has the stereochemistry shown for formula (Ia): [ka] [In the formula, R 1 , R 2 , n, X, and Ring A moieties are as described for compounds of formula (I).

[0159] In some embodiments, the compound is a compound of formula (IA) or (IB): [ka] [In the formula, R 1 , R 2 , R 3 , R 4 , R 5 , R 6 , R 9 , Z 1 , Z 2 , and n is as described for compounds of formula (I).

[0160] In some embodiments, the compound is of formula (IC), (ID), (IE), (IF), (IG), (IH), (II), or (IJ): [ka] [In the formula, R 1 , R 2 , R 5 , R 6 , R 9 , and n is as described for compounds of formula (I).

[0161] In some embodiments, the compound is of formula (II-A), (II-B), (II-C), (II-D), (II-E), (II-F), (II-G), or (II-H): [ka] [In the formula, R 1 , R 2 , R 5 , R 7, R 9 and n are as described for compounds of formula (I), and [ka] is a monocyclic C 3 ~C 6 Cycloalkyl, fused bicyclic C 4 ~C 8 Cycloalkyl, Bridged Bicyclic C 4 ~C 8 Cycloalkyl, spiro bicyclic C 5 ~C 8 cycloalkyl, or 5- to 6-membered heterocyclyl.

[0162] In some embodiments, the compound is of formula (II-A-1), (II-B-1), (II-C-1), (II-D-1), (II-E-1), (II-F-1), (II-G-1), or (II-H-1): [ka] [In the formula, R 1 , R 2 , R 5 , R 7 , R 9 and n are as described for compounds of formula (I), and [ka] is a monocyclic C 3 ~C 6 Cycloalkyl, fused bicyclic C 4 ~C 8 Cycloalkyl, Bridged Bicyclic C 4 ~C 8 Cycloalkyl, spiro bicyclic C 5 ~C 8 cycloalkyl, or 5- to 6-membered heterocyclyl.

[0163] In some embodiments, the compound is of formula (III-A), (III-B), (III-C), (III-D), (III-E), (III-F), (III-G), or (III-H): [ka] [In the formula, R 1 , R 2 , R 8 , R 9 and n are as described for compounds of formula (I), and [ka] is a 5-10 membered monocyclic, fused bicyclic, or bridged heterocyclyl, or a 5-10 membered monocyclic or bicyclic heteroaryl, each of which optionally contains 1-2 additional heteroatoms selected from the group consisting of N and O.

[0164] In some embodiments, the compound is of formula (III-A-1), (III-B-1), (III-C-1), (III-D-1), (III-E-1), (III-F-1), (III-G-1), or (III-H-1): [ka] [In the formula, R 1 , R 2 , R 8 , R 9 and n are as described for compounds of formula (I), and [ka] is a 5-10 membered monocyclic, fused bicyclic, or bridged heterocyclyl, or a 5-10 membered monocyclic or bicyclic heteroaryl, each of which optionally contains 1-2 additional heteroatoms selected from the group consisting of N and O.

[0165] In some embodiments, the compound is a compound of formula (IV-A) or (IV-B): [ka] [In the formula, R 1 , R 2 , R 3 , R 4 , Z 1 , Z 2 and n are as described for compounds of formula (I), and X is H, C 1 ~C 6 Alkyl or C 1 ~C 6 In some embodiments, X is H. In some embodiments, X is C 1 ~C 6 In some embodiments, X is C 1 ~C 6 It is haloalkyl.

[0166] In some embodiments, the compound is of formula (IV-C), (IV-D), (IV-E), (IV-F), (IV-G), (IV-H), (IV-I), or (IV-J): [ka] [In the formula, R 1 , R 2 and n are as described for compounds of formula (I), and X is H, C 1 ~C 6 Alkyl or C 1 ~C 6In some embodiments, X is H. In some embodiments, X is C 1 ~C 6 In some embodiments, X is C 1 ~C 6 It is haloalkyl.

[0167] In some embodiments, the compound is of formula (IV-C-1), (IV-D-1), (IV-E-1), (IV-F-1), (IV-G-1), (IV-H-1), (IV-I-1), or (IV-J-1): [ka] [In the formula, R 1 , R 2 and n are as described for compounds of formula (I), and X is H, C 1 ~C 6 Alkyl or C 1 ~C 6 In some embodiments, X is H. In some embodiments, X is C 1 ~C 6 In some embodiments, X is C 1 ~C 6 It is haloalkyl.

[0168] In any of the embodiments of formula (I), (Ia), (IA) through (IJ), (II-A) through (II-H), (II-A-1) through (II-H-1), (III-A) through (III-H), (III-A-1) through (III-H-1), (IV-A) through (IV-J), or (IV-C-1) through (IV-J-1), the absolute stereochemistry at the cyclobutyl carbon to which the cyano group is attached can be (R)- (using the Cahn-Ingold-Prelog sequencing rules). In any of the embodiments of Formula (I), (Ia), (IA) through (IJ), (II-A) through (II-H), (II-A-1) through (II-H-1), (III-A) through (III-H), (III-A-1) through (III-H-1), (IV-A) through (IV-J), or (IV-C-1) through (IV-J-1), the absolute stereochemistry at the cyclobutyl carbon to which the cyano group is attached can be (S)-.

[0169] [Table 1]

[0170] [Table 2]

[0171] [Table 3]

[0172] [Table 4]

[0173] [Table 5]

[0174]

[0169] In some embodiments, a compound selected from compound numbers 1 to 58 in Table 1, or a tautomer, a stereoisomer, or a pharma- ceutically acceptable salt thereof is provided.

[0175] In one aspect, provided herein is a method for preparing a compound of formula (I) as described herein. In another aspect, provided herein is an intermediate compound for preparing a compound of formula (I). Also provided herein is a compound that is an assay probe, and is optionally tagged, for example, with a fluorescent label. In a further aspect, provided herein is a method for assaying inhibition of Cbl-b. In one variation, provided herein is a method for assaying inhibition of Cbl-b, comprising pre-incubating Cbl-b with an assay probe, such as an assay probe tagged with a fluorescent label, followed by exposing the Cbl-b / assay probe mixture to a candidate compound, and then determining whether and to what extent the assay probe is displaced by the candidate compound, for example, by detecting a FRET signal.

[0176] In any of the pharmaceutical compositions, methods, or kits described herein, the Cbl-b inhibitor can be selected from one or more of the Cbl-b inhibitors disclosed in the following patent applications: compounds 1-719 (including the "a" and "b" variants thereof) of WO 2019 / 148005 or any compound of formula (IA), formula (I), formula (II-A), formula (II), formula (III-A), formula (III), or formula (IV) therein. The contents of WO 2019 / 148005 are incorporated herein by reference in their entirety.

[0177]

[0172] In some embodiments, compound 60 and / or compound 56 of Table 1, or a tautomer, a stereoisomer, or a pharma- ceutically acceptable salt thereof, is provided for use in the compositions and methods described herein.

[0178] In one embodiment, the small molecule Cbl-b inhibitors for the methods, pharmaceutical compositions, and kits disclosed herein have a molecular weight of 1,000 daltons or less, or about 1,000 daltons or less. In another embodiment, the small molecule Cbl-b inhibitors have a molecular weight of 900 daltons or less, or about 900 daltons or less. In another embodiment, the small molecule Cbl-b inhibitors have a molecular weight of 800 daltons or less, or about 800 daltons or less. In another embodiment, the small molecule Cbl-b inhibitors have a molecular weight of 750 daltons or less, or about 750 daltons or less. In another embodiment, the small molecule Cbl-b inhibitors have a molecular weight of 700 daltons or less, or about 700 daltons or less. In another embodiment, the small molecule Cbl-b inhibitors have a molecular weight of 650 daltons or less, or about 650 daltons or less. In another embodiment, the small molecule Cbl-b inhibitors have a molecular weight of 600 daltons or less, or about 600 daltons or less. For any of the foregoing embodiments, the lower molecular weight limit for the small molecule Cbl-b inhibitor may be 100 daltons, 200 daltons, or 300 daltons, or about 100 daltons, about 200 daltons, or about 300 daltons.

[0179]

[0174] The following scheme describes the method of synthesizing the compounds disclosed herein. The mixture of stereoisomers generated during synthesis, such as the racemic mixture of the final compound, can be separated into each enantiomer using common chromatographic methods, such as supercritical fluid chromatography combined with a chiral stationary phase, chiral column chromatography, or other methods known in the art. [ka] [In the formula, R 1 , R 2 , R 3 , X, Z 1 and n is as defined for compounds of formula (I); Y is Br or NH 2 and R a and R b is a suitable protecting group].

[0180] Compounds of general formula I-9 were synthesized as outlined in Scheme I. Rhodium-catalyzed coupling of boronic ester I-1 with alkene I-2 gave ester I-3. Triazole construction via hydrazide formation (I-4), cyclization, and desulfurization provided compounds I-6. Compounds I-6 (wherein Y is NH 2 Compound I-6 (where Y is Br) was treated with bromoester I-8 to provide compound I-9, which was subsequently converted to compound I-10 by reductive amination with a substituted piperidine. Compound I-6 (where Y is Br) was treated with piperidine derivative I-7 under palladium catalysis to directly provide compound I-10. [ka] [In the formula, R 1 , R 2 , R 4 , X, Z 2 and n is as defined for compounds of formula (I); R b is a suitable protecting group; and Y b is an aldehyde or bromomethyl.

[0181] Scheme II outlines the synthesis of compounds of general formula II-5. Methylpyridines or pyrimidines II-1 were oxidized to provide aldehydes or bromomethyls of formula II-2. Amino groups X were then introduced by reductive amination or substitution with substituted amines to provide compounds II-3, followed by ester hydrolysis under basic conditions to give compounds II-4. Carboxylic acids II-4 were then coupled with amines I-6 with coupling reagents such as HATU or T3P to give amides II-5. [ka] [where X, R 3 , and Z 1 is as defined for compounds of formula (I)].

[0182] Intermediate compounds of general formula I-5 used in the general synthesis outlined in Scheme I were synthesized as per Scheme III. Aldehyde III-1 was coupled with a substituted amine by reductive amination to provide intermediate III-2, which was treated with ammonia to provide compounds of formula I-5.

[0183] Compounds 12, 18-21, 25, 31, 49, and 53-57 had IC values ​​of less than 1 nM in the Cbl-b inhibition assay of Biological Example 1. 50 Compounds 4, 11, 16, 17, 23, 39, 40, 44, and 48 have IC values ​​of ≥ 1 nM and < 2 nM in the Cbl-b inhibition assay of Biological Example 1. 50 Compounds 1, 2, 5, 6, 13-15, 22, 24, 26-30, 32-37, 41-43, 45, 47, 50, and 58 have IC values ​​of 2 or greater and less than 5 nM in the Cbl-b inhibition assay of Biological Example 1. 50 Compounds 7, 9, 38, 46, and 52 have IC values ​​of 5 or greater and less than 20 nM in the Cbl-b inhibition assay of Biological Example 1. 50 Compounds 3, 8, 10, and 51 have IC values ​​of 20 nM or greater in the Cbl-b inhibition assay of Biological Example 1. 50 The values ​​shown are, in one embodiment, used in the pharmaceutical compositions and methods as disclosed herein.

[0184] In various embodiments, and as further described herein, the compounds as provided herein (as well as compositions comprising the compounds described herein, and methods using the compounds or compositions described herein) exhibit an IC 50In further embodiments, and as further described herein, the compounds as provided herein (as well as compositions comprising the compounds described herein, and methods using the compounds or compositions described herein) have an IC50 value of less than 1 nM, greater than 1 nM but less than 2 nM, greater than 2 nM but less than 5 nM, greater than 5 nM but less than 20 nM, or greater than 20 nM, as determined by the Cbl-b inhibition assay of Biological Example 1. 50 In further embodiments, and as further described herein, the compounds as provided herein (as well as compositions comprising the compounds described herein, and methods using the compounds or compositions described herein) have an IC 50 In further embodiments, and as further described herein, the compounds as provided herein (as well as compositions comprising the compounds described herein, and methods using the compounds or compositions described herein) have an IC 50 In a further embodiment, and as further described herein, the compounds as provided herein (as well as compositions comprising the compounds described herein, and methods using the compounds or compositions described herein) have an IC 50 In a further embodiment, and as further described herein, the compounds as provided herein (as well as compositions comprising the compounds described herein, and methods using the compounds or compositions described herein) have an IC 50 The value is 20 nM or greater.

[0185]

[0180] With regard to IL-2 secretion from immune cells (e.g., T cells) costimulated with anti-CD3 and anti-CD28 antibodies, the compounds provided herein (as well as compositions comprising the compounds described herein) induce a change of 15-fold or less, 15-20-fold, or more than 20-fold over baseline at inhibitor concentrations of 1 micromolar or 0.3 micromolar.

[0186]

[0181] With respect to IL-2 secretion from immune cells (e.g., T cells) stimulated with anti-CD3 antibodies, the compounds provided herein (as well as compositions comprising the compounds described herein) induce a change of less than 0.40-fold, 0.40-0.85-fold, or greater than 0.85-fold over baseline at inhibitor concentrations of 3 micromolar or 1 micromolar.

[0187]

[0182] In CD25 staining on the cell surface of immune cells (e.g., T cells) costimulated with anti-CD3 antibody and anti-CD28 antibody, the compounds provided herein (as well as compositions comprising the compounds described herein) induce a change of 1.24-fold or less, 1.24-fold to 1.39-fold, or greater than 1.39-fold over baseline at inhibitor concentrations of 1 micromolar or 0.3 micromolar.

[0188]

[0183] In CD25 staining on the cell surface of immune cells (e.g., T cells) stimulated with anti-CD3 antibodies, the compounds provided herein (as well as compositions comprising the compounds described herein) induce a change of less than 1.00-fold, 1.05-1.15-fold, or greater than 1.15-fold over baseline at inhibitor concentrations of 3 micromolar or 1 micromolar.

[0189] III. METHODS, MEDICINES, AND USES

[0184] Provided herein are methods of modulating the activity of immune cells (e.g., T cells, B cells, or NK cells), such as by contacting the immune cells with an effective amount of a Cbl-b inhibitor or composition thereof described herein. Also provided are in vitro methods of generating immune cells with modulated activity, referred to herein as "modified immune cells," where the modified immune cells can be administered by ex vivo methods to an individual in need thereof (e.g., an individual having cancer). Further provided are in vivo methods of modulating a response of an individual in need thereof (e.g., an individual having cancer), comprising administering an effective amount of a Cbl-b inhibitor or composition thereof described herein. Further provided herein are in vitro methods of generating an expanded lymphocyte population following in vivo lymphatic conditioning in an individual, where lymphatic conditioning occurs as a result of administering to the individual an effective amount of a Cbl-b inhibitor or composition thereof described herein. The expanded lymphocyte population can then be administered to the individual. The expanded lymphocyte population can then be administered to an individual having cancer. In some embodiments, the modified immune cells or expanded lymphocyte populations are generated from a biological sample containing immune cells obtained from an individual, such as a blood sample containing peripheral blood mononuclear cells or a tumor biopsy containing tumor infiltrating lymphocytes (TILs).

[0190]

[0185] In addition, a Cbl-b inhibitor is provided for use as a therapeutic active substance. A Cbl-b inhibitor is provided for use in the treatment or prevention of a disease or condition associated with Cbl-b activity. A Cbl-b inhibitor is also provided for use in the treatment of cancer. Further, a use of a Cbl-b inhibitor in the manufacture of a medicament for the treatment or prevention of a disease or condition associated with Cbl-b activity is provided. Also provided is a use of a Cbl-b inhibitor in the manufacture of a medicament for treating cancer. Furthermore, the present disclosure provides a method of treatment, a medicament, and a use comprising a Cbl-b inhibitor as part of a combination therapy for treating cancer involving one or more of an immune checkpoint inhibitor, an anti-neoplastic agent, and radiation therapy.

[0191] In some embodiments of the treatment methods, medicaments, and uses of the present disclosure, the cancer is a blood cancer, such as lymphoma, leukemia, or myeloma. In other embodiments of the treatment methods, medicaments, and uses of the present disclosure, the cancer is a non-blood cancer, such as sarcoma, carcinoma, or melanoma.

[0192] Hematological cancers include one or more leukemias, such as B-cell acute lymphoblastic leukemia ("BALL"), T-cell acute lymphoblastic leukemia ("TALL"), acute lymphoblastic leukemia (ALL); one or more chronic leukemias, including but not limited to chronic myeloid leukemia (CML) and chronic lymphocytic leukemia (CLL); one or more chronic leukemias, including but not limited to B-cell prolymphocytic leukemia, blastic plasmacytoid dendritic cell neoplasm, Burkitt's lymphoma, diffuse large B-cell lymphoma, follicular lymphoma, hairy cell leukemia, small cell type or These include, but are not limited to, large cell follicular lymphoma, malignant lymphoproliferative conditions, MALT lymphoma, mantle cell lymphoma, marginal zone lymphoma, multiple myeloma, myelodysplastic and myelodysplastic syndromes, non-Hodgkin's lymphoma, plasmablastic lymphoma, plasmacytoid dendritic cell neoplasm, Waldenstrom's macroglobulinemia, and additional blood cancers or conditions including "preleukemias," a group of diverse hematological conditions united by the ineffective production (or dysplasia) of myeloid blood cells.

[0193]

[0188] Non-hematological cancers include, but are not limited to, neuroblastoma, renal cell carcinoma, colon cancer, colorectal cancer, breast cancer, squamous cell carcinoma, melanoma, gastric cancer, brain cancer, lung cancer (e.g., NSCLC), pancreatic cancer, cervical cancer, ovarian cancer, liver cancer, bladder cancer, prostate cancer, testicular cancer, thyroid cancer, uterine cancer, adrenal cancer, and head and neck cancer.

[0194] In some embodiments, the efficacy of administering a Cbl-b inhibitor in treating a disease or disorder, such as cancer, is measured by determining a clinical outcome, such as a reduction in tumor size or tumor number, and / or survival rate. In some embodiments, "treating cancer" includes determining a patient's response to a treatment regimen based on the Response Evaluation Criteria in Solid Tumors (RECIST version 1.1) as described (see, for example, Eisenhauer et al., Eur J Cancer, 45:228-247, 2009; and Nishino et al., Am J Roentgenol, 195: 281-289, 2010). Response criteria for determining an objective anti-tumor response according to RECIST 1.1 include complete response (CR); partial response (PR); progressive disease (PD); and stable disease (SD).

[0195] A. Cell isolation and treatment

[0190] Methods for preparing and processing immune cells (e.g., modified immune cells) generated and used in the methods herein are provided. As used herein, the term "modified immune cells" refers to an immune cell or a cell population comprising an immune cell that has been cultured, incubated, and / or contacted with an effective amount of a Cbl-b inhibitor to modulate the activity of said immune cell. In some embodiments, the modified immune cells can be used in immunotherapy, such as in the context of adoptive immunotherapy.

[0196] 1. Sample In some embodiments, the immune cells to be modified or a cell population comprising the immune cells to be modified are isolated from a sample, such as a biological sample, e.g., a sample obtained or derived from an individual (e.g., a human). In some embodiments, the individual from which the immune cells are isolated is an individual having a particular disease or condition (e.g., cancer) or an individual in need of cell therapy or to whom cell therapy will be administered. The individual, in some embodiments, is a human in need of a particular therapeutic intervention, such as adoptive cell therapy, for which the immune cells are isolated, treated, and / or modified. Thus, the cells isolated from the individual, in some embodiments, are primary cells (e.g., primary human cells). As used herein, the term "primary cells" refers to cells isolated directly from a mammalian biological fluid or tissue (e.g., human biological fluid or tissue).

[0197] In some embodiments, the immune cells to be modified are hematopoietic cells, pluripotent stem cells, myeloid progenitor cells, lymphoid progenitor cells, T cells, B cells, and / or NK cells. As used herein, the term "hematopoietic cells" includes hematopoietic stem cells and hematopoietic progenitor cells. In some embodiments, the immune cells to be modified are present in a heterogeneous cell population or in a composition comprising a heterogeneous cell population. For example, the immune cells to be modified can be hematopoietic cells present in a heterogeneous cell population including cells such as differentiated cells derived from a tissue or organ. In some embodiments, the immune cells to be modified are present in an allogeneic cell population or in a composition comprising an allogeneic cell population. For example, the immune cells to be modified can be hematopoietic cells present in an allogeneic cell population including only hematopoietic cells. In some embodiments, the immune cells to be modified or the cell population comprising the immune cells to be modified include one or more immune cell subsets. For example, the one or more immune cell subsets can be CD4+ cells, CD8+ cells, and subpopulations thereof, such as subpopulations defined by function, activation state, maturity, differentiation potential, expansion, localization, persistence, surface marker profile, cytokine secretion profile, and / or degree of differentiation.

[0198] In some embodiments, biological samples as described herein include tissues, body fluids, and other samples taken directly from an individual, as well as samples resulting from one or more processing steps, such as separation, centrifugation, genetic manipulation (e.g., transduction with a viral vector encoding a recombinant chimeric receptor), washing, and / or incubation. Biological samples can be samples obtained directly from a biological source or samples that are processed. Biological samples include, but are not limited to, body fluids such as blood, plasma, serum, cerebrospinal fluid, synovial fluid, urine, and sweat, tissue and organ samples (e.g., samples from tissues or organs containing tumors), including processed samples derived therefrom. In some embodiments, the biological sample is a biological fluid sample or a biological tissue sample. In some embodiments, the biological sample is a biological tissue sample. In some aspects, the biological sample from which the immune cells are derived or isolated is a blood or blood-derived sample, or is derived from an apheresis or leukapheresis product.

[0199] Exemplary biological samples include whole blood, peripheral blood mononuclear cells (PBMCs), white blood cells, bone marrow, thymus, tissue biopsy, tumor, leukemia, lymphoma, lymph node, gut-associated lymphoid tissue, mucosa-associated lymphoid tissue, spleen, other lymphoid tissue, liver, lung, stomach, intestine, colon, kidney, pancreas, breast, bone, prostate, cervix, testis, ovary, tonsil, or other organ, and / or cells derived therefrom. In the context of cell therapy (e.g., adoptive cell therapy), biological samples include samples from autologous sources (i.e., samples obtained or derived from an individual in need of cell therapy) and samples from allogeneic sources (i.e., samples obtained or derived from an individual or source other than the individual in need of cell therapy).

[0200] In some embodiments, the immune cells to be modified or the cell population comprising the immune cells to be modified are derived from a cell line (e.g., a T cell line, a B cell line, a NK cell line, etc.). In some embodiments, the immune cells to be modified or the cell population comprising the immune cells to be modified are obtained from a xenogeneic source, such as from a mouse, a rat, a non-human primate, or a pig.

[0201] 2. Cell Processing and Isolation In some embodiments, the isolation of immune cells to be modified includes one or more preparation and / or cell separation steps. The one or more cell separation steps may be non-affinity-based separation or affinity-based separation. As an example, non-affinity-based separation may be centrifugation of the composition containing immune cells to be modified. In some embodiments, non-affinity-based separation methods include density-based cell separation methods, such as preparation of white blood cells from peripheral blood by lysing red blood cells and centrifugation through Percoll or Ficoll gradients. Affinity-based separation methods may include contacting the composition containing immune cells to be modified with antibody-coated beads. Antibody-coated beads contemplated herein include, but are not limited to, magnetic beads (e.g., Dynabeads®, marketed by Life Technologies, Carlsbad, CA; MACS® microbeads, marketed by Miltenyi Biotec Inc., Auburn, CA; or EasySep™ Direct RapidSpheres™, marketed by Stemcell Technologies, Vancouver, BC, Canada) coated with an antibody that binds to a marker expressed on the surface of the immune cells to be modified. In some embodiments, a specific subpopulation of T cells, e.g., cells that are positive for or otherwise highly express one or more surface markers, such as CD4+, CD8+, etc., are isolated by positive or negative selection techniques. Positive selection can be based on techniques that bind target cells (e.g., immune cells to be modified) to a reagent to secure it for further use. For example, T cells that are CD3+ can be positively selected using magnetic beads conjugated to anti-CD3 antibodies (e.g., MACS® CD3 human microbeads). Negative selection can be based on techniques that capture target cells (eg, immune cells to be modified) that did not bind to the reagent.For example, negative selection can be used to isolate total human primary T cells from peripheral blood mononuclear cells (PMBCs), where a cocktail of antibodies against surface markers CD14, CD15, CD16, CD19, CD34, CD36, CD56, CD123, and CD235a is incubated in a sample containing PBMCs, followed by passing the sample through magnetic beads to remove cells expressing these surface markers, and reserving cells remaining in the sample for subsequent processing. In some embodiments, the immune cells to be modified or cell populations containing immune cells are washed, centrifuged, and / or incubated in the presence of one or more reagents, for example, to remove undesirable components, enrich for desired components, and lyse or remove cells sensitive to a particular reagent. In some instances, immune cells are separated based on one or more properties, such as density, adhesion properties, size, sensitivity, and / or resistance to a particular component. The cell separation step does not require 100% enrichment or removal of a particular cell. In some embodiments, positive selection or enrichment of a particular type of immune cell (e.g., CD4+ T cells) refers to increasing the number or proportion of such cells. In some embodiments, removal or depletion of a particular type of cell that is not of interest, such as by negative selection, refers to decreasing the number or proportion of such cells.

[0202] In some embodiments, immune cells or cell populations comprising immune cells are obtained from the circulating blood of an individual, for example by apheresis or leukapheresis. In some aspects, the sample comprising immune cells to be modified contains lymphocytes, including T cells, B cells, and NK cells, as well as monocytes, granulocytes, red blood cells, and / or platelets, and in some aspects contains cells other than red blood cells and platelets.

[0203] In some embodiments, blood cells taken from an individual are washed to remove the plasma fraction for subsequent processing steps, and the cell population containing the immune cells to be modified is placed in a suitable buffer or medium, etc. In some embodiments, the cell population containing the immune cells to be modified is washed with phosphate buffered saline. In some embodiments, the washing solution does not contain calcium and / or magnesium. In some aspects, the washing step is accomplished with a semi-automated "flow-through" centrifuge. In some aspects, the washing step is accomplished with tangential flow filtration. In some embodiments, the immune cells to be modified or the cell population containing the immune cells to be modified are resuspended after washing in a variety of suitable buffers, such as, for example, calcium and / or magnesium free phosphate buffered saline. In some embodiments, the components of the blood cell sample are removed, and the immune cells to be modified or the cell population containing the immune cells to be modified are directly resuspended in a suitable cell culture medium.

[0204] Representative methods for processing and / or isolating immune cells, such as hematopoietic cells, from a sample containing a cell population containing hematopoietic cells (e.g., a sample containing PBMCs) are described in Biological Example 2 and Biological Example 3 herein. Methods and techniques for processing and / or isolating immune cells, such as hematopoietic cells, pluripotent stem cells, myeloid progenitor cells, lymphoid progenitor cells, T cells, B cells, and / or NK cells, are well known in the art. See, for example, U.S. Patent Application Publication No. 2017 / 0037369; U.S. Patent Application Publication No. 2012 / 0148553; U.S. Patent No. 6,461,645; U.S. Patent No. 6,352,694; and U.S. Patent No. 7,776,562.

[0205] 3. Incubation and Treatment

[0200] Provided herein are methods of modulating the activity of an immune cell, such as a treated and / or isolated immune cell as described above, by contacting the immune cell with an effective amount of a Cbl-b inhibitor as described herein. Also provided herein are modified immune cells produced by any of the methods described herein, such as by culturing a cell population containing an immune cell (e.g., a treated and / or isolated immune cell as described above) in the presence of an effective amount of a Cbl-b inhibitor to modulate the activity of the immune cell, thereby producing the modified immune cell.

[0206] In some embodiments, the immune cells to be modified (e.g., treated and / or isolated immune cells as described above) are incubated and / or cultured in a suitable culture medium prior to contacting the immune cells with a Cbl-b inhibitor provided herein. In some embodiments, the immune cells to be modified are incubated and / or cultured in a suitable culture medium at the same time as contacting the immune cells with a Cbl-b inhibitor provided herein.

[0207] The treated and / or separated immune cells to be modified or cell populations comprising immune cells to be modified can be differentiated and / or expanded in vitro. In some embodiments, the immune cells to be modified are hematopoietic cells, pluripotent stem cells, myeloid progenitor cells, lymphoid progenitor cells, T cells, B cells, and / or NK cells. In some embodiments, the immune cells to be modified are incubated in a suitable cell culture medium comprising a Cbl-b inhibitor as described herein prior to differentiation and / or expansion of the immune cells. In some embodiments, the immune cells to be modified are incubated in a suitable cell culture medium comprising a Cbl-b inhibitor as described herein after differentiation and / or expansion of the immune cells. The immune cells become modified (i.e., become modified immune cells) upon contact with an amount of a Cbl-b inhibitor provided herein effective to modulate the activity of said immune cells. In some embodiments, the immune cells to be modified are not differentiated and / or expanded in vitro and are therefore the same cell type as the modified immune cells contacted with the Cbl-b inhibitor. For example, T cells can be incubated in a suitable medium containing a Cbl-b inhibitor without differentiation of the T cells. In other embodiments, the immune cells to be modified are differentiated and / or expanded in vitro and are therefore of a different cell type than the modified immune cells contacted with the Cbl-b inhibitor. For example, hematopoietic cells can be incubated in a suitable medium containing a Cbl-b inhibitor and other agents that drive the differentiation of hematopoietic cells into mature hematopoietic cells. Thus, in some aspects of the embodiments herein, the modified immune cells are hematopoietic cells, pluripotent stem cells, myeloid progenitor cells, lymphoid progenitor cells, T cells, B cells, and / or NK cells. Methods for expanding and / or differentiating immune cells are well known in the art. See, for example, WO 2017 / 037083.

[0208]

[0203] An effective amount of a Cbl-b inhibitor is an amount or concentration of a Cbl-b inhibitor sufficient to modulate the activity of immune cells when compared to a reference sample. The reference sample can be immune cells that have not been contacted with a Cbl-b inhibitor. In some embodiments, the concentration of a Cbl-b inhibitor added to a composition (e.g., cell culture medium) containing immune cells to be modified is about 1 pM to about 100 μM, about 5 pM to about 100 μM, about 10 pM to about 100 μM, about 20 pM to about 100 μM, about 40 pM to about 100 μM, about 60 pM to about 100 μM, about 80 pM to about 100 μM, about 1 nM to about 100 μM, about 3 nM to about 100 μM, about 10 nM to about 100 μM, about 15 nM to about 100 μM, about 20 nM about 0.1 μM to about 100 μM, about 40 nM to about 100 μM, about 60 nM to about 100 μM, about 80 nM to about 100 μM, about 0.1 μM to about 100 μM, about 0.1 μM to about 90 μM, about 0.1 μM to about 80 μM, about 0.1 μM to about 70 μM, about 0.1 μM to about 60 μM, about 0.1 μM to about 50 μM, about 0.1 μM to about 40 μM, about 0.1 μM to about 30 μM, about 0.1 μM to about 20 μM, about 0.1 μM to about 10 μM, about 0.2 μM to about 10 μM, or about 0.3 μM to about 8 μM. In some embodiments, the concentration of the Cbl-b inhibitor added to the composition (e.g., cell culture medium) comprising the immune cells to be modified is about 1 pM, about 2 pM, about 3 pM, about 4 pM, about 5 pM, about 10 pM, about 20 pM, about 30 pM, about 40 pM, about 50 pM, about 60 pM, about 70 pM, about 80 pM, about 90 pM, about 1 nM, about 3 nM, about 5 nM, about 6 nM, about 7 nM, about 8 nM, about 9 nM, about 10 nM, about 1 pM, about 10 ... M, about 10 nM, about 20 nM, about 40 nM, about 50 nM, about 80 nM, about 0.1 μM, about 0.2 μM, about 0.3 μM, about 0.4 μM, about 0.5 μM, about 1 μM, about 5 μM, about 10 μM, about 15 μM, about 20 μM, about 25 μM, about 30 μM, about 40 μM, about 50 μM, about 60 μM, about 70 μM, about 80 μM, about 90 μM, or about 100 μM. In some embodiments, the concentration of the Cbl-b inhibitor added to the composition (e.g., cell culture medium) containing the immune cells to be modified is about 0.3 μM, about 1 μM, or about 4 μM. In some embodiments, the concentration of the Cbl-b inhibitor added to the composition (e.g., cell culture medium) containing the immune cells to be modified is about 1 μM or about 8 μM.

[0209] An effective amount of a Cbl-b inhibitor is in contact with an immune cell for a sufficient time to modulate the activity of the immune cell as compared to a reference sample, which can be immune cells that have not been contacted with the Cbl-b inhibitor but are incubated for the same length of time with a composition (e.g., cell culture medium) that includes the immune cells and the Cbl-b inhibitor. In some embodiments, the Cbl-b inhibitor is in contact with and / or incubated with the immune cells for about 1 minute to about 1 hour, about 5 minutes to about 1 hour, about 10 minutes to about 1 hour, about 15 minutes to about 1 hour, about 20 minutes to about 1 hour, about 30 minutes to about 1 hour, about 45 minutes to about 1 hour, about 1 hour to about 2 hours, about 1 hour to about 4 hours, about 1 hour to about 6 hours, about 1 hour to about 8 hours, about 1 hour to about 12 hours, about 1 hour to about 24 hours, about 2 hours to about 24 hours, about 6 hours to about 7 hours, about 6 hours to about 24 hours, about 8 hours to about 24 hours, about 10 hours to about 24 hours, about 15 hours to about 24 hours, about 20 hours to about 24 hours, about 12 hours to about 48 hours, about 24 hours to about 48 hours, or about 36 hours to about 48 hours. In some embodiments, the Cbl-b inhibitor is in contact with and / or incubated with the immune cells for about 1 minute, about 5 minutes, about 10 minutes, about 15 minutes, about 20 minutes, about 30 minutes, about 40 minutes, about 50 minutes, about 1 hour, about 2 hours, about 3 hours, about 4 hours, about 5 hours, about 6 hours, about 7 hours, about 8 hours, about 9 hours, about 10 hours, about 12 hours, about 14 hours, about 16 hours, about 18 hours, about 20 hours, about 22 hours, or about 24 hours. In some embodiments, the Cbl-b inhibitor is in contact with and / or incubated with the immune cells for about 1 day to about 7 days, about 2 days to about 7 days, about 3 days to about 7 days, about 4 days to about 7 days, about 5 days to about 7 days, or about 6 days to about 7 days. In some embodiments, the Cbl-b inhibitor is in contact with and / or incubated with the immune cells for about 7 to about 14 days, about 14 to about 21 days, or about 21 to about 28 days. In some embodiments, the Cbl-b inhibitor is in contact with and / or incubated with the immune cells for about 1 day, about 2 days, about 3 days, about 4 days, about 5 days, about 6 days, about 7 days, about 8 days, about 9 days, about 10 days, about 11 days, about 12 days, about 13 days, or about 14 days.

[0210] In some embodiments, immune cells or cell populations comprising immune cells are incubated under suitable conditions to induce proliferation, expansion, activation, and / or survival of immune cells. Suitable incubation conditions include, but are not limited to, the use of one or more of cell culture medium, temperature, incubation time, the presence of stimulants (e.g., anti-CD3 and / or anti-CD28 antibodies), and the presence of any other beneficial agents, such as growth factors, cytokines, chemokines, and / or recombinant soluble receptors.

[0211] In some embodiments, suitable conditions for inducing the proliferation, expansion, activation, and / or survival of immune cells include providing stimulatory conditions including an agent capable of activating immune cells (e.g., NK cells). For example, suitable conditions for inducing the proliferation, expansion, activation, and / or survival of T cells include providing stimulatory conditions including an agent capable of activating intracellular signaling in T cells. Full activation of a T cell generally requires recognition of an antigen by the T cell receptor, herein referred to as "TCR" (signal 1) and recognition of a costimulatory factor such as CD28 (signal 2). In some aspects, one or more agents turn on or initiate a TCR complex-mediated intracellular signaling cascade in a T cell. For example, a first agent can bind to a component of the TCR complex to activate the T cell, and a second agent can bind to a costimulatory molecule on the surface of the T cell to thereby stimulate the activated T cell. In some embodiments, the first agent stimulated a TCR / CD3 complex-associated signal in the T cell by specifically binding to CD3 (e.g., an anti-CD3 antibody). In further embodiments, the costimulatory molecule on the surface of the T cell may be CD28 and the second agent specifically binds to CD28 (e.g., an anti-CD28 antibody). Such agents include, but are not limited to, antibodies, bivalent antibody fragments, and binding molecules, including those specific for a TCR complex component (e.g., an anti-CD3 antibody) and / or those specific for a costimulatory receptor (e.g., an anti-CD28 antibody). In some embodiments, the agent that specifically binds to CD3 is an anti-CD3 antibody, a bivalent antibody fragment of an anti-CD3 antibody (e.g., a (Fab)2' fragment or a bivalent scFv fragment), a monovalent antibody fragment of an anti-CD3 antibody (e.g., a Fab fragment, an Fv fragment, or an scFv fragment), or a CD3 binding molecule (e.g., an aptamer). In some embodiments, agents that specifically bind to CD28 are anti-CD28 antibodies, bivalent antibody fragments of anti-CD28 antibodies (e.g., (Fab)2' fragments or bivalent scFv fragments), monovalent antibody fragments of anti-CD28 antibodies (e.g., Fab fragments, Fv fragments, or scFv fragments), and CD28 binding molecules (e.g., aptamers).One or more of the agents provided herein (e.g., anti-CD3 and anti-CD28 antibodies) can be bound to a solid support, such as, for example, beads, or crosslinked with an anti-Fc antibody. In some embodiments, the expansion method steps can further include adding an anti-CD3 and / or anti-CD28 antibody to the culture medium. In some embodiments, the stimulatory agent added to the cell culture medium includes one or more cytokines, such as, but not limited to, one or more of IL-2, IL-7, IL-15, and IL-21. For example, IL-2 can be added to the cell culture medium containing the immune cells and agents, such as, for example, anti-CD3 and / or anti-CD28 antibodies, at a concentration of at least about 10 units / mL.

[0212] In some embodiments, suitable conditions for inducing T cell proliferation, expansion, activation, and / or survival include providing stimulatory conditions or agents capable of activating intracellular signaling through the T cell receptor (TCR) complex, and a Cbl-b inhibitor as described herein. In some embodiments, an immune cell or a cell population comprising an immune cell is incubated with a first agent (e.g., an anti-CD3 antibody) that stimulates a T cell's TCR / CD3 complex-associated signal by specifically binding to CD3. In further embodiments, an immune cell or a cell population comprising an immune cell is incubated with a first agent (e.g., an anti-CD3 antibody) that stimulates a T cell's TCR / CD3 complex-associated signal by specifically binding to CD3, with a second agent (e.g., an anti-CD28 antibody) that binds to the costimulatory molecule CD28, and with a Cbl-b inhibitor at a concentration of about 1 pM to about 100 μM (e.g., about 0.3 μM, about 1 μM, or about 4 μM). In some embodiments, conditions suitable for inducing proliferation, expansion, activation, and / or survival of T cells when in the presence of a Cbl-b inhibitor do not require stimulation through a costimulatory molecule (e.g., CD28). Because the T cells are contacted with a Cbl-b inhibitor or a composition thereof, the costimulatory requirement for the T cells to enter an activated state can be avoided. In certain embodiments, an immune cell or a cell population comprising an immune cell is incubated with a first agent (e.g., an anti-CD3 antibody) that stimulates a TCR / CD3 complex-associated signal in the T cells by specifically binding to CD3, and with a Cbl-b inhibitor at a concentration of about 0.001 μM to about 1,000 μM, about 0.01 μM to about 100 μM, about 0.1 μM to about 10 μM, or about 0.1 μM to about 50 μM (e.g., about 1 μM or about 8 μM).

[0213] In some embodiments of the method of modulating immune cell activity, the immune cell is a T cell, and modulating the activity of the T cell includes increasing T cell activation and / or increasing T cell proliferation. T cells contemplated in the embodiments herein can be in a tolerant state even in the presence of an activator that binds to a component of the TCR complex, such as an anti-CD3 antibody, and in the presence of a stimulator that binds to a costimulatory molecule, such as an anti-CD28 antibody. In some embodiments, the method of modulating T cell activity includes contacting a T cell with an effective amount of a Cbl-b inhibitor or a composition thereof in the presence of an anti-CD3 antibody in combination with an anti-CD28 antibody. In some embodiments, the method of modulating T cell activity includes contacting a T cell with an effective amount of a Cbl-b inhibitor or a composition thereof, where the T cell has been previously contacted with an anti-CD3 antibody in combination with an anti-CD28 antibody. In some embodiments, modulation of T cell activity (e.g., increasing T cell activation and / or increasing T cell proliferation) does not require stimulation with a costimulatory CD28 molecule. In some embodiments, the method of modulating T cell activity comprises contacting a T cell with an effective amount of a Cbl-b inhibitor or composition thereof in the presence of an anti-CD3 antibody alone. In some embodiments, the method of modulating T cell activity comprises contacting a T cell with an effective amount of a Cbl-b inhibitor or composition thereof, where the T cell has been pre-contacted with one or more agents that activate the T cell (e.g., an anti-CD3 antibody), where the agents do not include an agent that stimulates a CD28 costimulatory molecule (e.g., an anti-CD28 antibody).

[0214] In some embodiments, the immune cell is a T cell, and modulating the activity of the T cell includes enhancing T cell activation and / or enhancing T cell proliferation. For example, T cells contemplated in the embodiments herein may be in an activated state, such as when in the presence of an agent that activates the T cell (e.g., an anti-CD3 antibody), and in some further embodiments, in the presence of an agent that stimulates the T cell (e.g., an anti-CD28 antibody). Contacting the T cell with a Cbl-b inhibitor or a composition thereof may lower the threshold required for activation, thus enhancing activation and / or proliferation of the T cell in the presence of an activator (e.g., an anti-CD3 antibody) and in some further embodiments, a stimulator (e.g., an anti-CD28 antibody). In some embodiments, the method of modulating the activity of a T cell includes contacting the T cell with an effective amount of a Cbl-b inhibitor or a composition thereof in the presence of an anti-CD3 antibody in combination with an anti-CD28 antibody. In some embodiments, the method of modulating T cell activity comprises contacting a T cell with an effective amount of a Cbl-b inhibitor or a composition thereof, where the T cell has been pre-contacted with an anti-CD3 antibody in combination with an anti-CD28 antibody. In some embodiments, modulation of T cell activity (e.g., enhanced T cell activation and / or enhanced T cell proliferation) does not require stimulation with a costimulatory CD28 molecule. In some embodiments, the method of modulating T cell activity comprises contacting a T cell with an effective amount of a Cbl-b inhibitor or a composition thereof in the presence of an anti-CD3 antibody alone. In some embodiments, the method of modulating T cell activity comprises contacting a T cell with an effective amount of a Cbl-b inhibitor or a composition thereof, where the T cell has been pre-contacted with one or more agents that activate the T cell (e.g., an anti-CD3 antibody).

[0215] In some embodiments, the immune cell is a T cell, and modulating the activity of the T cell includes reducing T cell dysfunction, including reducing T cell exhaustion, reducing T cell tolerance, and / or reducing T cell anergy. The general principles of T cell dysfunction are well known in the art (see, for example, Schietinger et al., Trends Immunol., 35: 51-60, 2014). Immune tolerance is a process that is part of the normal function of the immune system. Antigen-specific immune tolerance is characterized by a reduced responsiveness to an antigen, which is induced by previous exposure to that antigen. When a particular lymphocyte (e.g., T cell) encounters an antigen, the lymphocyte may be activated, leading to an antigen-specific immune response, or the lymphocyte (e.g., T cell) may be inactivated or eliminated, leading instead to antigen-specific immune tolerance. In some aspects, tolerance may occur by clonal anergy, peripheral clonal deletion, T cell suppression, and / or other forms of antigen-specific tolerance. In some embodiments, tolerance may result from or be characterized by the induction of anergy. In some aspects, anergy may occur because T cells are exposed to antigen in the absence of costimulation. In the absence of costimulatory signals, prolonged antigen recognition by TCR alone may lead to anergy (i.e., functional unresponsiveness). Anergic T cells may be unresponsive to subsequent antigen challenge and may have the ability to suppress other immune responses. Generally, in the natural environment, tolerance involves unresponsiveness or unproductive responsiveness to self-antigens. However, in some cases, tolerance may be induced to "non-self" antigens. Thus, in some aspects, the same mechanisms by which mature T cells that recognize self-antigens in peripheral tissues subsequently lose the ability to respond to those antigens may also control unresponsiveness to foreign or "non-self" antigens, such as those expressed by cancer cells. Thus, T cells contemplated in the embodiments herein may be in a tolerant state even in the presence of a stimulatory agent, such as an agent that binds to a costimulatory molecule, such as CD28.Contacting T cells with a Cbl-b inhibitor or a composition thereof provided herein can avoid aspects of T cell dysfunction, such as T cell tolerance, T cell anergy, and / or T cell exhaustion. In some embodiments, the method of modulating T cell activity (e.g., reducing T cell tolerance, reducing T cell anergy, and / or reducing T cell exhaustion) comprises contacting T cells with an effective amount of a Cbl-b inhibitor or a composition thereof. In some embodiments of the methods herein, modulating T cell activity (e.g., reducing T cell tolerance, reducing T cell anergy, and / or reducing T cell exhaustion) comprises contacting T cells with an effective amount of a Cbl-b inhibitor or a composition thereof in the presence of an anti-CD3 antibody in combination with an anti-CD28 antibody. In some embodiments of the methods herein, the method of modulating T cell activity (e.g., reducing T cell tolerance, reducing T cell anergy, and / or reducing T cell exhaustion) comprises contacting a T cell with an effective amount of a Cbl-b inhibitor or a composition thereof, where the T cell has been previously contacted with an anti-CD3 antibody in combination with an anti-CD28 antibody. In some embodiments, the modulation of T cell activity (e.g., reducing T cell tolerance, reducing T cell anergy, and / or reducing T cell exhaustion) does not require stimulation with a costimulatory CD28 molecule. In some embodiments of the methods herein, the method of modulating T cell activity (e.g., reducing T cell tolerance, reducing T cell anergy, and / or reducing T cell exhaustion) comprises contacting a T cell with an effective amount of a Cbl-b inhibitor or a composition thereof in the presence of an anti-CD3 antibody alone. In some embodiments, a method of modulating T cell activity (e.g., reducing T cell tolerance, reducing T cell anergy, and / or reducing T cell exhaustion) comprises contacting a T cell with an effective amount of a Cbl-b inhibitor or composition thereof, where the T cell has previously been contacted with one or more agents that activate T cells alone, such as an anti-CD3 antibody.

[0216]

[0211] T cell activation and T cell tolerance are tightly controlled processes that regulate immune responses. Accordingly, provided herein are methods of modulating T cell activity, where modulating T cell activity includes increasing T cell activation, increasing T cell proliferation, decreasing T cell exhaustion, and / or decreasing T cell tolerance. In some embodiments, modulating T cell activity (e.g., increasing T cell activation, increasing T cell proliferation, decreasing T cell exhaustion, and / or decreasing T cell tolerance) includes contacting T cells with an effective amount of a Cbl-b inhibitor or a composition thereof. In some embodiments of the methods herein, modulating T cell activity (e.g., increasing T cell activation, increasing T cell proliferation, decreasing T cell exhaustion, and / or decreasing T cell tolerance) includes contacting T cells with an effective amount of a Cbl-b inhibitor or a composition thereof in the presence of an anti-CD3 antibody in combination with an anti-CD28 antibody. In some embodiments of the methods herein, the method of modulating T cell activity (e.g., increasing T cell activation, increasing T cell proliferation, decreasing T cell exhaustion, and / or decreasing T cell tolerance) comprises contacting a T cell with an effective amount of a Cbl-b inhibitor or a composition thereof, where the T cell has been previously contacted with an anti-CD3 antibody in combination with an anti-CD28 antibody. In some embodiments, the modulation of T cell activity (e.g., increasing T cell activation, increasing T cell proliferation, decreasing T cell exhaustion, and / or decreasing T cell tolerance) does not require stimulation with a costimulatory CD28 molecule. In some embodiments of the methods herein, the method of modulating T cell activity (e.g., increasing T cell activation, increasing T cell proliferation, decreasing T cell exhaustion, and / or decreasing T cell tolerance) comprises contacting a T cell with an effective amount of a Cbl-b inhibitor or a composition thereof provided herein in the presence of an anti-CD3 antibody alone.In some embodiments, a method of modulating T cell activity (e.g., increasing T cell activation, increasing T cell proliferation, decreasing T cell exhaustion, and / or decreasing T cell tolerance) comprises contacting a T cell with an effective amount of a Cbl-b inhibitor or composition thereof, where the T cell has been pre-contacted with one or more agents that activate the T cell (e.g., an anti-CD3 antibody).

[0217] In some embodiments of the methods herein, increasing T cell activation includes increasing production of one or more cytokines from the T cell or surrounding immune cells (e.g., myeloid cells) in the activated T cell microenvironment. In some embodiments, the one or more cytokines include, but are not limited to, IFN-γ, IL-1β, IL-2, IL-4, IL-5, IL-6, IL-13, IL-18, TNFα, and GM-CSF. In some embodiments, the cytokine is one or more of IL-2, IFN-γ, TNFα, and GM-CSF. In some embodiments, the cytokine is a chemokine. In some embodiments, the one or more chemokines include, but are not limited to, IP-10, eotaxin, GROα, RANTES, MIP-1α, MIP-1β, MIP-2, MCP-1, and MCP-3. Increased expression of cytokines can be measured by ELISA.

[0218] In some embodiments of the methods herein, the increase in T cell activation comprises an increase in cell surface expression of one or more T cell activation markers. In some embodiments, the one or more T cell activation markers include, but are not limited to, CD25, CD44, CD62L, CD69, CD152 (CTLA4), CD154, CD137, and CD279. In some embodiments, the T cell activation marker is one or more of CD25, CD69, and CTLA4. The increase in expression of cell surface markers can be measured by FACS.

[0219]

[0214] Methods for experimentally determining increased T cell activation, increased T cell proliferation, decreased T cell exhaustion, and / or decreased T cell tolerance are well known in the art. In some embodiments, reference may be made to Biological Example 2 provided herein for representative methods for determining T cell activation. In some embodiments, reference may be made to Biological Example 3 provided herein for representative in vitro and in vivo methods for determining increased T cell activation, increased T cell proliferation, decreased T cell exhaustion, and / or decreased T cell tolerance.

[0220] In some embodiments of the method of modulating immune cell activity, the immune cell is a B cell, and modulating B cell activity comprises increasing B cell activation. In some embodiments, increasing B cell activation comprises increasing cell surface expression of one or more B cell activation markers. In some embodiments, the one or more B cell activation markers include, but are not limited to, CD69, CD86, and MHC class II (e.g., HLA-DR). In some embodiments, the B cell activation marker is CD69. The increased expression of cell surface markers can be measured by FACS. In some embodiments, increasing B cell activation comprises increasing activation of proteins in signal transduction pathways, such as those mediated by ERK, JNK, and Syk. The increased activation of said proteins can be detected by measuring the phosphorylation level of the protein using reagents available in the art, such as anti-phospho antibodies.

[0221] In some embodiments of the method of modulating immune cell activity, the immune cell is a NK cell, and modulating the activity of the NK cell comprises increasing NK cell activation. In some embodiments, the increase in NK cell activation comprises secretion of one or more cytokines. In some embodiments, the one or more cytokines include, but are not limited to, IFN-γ, TNFα, and MIP-1β. The increase in cytokine expression can be measured by ELISA. In some embodiments, the increase in NK cell activation comprises an increase in cell surface expression of one or more NK cell activation markers. In some embodiments, the one or more NK cell activation markers include, but are not limited to, CD69, and CD107a. The increase in cell surface marker expression can be measured by FACS. In some embodiments, the increase in NK cell activation comprises an increase in killing of target cells, such as tumor cells, including primary tumor cells, and tumor cells from cell lines, such as the K562 cell line.

[0222] Methods for experimentally determining increased B cell activation and NK cell activation are well known in the art (see, for example, Fauriat et al., Blood. 115: 2167-76, 2010; Beano et al., J. Transl. Med., 6:25 2008; Claus et al., J. Immunol. Methods, 341: 154-64, 2009; and Fujisaki et al., Cancer Res. 69: 4010-4017, 2009). In some embodiments, a representative method for determining B cell activation may be referenced to Biological Example 3 provided herein. In some embodiments, a representative method for determining NK cell activation may be referenced to Biological Example 3 provided herein.

[0223] Modulation of immune cell activity, such as T cells, B cells, or NK cells, may be measured by determining a baseline value of a parameter of interest (e.g., cytokine secretion). For example, in a sample obtained from an in vitro experiment in which cells are contacted with a Cbl-b inhibitor, T cell activation can be measured before contacting with or administering the Cbl-b inhibitor to determine a baseline value. A reference value is then obtained for T cell activation after contacting with or administering the Cbl-b inhibitor. The reference value is compared to the baseline value to determine the amount of T cell activation resulting from contacting or administering the Cbl-b inhibitor or composition thereof. For example, in some embodiments, immune cell (e.g., T cell) activation is increased by at least 0.1-fold in the sample when compared to a baseline value, where the baseline value is obtained before contacting immune cells (e.g., T cells) with a Cbl-b inhibitor or composition thereof. In some embodiments, immune cell (e.g., T cell) activation is increased by at least about 0.1-fold, about 0.2-fold, about 0.3-fold, about 0.4-fold, about 0.5-fold, about 0.6-fold, about 0.7-fold, about 0.8-fold, about 0.9-fold, about 1-fold, about 2-fold, about 4-fold, about 6-fold, about 8-fold, about 10-fold, about 20-fold, about 30-fold, about 40-fold, about 50-fold, about 75-fold, or about 100-fold (e.g., about 0.1-fold to about 100-fold, or about 1-fold to about 100-fold) above baseline values. Immune cell activation may be determined by measuring biological markers of activation, such as increased cytokine secretion, increased cell surface expression of activation markers (e.g., cell surface markers), or increased phosphorylation of proteins in downstream signaling pathways. For the parameter under test and the condition to which the immune cells are treated, a fold over baseline value indicative of immune cell activation can be determined. For example, to measure T cell activation, a baseline value can be obtained from T cells stimulated with anti-CD3 antibody combined with anti-CD28 antibody, but not incubated with Cbl-b inhibitor. A reference value is then obtained from T cells stimulated with anti-CD3 antibody combined with anti-CD28 antibody, but that have been in contact with or are in contact with Cbl-b inhibitor. A positive response of immune cell activation can then be determined based on the obtained reference value.Similar reference measurements can be obtained and compared to baseline values ​​to determine T cell activation, T cell proliferation, T cell depletion, T cell tolerance, B cell activation, and / or NK cell activation. Measurements of these parameters can be obtained using techniques well known in the art and those provided in Biological Examples 2 and 3.

[0224] The term "baseline" or "baseline value" as used herein may refer to a measurement or characteristic prior to administration of a therapeutic agent as disclosed herein (e.g., a composition comprising a Cbl-b inhibitor as described herein) or at the start of administration of the therapeutic agent. By comparing the baseline value to a reference value, an increase or decrease in immune cell function (e.g., increasing T cell activation, increasing T cell proliferation, decreasing T cell exhaustion, and / or decreasing T cell tolerance) may be determined. The term "reference" or "reference value" as used herein may refer to a measurement or characteristic after administration of a therapeutic agent as disclosed herein (e.g., a composition comprising a Cbl-b inhibitor as described herein). The reference value may be measured one or more times during an experimental time course, dosage regimen, or treatment cycle, or at the completion of an experimental time course, dosage regimen, or treatment cycle. A "reference value" may be an absolute value, a relative value, a value with upper and / or lower limits, a range of values, an arithmetic mean, a median, a mean, or a value compared to a baseline value. Similarly, a "baseline value" may be an absolute value, a relative value, a value with upper and / or lower limits, a range of values, an arithmetic mean, a median, a mean, or a value compared to a reference value. Reference and / or baseline values ​​can be obtained from one sample (e.g., one sample obtained from an individual), two different samples (e.g., samples obtained from two different individuals), or a group of samples (e.g., samples obtained from a group of 2, 3, 4, 5 individuals, or more).

[0225] In some embodiments, the positive response for T cell activation as measured by cytokine secretion (e.g., IL-2 secretion) by T cells stimulated with anti-CD3 antibody in combination with anti-CD28 antibody in the presence of a Cbl-b inhibitor is at least 2.5 times the baseline value for cytokine secretion (e.g., IL-2 secretion) obtained from T cells stimulated with anti-CD3 antibody in combination with anti-CD28 antibody in the absence of a Cbl-b inhibitor. In some embodiments, the positive response for T cell activation as measured by surface marker expression (e.g., CD25 surface marker staining) by T cells stimulated with anti-CD3 antibody in combination with anti-CD28 antibody in the presence of a Cbl-b inhibitor is at least 1.3 times the baseline value for surface marker expression (e.g., CD25 surface marker staining) obtained from T cells stimulated with anti-CD3 antibody in combination with anti-CD28 antibody in the absence of a Cbl-b inhibitor. In some embodiments, the baseline value can be obtained from T cells stimulated with anti-CD3 antibody alone and not incubated with a Cbl-b inhibitor. In some embodiments, a positive response for T cell activation as measured by cytokine secretion (e.g., IL-2 secretion) by T cells stimulated with anti-CD3 antibody alone in the presence of a Cbl-b inhibitor is at least 0.1 times the baseline value for cytokine secretion (e.g., IL-2 secretion) obtained from T cells stimulated with anti-CD3 antibody alone in the absence of a Cbl-b inhibitor. In some embodiments, a positive response for T cell activation as measured by surface marker expression (e.g., CD25 surface marker staining) by T cells stimulated with anti-CD3 antibody alone in the presence of a Cbl-b inhibitor is at least 0.6 times the baseline value for surface marker expression (e.g., CD25 surface marker staining) obtained from T cells stimulated with anti-CD3 antibody alone in the absence of a Cbl-b inhibitor.

[0226] In some aspects, provided herein is a method of making a modified immune cell, comprising culturing a cell population containing an immune cell in the presence of an effective amount of a Cbl-b inhibitor provided herein or a composition thereof to modulate the activity of the immune cell, thereby making the modified immune cell. In some embodiments, the immune cell is a T cell, a B cell, or a natural killer (NK) cell.

[0227] In some embodiments of the method for producing modified immune cells, the immune cells to be modified are cells selected from the group consisting of hematopoietic cells, pluripotent stem cells, myeloid progenitor cells, lymphoid progenitor cells, T cells, B cells, and NK cells. In some embodiments, the method further comprises culturing the immune cells with a stimulatory agent such as a cytokine or an antibody that binds to an activating protein expressed by the immune cells (e.g., an anti-CD3 antibody and / or an anti-CD28 antibody). In some embodiments, the immune cells to be modified are in a cell population containing immune cells, where the cell population is obtained as a sample from an individual. In some embodiments, the immune cells to be modified are in a cell population containing immune cells, where the cell population is obtained by culturing a biological sample from an individual (e.g., a blood sample, a bone marrow sample, etc.). In some embodiments, the immune cells are modified by contacting the cell population containing immune cells with a Cbl-b inhibitor or a composition thereof, thereby producing the modified immune cells. In some embodiments, the modified immune cells are cells selected from the group consisting of hematopoietic cells, pluripotent stem cells, myeloid progenitor cells, lymphoid progenitor cells, T cells, B cells, and NK cells. In some embodiments, the immune cells are of the same cell type as the modified immune cells. For example, the immune cells can be inactive T cells and the modified immune cells can be activated T cells. In some embodiments, the immune cells are of a different cell type than the modified immune cells. For example, the immune cells can be hematopoietic stem cells and the modified immune cells can be NK cells differentiated from hematopoietic stem cells. In some embodiments of the method of making the modified immune cells, the method further comprises recovering the modified immune cells. In some embodiments, the cell population containing the immune cells, the immune cells, or the modified immune cells are from an individual (e.g., a human). In some embodiments, the immune cells or the modified immune cells are human immune cells or human modified immune cells, respectively.

[0228]

[0223] Further provided herein is a modified immune cell produced by any of the methods described herein, such as culturing a cell population containing immune cells in the presence of an effective amount of a Cbl-b inhibitor to modulate the activity of the immune cells, thereby producing the modified immune cell.

[0229] In some embodiments, the Cbl-b inhibitor provided herein is cell membrane permeable.Thus, in some embodiments, the modified immune cells provided herein can include the Cbl-b inhibitor described herein, such as in the cytoplasm of the modified immune cells.

[0230] In some aspects, provided herein is an isolated modified immune cell, wherein the modified immune cell has been contacted or is in contact with a Cbl-b inhibitor or composition thereof described herein. In some embodiments, the modified immune cell is a T cell, a B cell, or a natural killer (NK) cell. In some embodiments, the modified immune cell is a hematopoietic cell, a pluripotent stem cell, a myeloid progenitor cell, a lymphoid progenitor cell, a T cell, a B cell, or a NK cell.

[0231] In some embodiments of the isolated modified immune cells, the modified immune cells are T cells, and the T cells exhibit increased T cell activation, increased T cell proliferation, reduced T cell exhaustion, and / or reduced T cell tolerance. In some embodiments, the increased T cell activation comprises increased production of one or more cytokines from the T cells or surrounding immune cells (e.g., myeloid cells) in the activated T cell microenvironment. In some embodiments, the one or more cytokines include, but are not limited to, IFN-γ, IL-1β, IL-2, IL-4, IL-5, IL-6, IL-13, IL-18, TNFα, and GM-CSF. In some embodiments, the one or more cytokines are one or more selected from the group consisting of IL-2, IFN-γ, TNFα, and GM-CSF. In some embodiments, the cytokine is a chemokine. In some embodiments, the one or more chemokines include, but are not limited to, IP-10, eotaxin, GROα, RANTES, MIP-1α, MIP-1β, MIP-2, MCP-1, and MCP-3. In some embodiments, the increase in T cell activation comprises an increase in cell surface expression of one or more T cell activation markers. In some embodiments, the one or more T cell activation markers include, but are not limited to, CD25, CD44, CD62L, CD69, CD152 (CTLA4), CD154, CD137, and CD279. In some embodiments, the one or more T cell activation markers include, but are not limited to, CD25, CD69, and CTLA4. In some embodiments, the T cell activation marker is CD25 and / or CD69. In some embodiments, the T cells have been or are in contact with an anti-CD3 antibody. In some embodiments, the T cells have been or are in contact with an anti-CD3 antibody in combination with an anti-CD28 antibody.

[0232] In some embodiments of the isolated modified immune cells, the modified immune cells are NK cells, and the NK cells exhibit increased NK cell activation. In some embodiments, the increased NK cell activation comprises increased secretion of one or more cytokines (e.g., IFN-γ, TNFα, and / or MIP-1β). In some embodiments, the increased NK cell activation comprises increased cell surface expression of one or more NK cell activation markers (e.g., CD69 and / or CD107a).

[0233] In some embodiments of the isolated modified immune cells, the modified immune cells are B cells and the B cells exhibit increased B cell activation. In some embodiments, increased B cell activation comprises increased cell surface expression of one or more B cell activation markers (e.g., CD69, CD86, and / or HLA-DR).

[0234] In some embodiments of any of the methods or modified immune cells provided herein, the immune cell or modified immune cell is a mammalian cell (e.g., a human cell). In some embodiments, the immune cell or modified immune cell is a human cell.

[0235]

[0230] In some embodiments, incubation is performed according to techniques such as those described in U.S. Patent No. 6,040,177; Klebanoff et al., J Immunother., 35: 651-660, 2012; Terakura et al., Blood, 119: 72-82, 2012; and Wang et al., J Immunother., 35:689-701, 2012.

[0236] The immune cells or modified immune cells to be modified provided herein can be engineered to express a recombinant chimeric receptor, such as a chimeric antigen receptor (CAR). In some embodiments, a CAR comprises, from its N-terminus to its C-terminus, an extracellular ligand binding domain, a transmembrane domain, an intracellular costimulatory domain, and an activating cytoplasmic signaling domain. In some embodiments, a CAR comprises, from its N-terminus to its C-terminus, an extracellular ligand binding domain, a transmembrane domain, and an activating cytoplasmic signaling domain. The immune cells can be engineered to express a recombinant chimeric receptor (e.g., a CAR) before, during, or after contact with a Cbl-b inhibitor provided herein. In some embodiments, the immune cells to be modified ...). In some embodiments, the immune cells to be modified can be engineered to express a recombinant chimeric receptor (e.g., a CAR) before, during, or after contact with a Cbl-b inhibitor provided herein. + T cells or CD8 + In further embodiments, the T cell comprises a recombinant chimeric receptor, such as a CAR. In some embodiments, the modified immune cell is a modified T cell (e.g., a CD4 + T cells or CD8 + In a further embodiment, the modified T cell comprises a recombinant chimeric receptor, such as a CAR. Methods for generating immune cells expressing recombinant chimeric receptors are well known in the art, such as by introducing a nucleic acid encoding a recombinant chimeric receptor (e.g., a CAR) into an immune cell (e.g., a T cell) via a vector (e.g., a viral vector). See, for example, WO 2017 / 096329 and U.S. Patent Application Publication No. 2017 / 0204372.

[0237] In particular, the disclosure provides a method of generating an expanded lymphocyte population, comprising: (a) obtaining a biological sample comprising lymphocytes from an individual having cancer, the individual having received or being administered an effective amount of a Cbl-b inhibitor as a monotherapy or as part of a combination therapy; and (b) culturing the lymphocytes in a cell culture medium comprising at least one T cell growth factor to generate an expanded lymphocyte population. In some embodiments, the lymphocytes are tumor infiltrating lymphocytes (TILs). In some embodiments, the lymphocytes are TILs isolated or to be isolated from a tumor of a mammalian subject having cancer. In other embodiments, the lymphocytes are peripheral blood mononuclear cells (PBMCs). In some embodiments, the at least one T cell growth factor comprises one or more of the group consisting of IL-2, IL-7, IL-15, and IL-21, and optionally the at least one T cell growth factor comprises IL-2. In some embodiments, the cell culture medium further comprises an anti-CD3 antibody, or both an anti-CD3 antibody and an anti-CD28 antibody. In some embodiments, the cell culture medium further comprises a Cbl-b inhibitor. In some embodiments, the cell culture medium further comprises irradiated feeder cells. In some embodiments, the individual is a human patient. Also provided herein is a composition comprising an expanded TIL population produced by the aforementioned method and a physiologically acceptable buffer.

[0238] In some embodiments, methods for isolating and processing immune cells to be modified or modified immune cells (i.e., modified immune cells) include freezing (e.g., cryopreserving) the cells either before or after isolation, incubation (e.g., incubation with a Cbl-b inhibitor), and / or manipulation (e.g., introduction of a nucleic acid encoding a recombinant chimeric receptor into the immune cells). A variety of freezing solutions and parameters known in the art can be used.

[0239] B. Adoptive cell therapy

[0234] Modified immune cells, such as expanded lymphocyte populations, or compositions thereof, produced by the methods described herein can be used as therapeutic agents in methods of treating individuals in need thereof, such as individuals with cancer. Such methods of treatment include adoptive cell therapy. In some embodiments, the methods of treatment include isolating cells from an individual, preparing, treating, culturing, and / or manipulating them as described herein, and reintroducing them into the same individual, either before or after cryopreservation. In some embodiments, the methods of treatment include isolating cells from an individual, preparing, treating, culturing, and / or manipulating them as described herein, and reintroducing them into another individual, either before or after cryopreservation.

[0240]

[0235] Thus, in some aspects, provided herein is a method of modulating an immune response in an individual, comprising administering to an individual in need thereof (e.g., an individual having a T cell dysfunction disorder) an effective amount of a modified immune cell as described herein or a composition thereof. In some embodiments, the individual has cancer. In some embodiments, provided herein is a method of treating a cancer responsive to inhibition of Cbl-b activity, comprising administering to an individual having a cancer responsive to inhibition of Cbl-b activity an effective amount of a modified immune cell as described herein or a composition thereof. In some embodiments, provided herein is a method of inhibiting abnormal cell proliferation, comprising administering to an individual in need thereof an effective amount of a modified immune cell as described herein or a composition thereof. The term "abnormal cell proliferation" as used herein includes hyperplasia or cancer cell proliferation. The cancer cells may be derived from a hematological cancer, such as lymphoma, leukemia, or myeloma. In other embodiments, the cancer cells may be derived from a non-hematological cancer, such as a sarcoma, carcinoma, or melanoma.

[0241] In certain embodiments, an individual in need of treatment, such as an individual having cancer or a T cell dysfunction disorder, is administered a composition comprising modified immune cells provided herein in a range of about 1 million to about 100 billion cells, such as, for example, 1 million to about 50 billion cells (e.g., about 5 million cells, about 25 million cells, about 500 million cells, about 1 billion cells, about 5 billion cells, about 20 billion cells, about 30 billion cells, about 40 billion cells, or a range defined by any two of the aforesaid values), such as, for example, about 10 million to about 100 billion cells (e.g., about 20 million cells, about 30 million cells, about 400 million cells, or a range defined by any two of the aforesaid values). 0 million cells, about 60 million cells, about 70 million cells, about 80 million cells, about 90 million cells, about 10 billion cells, about 25 billion cells, about 50 billion cells, about 75 billion cells, about 90 billion cells, or a range defined by any two of the foregoing values), and in some cases, about 100 million cells to about 50 billion cells (e.g., about 120 million cells, about 250 million cells, about 350 million cells, about 450 million cells, about 650 million cells, about 800 million cells, about 900 million cells, about 3 billion cells, about 30 billion cells, about 45 billion cells), or any value between these ranges.

[0242] The modified immune cells and compositions thereof are administered using standard administration techniques, formulations, and / or devices. Formulations and devices for storing and administering the compositions are provided, such as syringes and vials. Formulations or pharmaceutical compositions comprising the modified immune cells include those for intravenous, intraperitoneal, subcutaneous, or intramuscular administration. In some embodiments, the modified immune cells are administered parenterally. As used herein, the term "parenteral" includes, but is not limited to, intravenous, intramuscular, subcutaneous, and intraperitoneal administration. In some embodiments, the cell population is administered to a subject using peripheral systemic delivery by intravenous, intraperitoneal, or subcutaneous injection. The modified immune cell compositions can be provided as sterile liquid formulations, such as isotonic aqueous solutions, suspensions, emulsions, dispersions, or viscous compositions, which in some aspects may be buffered to a selected pH. Viscous compositions can be formulated within an appropriate viscosity range to provide extended contact time with a particular tissue. Liquid or viscous compositions may contain a carrier, which may be a solvent or dispersion medium containing, for example, water, saline, phosphate buffered saline, polyol (e.g., glycerol, propylene glycol, and liquid polyethylene glycol), and suitable mixtures thereof. Sterile injectable solutions may be prepared by incorporating the modified immune cells in a solvent, such as by mixing with a suitable carrier, diluent, or excipient, such as sterile water, saline, glucose, dextrose, or the like.

[0243] In some embodiments, the modified immune cells are co-administered with one or more additional therapeutic agents or in connection with another therapeutic intervention, either at the same time or sequentially in any order. For example, in some therapeutic regimens of the present disclosure, both the modified immune cells and a Cbl-b inhibitor are administered to a mammalian subject in need thereof, where the Cbl-b inhibitor is a compound of formula (I), (Ia), (IA)-(IJ), (II-A)-(II-H), (II-A-1)-(II-H-1), (III-A)-(III-H), (III-A-1)-(III-H-1), (IV-A)-(IV-J), or (IV-C-1)-(IV-J-1), or any variation thereof. Thus, in some embodiments, the therapeutic regimen includes both adoptive cell therapy and chemotherapy.

[0244] After the modified immune cells are administered to an individual (e.g., a human), the biological activity of the modified immune cell population can be measured by methods known in the art. Parameters to be determined include specific binding of the modified immune cells or other immune cells to antigens in vivo (e.g., by imaging) or ex vivo (e.g., by ELISA or flow cytometry). In some embodiments, the ability of the modified immune cells to destroy target cells can be measured using a cytotoxicity assay (see, e.g., Kochenderfer et al., J. Immunotherapy, 32: 689-702, 2009; and Herman et al., J. Immunological Methods, 285: 25-40, 2004). In some embodiments, the biological activity of the modified immune cells can also be measured by assaying the expression and / or secretion of certain cytokines, such as IL-2 and IFNγ.

[0245] C. Administration of Cbl-b inhibitors In some embodiments, a Cbl-b inhibitor or composition thereof can be administered directly to an individual to modulate an immune response, treat a disease or condition (e.g., cancer and / or abnormal cell proliferation) and / or inhibit Cbl-b activity in the individual. The Cbl-b inhibitor can be a compound of Table 1, a tautomer thereof, a stereoisomer thereof, or a pharma- ceutically acceptable salt thereof.

[0246] In some embodiments, provided herein is a method of modulating an immune response comprising administering to an individual an effective amount of a Cbl-b inhibitor provided herein or a composition thereof to modulate the individual's immune response. In some embodiments, the individual has a cancer, such as a hematological or non-hematological cancer described herein.

[0247] In some embodiments, provided herein is a method of treating a cancer responsive to inhibition of Cbl-b activity, comprising administering to an individual an effective amount of a Cbl-b inhibitor provided herein or a composition thereof to treat the cancer responsive to inhibition of Cbl-b activity. In some embodiments, the cancer is a hematological or non-hematological cancer, such as those described herein.

[0248]

[0243] In some embodiments, the present specification provides a method for inhibiting abnormal cell growth (e.g., hyperplasia), comprising administering to an individual an effective amount of a Cbl-b inhibitor or composition thereof provided herein to inhibit abnormal cell growth in the individual.

[0249]

[0244] In some embodiments, the present specification provides a method for inhibiting Cbl-b activity, the method comprising administering to an individual an effective amount of a Cbl-b inhibitor or composition thereof provided herein to inhibit Cbl-b activity in the individual.

[0250]

[0245] In some embodiments, the appropriate dosage of an active agent, such as for modulating the immune response of an individual in need thereof (e.g., an individual having a T cell dysfunction disorder), treating a disease or condition in an individual (e.g., an individual having cancer and / or abnormal cell proliferation) and / or inhibiting Cbl-b activity in an individual, will depend on the type of condition, disease or disorder to be treated, the severity and course of the condition, disease or disorder as defined above, whether the agent is administered for prophylactic or therapeutic purposes, previous treatments, the subject's medical history and response to the Cbl-b inhibitor, and the discretion of the attending physician.

[0251]

[0246] The Cbl-b inhibitor or composition thereof is preferably administered to an individual at one time or over a series of treatments. In some embodiments, the treatment includes multiple administrations of the Cbl-b inhibitor or composition thereof, where the interval between administrations can vary. For example, the interval between the first and second administrations is about 1 month, and the interval between subsequent administrations is about 3 months. In some embodiments, the Cbl-b inhibitor is administered at a flat dose. In some embodiments, the Cbl-b inhibitor is administered to an individual at a fixed dose based on the individual's body weight (e.g., mg / kg).

[0252] In some aspects of the present disclosure, the cancer is a blood cancer. For example, the blood cancer can be lymphoma, leukemia, or myeloma. In other aspects of the present disclosure, the cancer is a non-blood cancer. In particular, the non-blood cancer can be carcinoma, sarcoma, or melanoma.

[0253] In some embodiments, the Cbl-b inhibitor is co-administered with one or more additional therapeutic agents or in connection with another therapeutic intervention, either at the same time or sequentially in any order. For example, in some therapeutic regimens of the present disclosure, both the Cbl-b inhibitor and the modified immune cells are administered to a mammalian subject in need thereof, where the Cbl-b inhibitor is a compound of formula (I), (Ia), (IA)-(IJ), (II-A)-(II-H), (II-A-1)-(II-H-1), (III-A)-(III-H), (III-A-1)-(III-H-1), (IV-A)-(IV-J), or (IV-C-1)-(IV-J-1), or any variation thereof. The Cbl-b inhibitor can be a compound of Table 1, a tautomer thereof, a stereoisomer thereof, or a pharma- ceutically acceptable salt thereof. Thus, in some embodiments, the treatment regimen includes both adoptive cellular therapy and chemotherapy.

[0254] In some embodiments, the effectiveness of administration of a Cbl-b inhibitor in the methods herein (e.g., methods of modulating an immune response in an individual) may be determined by measuring the biological activity of immune cells present in a sample (e.g., a blood sample) isolated from the individual under treatment. For example, the effectiveness of the treatment may be determined by measuring the ability of immune cells isolated from the individual following treatment with a Cbl-b inhibitor to destroy target cells in a cytotoxicity assay. In some embodiments, the biological activity of immune cells present in a sample (e.g., a blood sample) may be measured by assaying the expression and / or secretion of certain cytokines, such as IL-2 and IFNγ.

[0255]

[0250] The present disclosure provides a method of treating cancer, comprising administering an effective amount of a Cbl-b inhibitor to an individual having cancer, and administering an effective amount of an additional therapeutic agent to the individual. Also provided is a method of treating an individual having cancer, comprising administering an effective amount of a Cbl-b inhibitor to the individual; and administering an effective amount of an additional therapeutic agent to the individual. In addition, the present disclosure provides a method of increasing an anti-cancer immune response, comprising administering an effective amount of a Cbl-b inhibitor to an individual having cancer, and administering an effective amount of an additional therapeutic agent to the individual. Further provided is a method of treating cancer, comprising administering an effective amount of a Cbl-b inhibitor to an individual having cancer, where the individual has been or is receiving an effective amount of an additional therapeutic agent.

[0256] In some embodiments of the method of the preceding paragraph, the Cbl-b inhibitor and the additional therapeutic agent are administered sequentially, in any order. As used herein, the terms "sequentially," "sequentially," and "sequentially" refer to administration of the Cbl-b inhibitor followed by the additional therapeutic agent, or administration of the additional therapeutic agent followed by the Cbl-b inhibitor. For example, sequential administration may involve a post-induction treatment phase that includes administration of the Cbl-b inhibitor in the absence of the additional therapeutic agent during the induction phase (first treatment), followed by administration of the additional therapeutic agent. The method may further include a maintenance phase that includes administration of the Cbl-b inhibitor or the additional therapeutic agent. Alternatively, sequential administration may involve a post-induction treatment phase that includes administration of the additional therapeutic agent in the absence of the Cbl-b inhibitor during the induction phase (first treatment), followed by administration of the Cbl-b inhibitor. The method may further include a maintenance phase that includes administration of the Cbl-b inhibitor or the additional therapeutic agent.

[0257] In some embodiments of the combination therapy, the Cbl-b inhibitor and the additional therapeutic agent are administered simultaneously. As used herein, the terms "simultaneously," "at the same time," and "concurrently" refer to the administration of the Cbl-b inhibitor and the additional therapeutic agent during the same visit or during the same treatment phase. For example, both the Cbl-b inhibitor and the additional therapeutic agent may be administered during one or more of the induction phase, treatment phase, and maintenance phase. However, simultaneous administration does not require that the Cbl-b inhibitor and the additional therapeutic agent be present together in a single formulation or pharmaceutical composition, or that the Cbl-b inhibitor and the additional therapeutic agent be administered at exactly the same time.

[0258] 1. Combination therapy including Cbl-b inhibitors and immune checkpoint inhibitors In some embodiments of the combination therapy of the present disclosure, the additional therapeutic agent comprises an immune checkpoint inhibitor. In some embodiments of the combination therapy of the present disclosure for treating cancer, the additional therapeutic agent comprises an immune checkpoint inhibitor. The term "immune checkpoint" refers to a signaling pathway that prevents activation of immune cells, while the term "immune checkpoint inhibitor" refers to a compound that interferes with an immune checkpoint to remove the brakes on immune cell activation. In some embodiments, the immune checkpoint inhibitor is an antagonist of at least one inhibitory checkpoint molecule. In some embodiments, the inhibitory checkpoint molecule is selected from the group consisting of PD-1 (CD279), PD-L1 (CD274), CTLA-4 (CD125), LAG3 (CD223), PVR (CD155), PVRL2 (CD112), PVRL3 (CD113), TIGIT, TIM3 (CD366), and VISTA. In some embodiments, the immune checkpoint inhibitor is an antagonist of at least one inhibitory checkpoint molecule selected from the group consisting of PD-1 (CD279), PD-L1 (CD274), and CTLA-4 (CD152).

[0259] PD-1 refers to programmed cell death protein 1 (PD-1). PD-1 antagonists suitable for the treatment methods, medicaments, and uses of the present disclosure include any chemical compound or biological molecule that blocks the binding of PD-L1 expressed on cancer cells or antigen presenting cells to PD-1 expressed on lymphocytes (T cells, B cells, and / or NK cells). Alternative names or synonyms for PD-1 and its ligands include CD279, PDCD1, PD1, and SLEB2 for PD-1; and CD274, PDCD1L1, PDL1, B7H1, B7-4, and B7-H for programmed cell death 1 ligand 1 (PD-L1). In some embodiments where a human subject is under treatment, the PD-1 antagonist blocks the binding of human PD-L1 to human PD-1. The amino acid sequence of the mature form of human PD-1 is listed in NCBI locus number NP_005009 as residues 21 to 288. The amino acid sequence of the mature form of human PD-L1 is listed in NCBI locus number NP_054862 as residues 19 to 290.

[0260] CTLA-4 refers to cytotoxic T-lymphocyte associated protein 4. CTLA-4 antagonists suitable for the treatment methods, medicaments, and uses of the present disclosure include any chemical compound or biological molecule that blocks CTLA-4 expressed on lymphocytes (T cells, B cells, and / or NK cells) from binding to ligands (CD80 and / or CD86) expressed on antigen presenting cells. Alternative names or synonyms for CTLA-4 include CD152, CTLA4, ALPS5, CELIAC3, GRD4, GSE, and IDDM12. In some embodiments where a human subject is under treatment, the CTLA-4 antagonist blocks human CTLA-4 from binding to a human ligand. The amino acid sequence of the mature form of human CTLA-4 is listed in NCBI locus number NP_005205 ​​as residues 36-223.

[0261] LAG3 refers to lymphocyte activation gene 3 protein. LAG3 antagonists suitable for the treatment methods, medicaments, and uses of the present disclosure include any chemical compound or biological molecule that blocks LAG3 expressed on lymphocytes (T cells, B cells, and / or NK cells) from binding to a ligand (MHC class II) expressed on an antigen presenting cell. LAG3 is also known as CD223. In some embodiments where a human subject is under treatment, the LAG3 antagonist blocks human LAG3 from binding to a human ligand. The amino acid sequence of the mature form of human LAG3 is listed in NCBI locus number NP_002277 as residues 23-525.

[0262] PVR refers to poliovirus receptor. PVR antagonists suitable for the treatment methods, medicaments, and uses of the present disclosure include any chemical compound or biological molecule that blocks PVR expressed on cancer cells or antigen presenting cells from binding to TIGIT expressed on lymphocytes (T cells, B cells, and / or NK cells). Alternative names or synonyms for PVR include CD155, PVS, HVED, NECL5, nectin-like protein 5, and TAGE4. In some embodiments where a human subject is under treatment, the PVR antagonist blocks human PVR from binding to human TIGIT. There are multiple isoforms of human PVR. The amino acid sequence of the alpha isoform of human PVR is listed in NCBI locus number NP_006496. The amino acid sequence of the beta isoform of human PVR is listed in NCBI locus number NP_001129240. The amino acid sequence of the gamma isoform of human PVR is listed under NCBI locus number NP_001129241. The amino acid sequence of the delta isoform of human PVR is listed under NCBI locus number NP_001129242.

[0263] PVRL2 refers to poliovirus receptor related 2. PVRL2 antagonists suitable for the treatment methods, medicaments, and uses of the present disclosure include any chemical compound or biological molecule that blocks PVRL2 expressed on cancer cells or antigen presenting cells from binding to TIGIT expressed on lymphocytes (T cells, B cells, and / or NK cells). Alternative names or synonyms for PVRL2 include CD112, NECTIN2, HVEB, herpes virus entry mediator B, PRR2, and PVRR2. In some embodiments where a human subject is under treatment, the PVRL2 antagonist blocks human PVRL2 from binding to human TIGIT. The amino acid sequence of the alpha isoform of human PVRL2 is listed in NCBI locus number NP_002847. The amino acid sequence of the delta isoform of human PVRL2 is listed in NCBI locus number NP_001036189.

[0264] PVRL3 refers to poliovirus receptor related 3. PVRL3 antagonists suitable for the treatment methods, medicaments, and uses of the present disclosure include any chemical compound or biological molecule that blocks PVRL3 expressed on cancer cells or antigen presenting cells from binding to TIGIT expressed on lymphocytes (T cells, B cells, and / or NK cells). Alternative names or synonyms for PVRL3 include CD113, NECTIN3, PRR3, and PVRR3. In some embodiments where a human subject is under treatment, the PVRL3 antagonist blocks human PVRL3 from binding to human TIGIT. The amino acid sequence of isoform 1 of human PVRL3 is listed in NCBI locus number NP_056295. The amino acid sequence of isoform 2 of human PVRL3 is listed in NCBI locus number NP_001230215. The amino acid sequence of human PVRL3 isoform 3 is listed under NCBI locus number NP_001230217.

[0265]

[0260] TIGIT refers to a T cell immunoreceptor protein having Ig and ITIM domains. TIGIT antagonists suitable for the treatment methods, medicines, and uses of the present disclosure include any chemical compound or biological molecule that blocks TIGIT expressed on lymphocytes (T cells, B cells, or NK cells) from binding to ligands (CD112, CD113, and / or CD155) expressed on cancer cells or antigen-presenting cells. Alternative names or synonyms for TIGIT include VSIG9, V-set and immunoglobulin domain-containing 9, VSTM3, V-set and transmembrane domain-containing 3, and Washington University Cell Adhesion Molecule (WUCAM). In some embodiments where a human subject is under treatment, the TIGIT antagonist blocks human TIGIT from binding to a human ligand. The amino acid sequence of the mature form of human TIGIT is listed in NCBI locus number NP_776160 as residues 22-244.

[0266] TIM3 refers to T cell immunoglobulin and mucin domain-containing 3 protein. TIM3 antagonists suitable for the treatment methods, medicines, and uses of the present disclosure include any chemical compound or biological molecule that blocks TIM3 expressed on lymphocytes (T cells, B cells, or NK cells) from binding to a ligand (galectin-9 phosphatidylserine) expressed on antigen presenting cells. Alternative names or synonyms for TIM3 include CD366, HAVCR2, Hepatitis A virus cellular receptor 2, KIM3, and SPTCL. In some embodiments where a human subject is under treatment, the TIM3 antagonist blocks human TIM3 from binding to a human ligand. The amino acid sequence of the mature form of human TIM3 is listed in NCBI locus number NP_116171 as residues 22-301.

[0267] VISTA refers to V-domain Ig T cell activation suppressor. VISTA antagonists suitable for the treatment methods, medicaments, and uses of the present disclosure include any chemical compound or biological molecule that blocks VISTA expressed on lymphocytes (T cells, B cells, and / or NK cells) from binding to a ligand expressed on a cancer cell or an antigen presenting cell. Alternative names or synonyms for VISTA include VSIR, V-set immunoregulatory receptor, PD-1H, B7H5, GI24, PP2135, SISP1, and Dies1. In some embodiments where a human subject is under treatment, the VISTA antagonist blocks human VISTA from binding to a human ligand. The amino acid sequence of the mature form of human VISTA is listed in NCBI locus number NP_071436 as residues 33-311.

[0268] The immune checkpoint inhibitor may be a biological molecule. For example, the immune checkpoint inhibitor may include an antibody or an antigen-binding fragment thereof. The antibody or fragment may be a monoclonal antibody (mAb), such as a human antibody, a humanized antibody, or a chimeric antibody, and may include a human constant region. In some embodiments, the human constant region is selected from the group consisting of IgG1, IgG2, IgG3, and IgG4 constant regions, and in certain embodiments, the human constant region is an IgG1 or IgG4 constant region. In some embodiments, the antibody or fragment is a bispecific antibody. In some embodiments, the antigen-binding fragment includes one of the group consisting of Fab, Fab'-SH, F(ab')2, scFv, and Fv fragments.

[0269] In some embodiments, the at least one inhibitory checkpoint molecule comprises PD-1. In some embodiments, the immune checkpoint inhibitor is selected from the group consisting of pembrolizumab, nivolumab, cemiplimab, and biosimilars thereof. In one embodiment, the anti-PD-1 antibody is pembrolizumab (MK-3475, marketed as KEYTRUDA® by Merck & Co.). In one embodiment, the anti-PD-1 antibody is nivolumab (BMS-936558 or MDX-1106, marketed as OPDIVO® by Bristol-Myers Squibb). In one embodiment, the anti-PD-1 antibody is cemiplimab (REGN2810, Regeneron). In some embodiments, the immune checkpoint inhibitor is a variant of pembrolizumab, nivolumab, or cemiplimab.

[0270] In some embodiments, the at least one inhibitory checkpoint molecule comprises PD-L1. In some embodiments, the immune checkpoint inhibitor is selected from the group consisting of atezolizumab, avelumab, durvalumab, and biosimilars thereof. In one embodiment, the anti-PD-L1 antibody is atezolizumab (marketed as TECENTRIQ® by Genentech, Inc.). In one embodiment, the anti-PD-L1 antibody is avelumab (marketed as BAVENCIO® by EMD Serono, Inc. and Pfizer, Inc.). In one embodiment, the anti-PD-L1 antibody is durvalumab (MEDI4736, marketed as IMFINZI® by AstraZeneca). In some embodiments, the immune checkpoint inhibitor is a variant of atezolizumab, avelumab, or durvalumab.

[0271] In some embodiments, the at least one inhibitory checkpoint molecule is CTLA-4. In some embodiments, the immune checkpoint inhibitor is selected from the group consisting of ipilimumab, tremelimumab, and biosimilars thereof. In one embodiment, the anti-CTLA4 antibody is ipilimumab (MDX-010 or BMS-734016, marketed as YERVOY® by Bristol-Myers Squibb). In one embodiment, the anti-CTLA4 antibody is tremelimumab (ticilimumab, CP-675,206, developed by AstraZeneca). In some embodiments, the immune checkpoint inhibitor is ipilimumab, or a variant of tremelimumab.

[0272] In some embodiments, the monoclonal antibody is a "variant" antibody that comprises the same heavy and light chain sequences as in a "reference" antibody, except that it has 3, 2, or 1 conservative amino acid substitutions at positions outside the light chain CDRs and / or 6, 5, 4, 3, 2, or 1 conservative amino acid substitutions at positions outside the heavy chain CDRs (e.g., the variant positions are located in framework or constant regions). In other words, the reference and variant antibodies differ from each other because they comprise identical CDR sequences but have conservative amino acid substitutions at no more than 3 or no more than 6 other positions in their full-length light and heavy chain sequences, respectively. The variant antibody is substantially similar to the reference antibody in terms of the following properties: binding affinity to an inhibitory checkpoint molecule and ability to block binding of an inhibitory checkpoint molecule to its ligand.

[0273]

[0268] In other embodiments, an immune checkpoint inhibitor may comprise an immunoadhesin comprising an inhibitory checkpoint molecule binding domain of one of its ligands fused to a constant region, such as the Fc region, of an immunoglobulin molecule.

[0274]

[0269] As used herein, the term "biosimilar" refers to a biological product that is similar but has no clinically meaningful differences in safety and efficacy from the originator product approved by the Federal Drug Administration (FDA). For example, there may be differences between a biosimilar product and the originator product in terms of clinically inactive ingredients (e.g., different formulation excipients, slight differences in glycosylation, etc.). Clinically meaningful properties can be determined through pharmacokinetic and pharmacodynamic studies. In some embodiments, a biosimilar product is an interchangeable product as determined by the FDA.

[0275] 2. Combination therapy including a Cbl-b inhibitor and an anti-neoplastic agent In some embodiments of the combination therapy of the present disclosure, the additional therapeutic agent comprises an anti-neoplastic agent. In some embodiments of the combination therapy herein for treating cancer, the additional therapeutic agent comprises an anti-neoplastic agent. As used herein, the terms "anti-neoplastic agent" and "antineoplastic agent" refer to therapeutic agents classified under the Anatomical Therapeutic Chemical Classification System (ATC) code L01 developed by the World Health Organization. In some embodiments, the anti-neoplastic agent is classified into one of the groups consisting of cytotoxic antibiotics (ATC code L01D), plant alkaloids (ATC code L01C), antimetabolites (ATC code L01B), alkylating agents (ATC code L01A), and other anti-neoplastic agents (ATC code L01X). In some embodiments, the anti-neoplastic agent is a small molecule drug (e.g., a cancer chemotherapeutic agent) as opposed to a biological molecule.

[0276]

[0271] Cytotoxic antibiotics are suitable antineoplastic agents for the treatment methods, medicaments and uses of the present disclosure. In some embodiments, the cytotoxic antibiotic is selected from the group consisting of ixabepilone, mitomycin, plicamycin, bleomycin, pixantrone, amrubicin, valrubicin, pirarubicin, mitoxantrone, idarubicin, zorubicin, aclarubicin, epirubicin, daunorubicin, doxorubicin, and dactinomycin.

[0277]

[0272] Plant alkaloids are suitable anti-neoplastic agents for the treatment methods, medicaments, and uses of the present disclosure. In some embodiments, the plant alkaloids are selected from the group consisting of trabectedin, cabazitaxel, paclitaxel poliglumex, docetaxel, paclitaxel, demecolcine, teniposide, etoposide, vintafolide, vinflunine, vinorelbine, vindesine, vincristine, and vinblastine.

[0278]

[0273] Antimetabolites are suitable anti-neoplastic agents for the treatment methods, medicaments and uses of the present disclosure. In some embodiments, the antimetabolites are pyrimidine analogs, purine analogs, or folic acid analogs. In some embodiments, the antimetabolites are selected from the group consisting of floxuridine, trifluridine, tegafur, fluorouracil, decitabine, azacitidine, capecitabine, gemcitabine, carmofur, tegafur, fluorouracil, cytarabine, nelarabine, clofarabine, fludarabine, cladribine, thioguanine, mercaptopurine, pralatrexate, pemetrexed, raltitrexed, and methotrexate.

[0279]

[0274] Alkylating agents are suitable antineoplastic agents for the treatment methods, medicaments, and uses of the present disclosure. In some embodiments, the alkylating agent is selected from the group consisting of dacarbazine, temozolomide, pipobroman, mitobronitol, etoglucide, uracil mustard, ranimustine, nimustine, fotemustine, streptozocin, semustine, lomustine, carmustine, carboquone, triaziquone, thiotepa, mannosulfan, treosulfan, busulfan, bendamustine, prednimustine, trofosfamide, ifosfamide, mechlorethamine, melphalan, chlorambucil, and cyclophosphamide.

[0280]

[0275] In other embodiments, the antineoplastic agent comprises another antineoplastic agent selected from the group consisting of platinum compounds (ATC Code L01XA), methylhydrazines (ATC Code L01XB), sensitizers (ATC Code L01XD), protein kinase inhibitors (ATC Code L01XE), and other agents (ATC Code L01XA).

[0281]

[0276] Platinum compounds are suitable anti-neoplastic agents for the treatment methods, medicaments, and uses of the present disclosure. In some embodiments, the platinum compound is selected from the group consisting of cisplatin, carboplatin, oxaliplatin, satraplatin, and polyplatylene.

[0282] 3. Combination therapy including Cbl-b inhibitors and radiation therapy

[0277] The present disclosure provides a method of treating cancer, comprising administering an effective amount of a Cbl-b inhibitor to an individual having cancer, and administering an effective amount of radiation therapy to the individual. Also provided is a method of treating an individual having cancer, comprising administering an effective amount of Cbl-b to the individual, and administering an effective amount of radiation therapy to the individual. In addition, the present disclosure provides a method of increasing an anti-cancer immune response, comprising administering an effective amount of a Cbl-b inhibitor to an individual having cancer, and administering an effective amount of radiation therapy to the individual. Furthermore, a method of treating cancer is provided, comprising administering an effective amount of a Cbl-b inhibitor to an individual having cancer, where the individual has been or is receiving an effective amount of radiation therapy.

[0283]

[0278] In some embodiments, the radiation therapy is external beam radiation therapy. In other embodiments, the radiation therapy is internal radiation therapy. In some embodiments, the radiation therapy is ablative radiation therapy.

[0284]

[0279] In some embodiments, the combination treatment regimen of the present disclosure includes administration of a Cbl-b inhibitor, radiation therapy, and one or both of an immune checkpoint inhibitor and an anti-neoplastic agent.

[0285]

[0280] Provided herein is a method of treating cancer, comprising administering to an individual having cancer a combination therapy comprising an effective amount of a Cbl-b inhibitor and an effective amount of a cancer vaccine. Also provided is a pharmaceutical comprising a Cbl-b inhibitor for use in combination with a cancer vaccine to treat cancer, and a pharmaceutical comprising both a Cbl-b inhibitor and a cancer vaccine for use in treating cancer. Further provided is the use of a Cbl-b inhibitor in the manufacture of a pharmaceutical for treating cancer in an individual when administered in combination with a cancer vaccine. Further provided is the use of a Cbl-b inhibitor and a cancer vaccine in the manufacture of one or more pharmaceuticals for treating cancer. In some embodiments, the Cbl-b inhibitor is a "small molecule".

[0286] Also provided herein is a method of treating cancer, comprising administering to an individual having cancer a combination therapy comprising an effective amount of a Cbl-b inhibitor and an effective amount of an oncolytic virus. Also provided is a pharmaceutical comprising a Cbl-b inhibitor for use in combination with an oncolytic virus to treat cancer, and a pharmaceutical comprising both a Cbl-b inhibitor and an oncolytic virus for use in treating cancer. Further provided is the use of a Cbl-b inhibitor in the manufacture of a pharmaceutical for treating cancer in an individual when administered in combination with an oncolytic virus. Further provided is the use of a Cbl-b inhibitor and an oncolytic virus in the manufacture of one or more pharmaceuticals for treating cancer. In some embodiments, the Cbl-b inhibitor is a "small molecule".

[0287] In some embodiments of the treatment methods, medicaments and uses of the present disclosure, the cancer is a blood cancer, such as lymphoma, leukemia or myeloma. In other embodiments of the treatment methods, medicaments and uses of the present disclosure, the cancer is a non-blood cancer, such as sarcoma, carcinoma or melanoma.

[0288] Hematological cancers include one or more leukemias, such as B-cell acute lymphoblastic leukemia ("BALL"), T-cell acute lymphoblastic leukemia ("TALL"), acute lymphoblastic leukemia (ALL); one or more chronic leukemias, including but not limited to chronic myelocytic leukemia (CML) and chronic lymphocytic leukemia (CLL); one or more chronic leukemias, including but not limited to B-cell prolymphocytic leukemia, blastic plasmacytoid dendritic cell neoplasm, Burkitt's lymphoma, diffuse large B-cell lymphoma, follicular lymphoma, hairy cell leukemia, small cell type or These include, but are not limited to, large cell follicular lymphoma, malignant lymphoproliferative conditions, MALT lymphoma, mantle cell lymphoma, marginal zone lymphoma, multiple myeloma, myelodysplastic and myelodysplastic syndromes, non-Hodgkin's lymphoma, plasmablastic lymphoma, plasmacytoid dendritic cell neoplasm, Waldenstrom's macroglobulinemia, and additional blood cancers or conditions including "preleukemias," a group of diverse hematological conditions united by the ineffective production (or dysplasia) of myeloid blood cells.

[0289]

[0284] Non-hematological cancers include, but are not limited to, neuroblastoma, renal cell carcinoma, colon cancer, colorectal cancer, breast cancer, squamous cell carcinoma, melanoma, gastric cancer, brain cancer, lung cancer (e.g., NSCLC), pancreatic cancer, cervical cancer, ovarian cancer, liver cancer, bladder cancer, prostate cancer, testicular cancer, thyroid cancer, uterine cancer, adrenal cancer, and head and neck cancer.

[0290] In some embodiments, the efficacy of administering an activation threshold-reducing agent or a costimulatory requirement-reducing agent, such as a Cbl-b inhibitor, in treating cancer is measured by determining a clinical outcome, such as a reduction in tumor size or tumor number, and / or survival rate. In some embodiments, "treating cancer" includes determining a patient's response to a treatment regimen based on the Response Evaluation Criteria in Solid Tumors (RECIST version 1.1) as described (see, e.g., Eisenhauer et al., Eur J Cancer, 45:228-247, 2009; and Nishino et al., Am J Roentgenol, 195: 281-289, 2010). Response criteria for determining an objective anti-tumor response according to RECIST 1.1 include complete response (CR); partial response (PR); progressive disease (PD); and stable disease (SD).

[0291]

[0286] Also provided herein is a method of treating cancer, comprising administering to an individual having cancer a combination therapy comprising an effective amount of an agent (activation threshold reducing agent) that lowers the activation threshold of immune cells (e.g., T cells, B cells, and / or NK cells) and an effective amount of a cancer vaccine. Also provided are medicaments comprising an activation threshold reducing agent for use in combination with a cancer vaccine to treat cancer, and medicaments comprising both an activation threshold reducing agent and a cancer vaccine for use in treating cancer. Further provided is the use of an activation threshold reducing agent in the manufacture of a medicament for treating cancer in an individual when administered in combination with a cancer vaccine. Further provided is the use of an activation threshold reducing agent and a cancer vaccine in the manufacture of one or more medicaments for treating cancer.

[0292]

[0287] Also provided herein is a method of treating cancer, comprising administering to an individual having cancer a combination therapy comprising an effective amount of an agent (activation threshold-reducing agent) that reduces the activation threshold of immune cells (e.g., T cells, B cells, and / or NK cells) and an effective amount of an oncolytic virus. Also provided are medicaments comprising an activation threshold-reducing agent for use in combination with an oncolytic virus to treat cancer, and medicaments comprising both an activation threshold-reducing agent and an oncolytic virus for use in treating cancer. Further provided is the use of an activation threshold-reducing agent in the manufacture of a medicament for treating cancer in an individual when administered in combination with an oncolytic virus. Further provided is the use of an activation threshold-reducing agent and an oncolytic virus in the manufacture of one or more medicaments for treating cancer.

[0293]

[0288] In some embodiments, the agent that lowers the activation threshold (activation threshold reducer) is an agent that reduces the costimulatory requirement of an immune cell (e.g., a T cell, a B cell, and / or a NK cell) (costimulatory requirement reducer). In some embodiments, the agent that lowers the activation threshold (activation threshold reducer) is an agent that promotes tumor immunosurveillance. In some embodiments, the agent that lowers the activation threshold (activation threshold reducer) is a Cbl-b inhibitor. In some embodiments, the agent that reduces the costimulatory requirement is a Cbl-b inhibitor. In some embodiments, the agent that promotes tumor immunosurveillance is a Cbl-b inhibitor.

[0294] In some embodiments, an activation threshold lowering agent, such as a Cbl-b inhibitor, has the ability to increase T cell activation and / or T cell proliferation. In some embodiments, an activation threshold lowering agent, such as a Cbl-b inhibitor, has the ability to reduce T cell exhaustion, T cell tolerance, and / or T cell anergy.

[0295] In some embodiments, the activation threshold reducing agent, such as a Cbl-b inhibitor, has the ability to increase production of one or more cytokines by T cells or surrounding immune cells (e.g., myeloid cells) in the activated T cell microenvironment. In some embodiments, the one or more cytokines include, but are not limited to, IFN-γ, IL-1β, IL-2, IL-4, IL-5, IL-6, IL-13, IL-18, TNFα, and GM-CSF. In some embodiments, the cytokine is one or more of IL-2, IFN-γ, TNFα, and GM-CSF. In some embodiments, the cytokine is a chemokine. In some embodiments, the one or more chemokines include, but are not limited to, IP-10, eotaxin, GROα, RANTES, MIP-1α, MIP-1β, MIP-2, MCP-1, and MCP-3. Increased expression of cytokines can be measured by ELISA.

[0296] In some embodiments, the activation threshold reducing agent, such as a Cbl-b inhibitor, has the ability to increase cell surface expression of one or more T cell activation markers. In some embodiments, the one or more T cell activation markers include, but are not limited to, CD25, CD44, CD62L, CD69, CD152 (CTLA4), CD154, CD137, and CD279. In some embodiments, the T cell activation marker is one or more of CD25, CD69, and CTLA4. The increase in expression of the cell surface markers can be measured by FACS.

[0297]

[0292] Methods for experimentally determining increased T cell activation, increased T cell proliferation, decreased T cell exhaustion, and / or decreased T cell tolerance are well known in the art. In some embodiments, reference may be made to Biological Example 9 and / or Biological Example 13 provided herein for representative methods for determining T cell activation. In some embodiments, reference may be made to Biological Example 10 and / or Biological Example 14 for representative in vitro and in vivo methods for determining increased T cell activation, increased T cell proliferation, decreased T cell exhaustion, and / or decreased T cell tolerance.

[0298] In some embodiments, the activation threshold reducing agent, such as a Cbl-b inhibitor, has the ability to increase B cell activation. In some embodiments, the increase in B cell activation includes an increase in cell surface expression of one or more B cell activation markers. In some embodiments, the one or more B cell activation markers include, but are not limited to, CD69, CD86, and MHC class II (e.g., HLA-DR). In some embodiments, the B cell activation marker is CD69. The increase in cell surface marker expression can be measured by FACS. In some embodiments, the increase in B cell activation includes an increase in activation of proteins in signal transduction pathways, such as those mediated by ERK, JNK, and Syk. The increase in activation of proteins can be detected by measuring the phosphorylation level of the protein using reagents, such as anti-phospho antibodies, available in the art.

[0299] In some embodiments, the activation threshold reducing agent, such as a Cbl-b inhibitor, has the ability to increase NK cell activation. In some embodiments, the increase in NK cell activation includes secretion of one or more cytokines. In some embodiments, the one or more cytokines include, but are not limited to, IFN-γ, TNFα, and MIP-1β. The increase in cytokine expression can be measured by ELISA. In some embodiments, the increase in NK cell activation includes an increase in cell surface expression of one or more NK cell activation markers. In some embodiments, the one or more NK cell activation markers include, but are not limited to, CD69 and CD107a. The increase in cell surface marker expression can be measured by FACS. In some embodiments, the increase in NK cell activation includes an increase in killing of target cells, such as tumor cells, including primary tumor cells, and tumor cells from cell lines, such as the K562 cell line.

[0300]

[0295] Methods for experimentally determining the increase in B cell activation and NK cell activation are well known in the art. In some embodiments, Biological Example 10 and / or Biological Example 14 can be referred to for representative methods for determining B cell activation. In some embodiments, Biological Example 10 and / or Biological Example 14 can be referred to for representative methods for determining NK cell activation.

[0301] Modulation of immune cell activity, such as T cells, B cells, or NK cells, may be measured by determining a baseline value of a parameter of interest (e.g., cytokine secretion). For example, in a sample obtained from an in vitro experiment in which cells are contacted with a Cbl-b inhibitor, T cell activation can be measured before contacting with or administering the Cbl-b inhibitor to determine a baseline value. A reference value is then obtained for T cell activation after contacting with or administering the Cbl-b inhibitor. The reference value is compared to the baseline value to determine the amount of T cell activation resulting from contact or administration of a Cbl-b inhibitor or composition thereof. For example, in some embodiments, immune cell (e.g., T cell) activation is increased by at least 0.1-fold in the sample when compared to a baseline value, where the baseline value is obtained before contacting immune cells (e.g., T cells) with a Cbl-b inhibitor or composition thereof. In some embodiments, immune cell (e.g., T cell) activation is increased by about 0.1-fold, about 0.2-fold, about 0.3-fold, about 0.4-fold, about 0.5-fold, about 0.6-fold, about 0.7-fold, about 0.8-fold, about 0.9-fold, about 1-fold, about 2-fold, about 4-fold, about 6-fold, about 8-fold, about 10-fold, about 20-fold, about 30-fold or more and about 50-fold or less than the baseline value. Immune cell activation may be determined by measuring biological markers of activation, such as increased cytokine secretion, increased cell surface expression of activation markers (e.g., cell surface markers), or increased phosphorylation of proteins in downstream signaling pathways. For the parameter under test and the condition to which the immune cells were treated, a fold increase over baseline value indicative of immune cell activation can be determined. For example, to measure T cell activation, a baseline value can be obtained from T cells stimulated with anti-CD3 antibody in combination with anti-CD28 antibody, but not incubated with a Cbl-b inhibitor. A reference value is then obtained from T cells stimulated with anti-CD3 antibody in combination with anti-CD28 antibody, which have been or are in contact with a Cbl-b inhibitor. A positive response of immune cell activation can then be determined from the obtained reference value.Similar reference measurements can be obtained and compared to baseline values ​​to determine T cell activation, T cell proliferation, T cell depletion, T cell tolerance, B cell activation, and / or NK cell activation. Measurements of these parameters can be obtained using techniques well known in the art and those provided in Biological Examples 9, 10, 13, and 14.

[0302] The term "baseline" or "baseline value" as used herein may refer to a measurement or characteristic prior to administration of a therapeutic agent as disclosed herein (e.g., a composition comprising a Cbl-b inhibitor as described herein) or at the start of administration of the therapeutic agent. By comparing the baseline value to a reference value, an increase or decrease in immune cell function (e.g., increasing T cell activation, increasing T cell proliferation, decreasing T cell exhaustion, and / or decreasing T cell tolerance) may be determined. The term "reference" or "reference value" as used herein may refer to a measurement or characteristic after administration of a therapeutic agent as disclosed herein (e.g., a composition comprising a Cbl-b inhibitor as described herein). The reference value may be measured one or more times during an experimental time course, dosage regimen, or treatment cycle, or at the completion of an experimental time course, dosage regimen, or treatment cycle. A "reference value" may be an absolute value, a relative value, a value with upper and / or lower limits, a range of values, an arithmetic mean, a median, a mean, or a value compared to a baseline value. Similarly, a "baseline value" may be an absolute value, a relative value, a value with upper and / or lower limits, a range of values, an arithmetic mean, a median, a mean, or a value compared to a reference value. Reference and / or baseline values ​​can be obtained from one sample (e.g., one sample obtained from an individual), two different samples (e.g., samples obtained from two different individuals), or a group of samples (e.g., samples obtained from a group of 2, 3, 4, 5 or more individuals).

[0303] In some embodiments, a positive response for T cell activation as measured by cytokine secretion (e.g., IL-2 secretion) by T cells stimulated with anti-CD3 antibody in combination with anti-CD28 antibody in the presence of a Cbl-b inhibitor is at least 2.5 times the baseline value for cytokine secretion (e.g., IL-2 secretion) obtained from T cells stimulated with anti-CD3 antibody in combination with anti-CD28 antibody in the absence of a Cbl-b inhibitor. In some embodiments, a positive response for T cell activation as measured by surface marker expression (e.g., CD25 surface marker staining) by T cells stimulated with anti-CD3 antibody in combination with anti-CD28 antibody in the presence of a Cbl-b inhibitor is at least 1.3 times the baseline value for surface marker expression (e.g., CD25 surface marker staining) obtained from T cells stimulated with anti-CD3 antibody in combination with anti-CD28 antibody in the absence of a Cbl-b inhibitor. In some embodiments, the baseline value can be obtained from T cells stimulated with anti-CD3 antibody alone and not incubated with a Cbl-b inhibitor. In some embodiments, a positive response for T cell activation as measured by cytokine secretion (e.g., IL-2 secretion) by T cells stimulated with anti-CD3 antibody alone in the presence of a Cbl-b inhibitor is at least 0.1 times the baseline value for cytokine secretion (e.g., IL-2 secretion) obtained from T cells stimulated with anti-CD3 antibody alone in the absence of a Cbl-b inhibitor. In some embodiments, a positive response for T cell activation as measured by surface marker expression (e.g., CD25 surface marker staining) by T cells stimulated with anti-CD3 antibody alone in the presence of a Cbl-b inhibitor is at least 0.6 times the baseline value for surface marker expression (e.g., CD25 surface marker staining) obtained from T cells stimulated with anti-CD3 antibody alone in the absence of a Cbl-b inhibitor.

[0304]

[0299] The present disclosure provides a method of treating cancer, comprising administering an effective amount of a Cbl-b inhibitor to an individual having cancer, and administering an effective amount of a cancer vaccine to the individual. Also provided is a method of treating an individual having cancer, comprising administering an effective amount of a Cbl-b inhibitor to the individual; and administering an effective amount of a cancer vaccine to the individual. In addition, the present disclosure provides a method of increasing an anti-cancer immune response, comprising administering an effective amount of a Cbl-b inhibitor to an individual having cancer, and administering an effective amount of a cancer vaccine to the individual. Further provided is a method of treating cancer, comprising administering an effective amount of a Cbl-b inhibitor to an individual having cancer, where the individual has been or is receiving an effective amount of a cancer vaccine.

[0305]

[0300] In addition, the present disclosure provides a method of treating cancer, comprising administering an effective amount of a Cbl-b inhibitor to an individual having cancer, and administering an effective amount of an oncolytic virus to the individual. Also provided is a method of treating an individual having cancer, comprising administering an effective amount of a Cbl-b inhibitor to the individual; and administering an effective amount of an oncolytic virus to the individual. In addition, the present disclosure provides a method of increasing an anti-cancer immune response, comprising administering an effective amount of a Cbl-b inhibitor to an individual having cancer, and administering an effective amount of an oncolytic virus to the individual. Further provided is a method of treating cancer, comprising administering an effective amount of a Cbl-b inhibitor to an individual having cancer, where the individual has been or is receiving an effective amount of an oncolytic virus.

[0306] In some embodiments of the method of the preceding paragraph, the Cbl-b inhibitor and the cancer vaccine are administered sequentially in any order. In certain embodiments, as used herein, the terms "sequentially," "sequentially," and "sequentially" refer to administration of a cancer vaccine followed by a Cbl-b inhibitor, or administration of a cancer vaccine followed by a Cbl-b inhibitor. For example, sequential administration may involve administration of a Cbl-b inhibitor in the absence of a cancer vaccine during an induction phase (first-line treatment), followed by a post-induction treatment phase including administration of both the cancer vaccine and the Cbl-b inhibitor. The method may further include a maintenance phase including administration of a Cbl-b inhibitor or administration of a further dose of the cancer vaccine. Alternatively, sequential administration may involve administration of a cancer vaccine in the absence of a Cbl-b inhibitor during an induction phase (first-line treatment), followed by administration of a Cbl-b inhibitor. The method may further include a maintenance phase including administration of a Cbl-b inhibitor or a further dose of the cancer vaccine.

[0307] In some embodiments of the method of the preceding paragraph, the Cbl-b inhibitor and the oncolytic virus are administered sequentially in any order. In certain embodiments, as used herein, the terms "sequentially," "sequentially," and "sequentially" refer to administration of the Cbl-b inhibitor after the oncolytic virus, or administration of the oncolytic virus after the Cbl-b inhibitor. For example, sequential administration may involve a post-induction treatment phase that includes administration of the Cbl-b inhibitor in the absence of the oncolytic virus during the induction phase (first-line treatment), followed by administration of both the oncolytic virus and the Cbl-b inhibitor. The method may further include a maintenance phase that includes administration of the Cbl-b inhibitor or administration of an additional dose of the oncolytic virus. Alternatively, sequential administration may involve a post-induction treatment phase that includes administration of the oncolytic virus in the absence of the Cbl-b inhibitor during the induction phase (first-line treatment), followed by administration of the Cbl-b inhibitor. The method may further include a maintenance phase comprising administration of a Cbl-b inhibitor or an additional dose of the oncolytic virus.

[0308] In some embodiments of the combination therapy, the Cbl-b inhibitor and the cancer vaccine are administered simultaneously. In certain embodiments, as used herein, the terms "simultaneously," "at the same time," and "concurrently" refer to the administration of the Cbl-b inhibitor and the cancer vaccine during the same visit or during the same treatment phase. For example, both the Cbl-b inhibitor and the cancer vaccine can be administered during one or more of the induction phase, the treatment phase, and the maintenance phase. However, simultaneous administration does not require that the Cbl-b inhibitor and the cancer vaccine are present together in a single formulation or pharmaceutical composition, or that the Cbl-b inhibitor and the cancer vaccine are administered at exactly the same time.

[0309] In some embodiments of the combination therapy, the Cbl-b inhibitor and the oncolytic virus are administered simultaneously. In certain embodiments, as used herein, the terms "simultaneously," "at the same time," and "concurrently" refer to the administration of the Cbl-b inhibitor and the oncolytic virus during the same visit or during the same treatment phase. For example, both the Cbl-b inhibitor and the oncolytic virus can be administered during one or more of the induction phase, the treatment phase, and the maintenance phase. However, simultaneous administration does not require that the Cbl-b inhibitor and the oncolytic virus are present together in a single formulation or pharmaceutical composition, or that the Cbl-b inhibitor and the oncolytic virus are administered at exactly the same time.

[0310] In some aspects, the treatment includes multiple administrations of the Cbl-b inhibitor or a composition thereof, where the interval between administrations can vary. In some embodiments, the Cbl-b inhibitor is administered to an individual at a flat dose (e.g., mg / adult or mg / child). In some embodiments, the Cbl-b inhibitor is administered to an individual at a fixed dose based on the individual's body weight (e.g., mg / kg).

[0311] In some embodiments, the efficacy of the combination therapy disclosed herein may be determined by measuring the biological activity of immune cells present in a sample isolated from an individual under treatment. For example, the ability of immune cells isolated from a treated individual to destroy target cells using a cytotoxicity assay may be used to determine the efficacy of the treatment. In some embodiments, the biological activity of immune cells present in a sample may be measured by assaying the expression and / or secretion of certain cytokines, such as IL-2 and IFNγ.

[0312]

[0307] The term "cancer vaccine", as used herein, unless otherwise specified, refers to a "therapeutic cancer vaccine" that will be administered to an individual with cancer for the purpose of treating the cancer (and optionally preventing the recurrence of the cancer). In contrast, a "prophylactic cancer vaccine" (prophylactic cancer vaccine) will be administered to an individual without cancer for the purpose of preventing cancer or reducing the individual's risk of developing cancer. Examples of prophylactic cancer vaccines are human papillomavirus vaccines for the prevention of squamous cell carcinoma and hepatitis B virus vaccines for the prevention of hepatocellular carcinoma. A cancer vaccine is an immunogenic composition that includes a pharma- ceutically acceptable excipient and at least one tumor antigen, such as a tumor-specific antigen or a tumor-associated antigen.

[0313] As used herein, the terms "oncolytic virus" and "OV" refer to a virus that infects and kills cancer cells. Cancer cell death is the result of both direct cell lysis and induction of anti-tumor immunity. In some embodiments, an "oncolytic virus" is a replication-competent virus, which selectively replicates in cancer cells. In other embodiments, an "oncolytic virus" is a replication-deficient virus, which does not replicate in cancer cells, either as a result of genetic manipulation or inactivation (e.g., UV irradiation or heat) of the oncolytic virus.

[0314] In some embodiments, the tumor antigens include "common tumor antigens" that are common to many cancers of the same type. Non-limiting examples of common tumor antigens are breast cancer antigen HER2, prostate cancer antigens PAP and PSA, and melanoma antigens MART-1 and MAGE. In other embodiments, the tumor antigens include "neo-antigens" that arise as a result of tumor-specific DNA alterations (e.g., somatic mutations). Thus, neo-antigens typically have amino acid sequences that are not present in normal mammalian genomes (Schumacher and Schreiber, Science, 348: 69-74, 2015). Non-limiting examples of neo-antigens are BRAF V600E, KRAS G12D, KRAS G12V, PIK3CA H1047R, and PIC3CA E545K. Currently, the tumor-specific neoantigen database (TSNAdb) is available free of charge (Wu et al., Genomics Proteomics Bioinformatics 16: 276-282, 2018).

[0315]

[0310] Various techniques are suitable for identifying neoantigens for inclusion in a cancer vaccine as part of a combination treatment that includes an activation threshold reducing agent such as a Cbl-b inhibitor. For example, neoantigens can be identified by a method that includes isolating DNA from a tumor biopsy obtained from an individual, sequencing the DNA, and identifying one or more neoantigens by computer analysis of the sequence (Aldous and Dong, Bioorg Med Chem, 26: 2842-2849, 2018). In some embodiments, the computer analysis involves identifying peptides 8-11 amino acids long that are predicted to bind to at least one HLA allele expressed by cells of the tumor, and that contain at least one missense mutation (Wu et al., Genomics Proteomics Bioinformatics 16: 276-282, 2018). The inclusion of neoantigens in a cancer vaccine may be advantageous in overcoming tolerance and reducing the risk of autoimmunity.

[0316]

[0311] Cancer vaccine platforms suitable for use in the methods, medicaments, and uses disclosed herein include, but are not limited to, synthetic peptides, recombinant proteins, nucleic acids (DNA or mRNA), microbial vectors, tumor cells, and antigen-presenting cells (see, e.g., DeMaria and Bilusic, Hematol Oncol Cin North Am, 33: 199-214, 2019; and Maeng and Berzofsky, F1000Research 2019, 8(F1000 Faculty Rev): 654, 2019).

[0317] In some embodiments, the tumor antigen of the cancer vaccine comprises at least one synthetic peptide or recombinant protein. In some embodiments, the synthetic peptide is at least 8 amino acids long, and in certain embodiments, less than 80 amino acids long. In some embodiments, the tumor antigen comprises multiple synthetic peptides, or the tumor antigen comprises a synthetic peptide or recombinant protein comprising the amino acid sequence of two, three, or more epitopes. An "epitope" is the portion of an antigen to which an antibody or B-cell receptor binds, or the portion presented for T-cell receptor binding by a major histocompatibility complex molecule (MHC class I or class II) on the surface of a cell, such as a tumor cell or dendritic cell. In some embodiments, the epitope is a "linear epitope" made up of contiguous amino acids of the tumor antigen sequence (primary structure). In some embodiments, the epitope is a "conformational epitope" made up of non-contiguous amino acids of the tumor antigen (tertiary structure). In some embodiments, the tumor antigen comprises a recombinant protein comprising both one or more linear epitopes and one or more conformational epitopes.

[0318] In some embodiments, the tumor antigen is encoded by a DNA or mRNA molecule. In some embodiments, the tumor antigen is encoded by a nucleic acid of a microbial vector, or, in other words, the cancer vaccine comprises a microbial vector. In some embodiments, the microbial vector is a live attenuated microbial vector. In one embodiment, the live attenuated microbial vector is TICE® BCG, a live culture preparation of the Bacillus Calmette-Guerin (BCG) strain of Mycobacterium bovis, marketed by Organon USA, Inc. (Roseland, NJ). TICE® BCG is approved by the Federal Drug Administration (FDA) for intravesical use upon reconstitution with sterile saline (e.g., a pharma- ceutical acceptable excipient), and is indicated for the treatment and prevention of bladder intraepithelial neoplasia, and for the prevention of primary or recurrent Ta and / or T1 papillary tumors following transurethral resection.

[0319] In some embodiments, the microbial vector is a recombinant microbial vector, such as a recombinant viral vector or a recombinant bacterial vector. Recombinant viral vectors suitable for use in the combination therapy of the present disclosure include, but are not limited to, retroviruses, lentiviruses, adenoviruses, adeno-associated viruses, poxviruses, and herpes viruses (Chulpanova et al., Biomedicines, 6: 94, 2018). In some embodiments, the microbial vector is a recombinant bacterial vector. Recombinant bacterial vectors suitable for use in the combination treatments of the present disclosure include, but are not limited to, Clostridium (C. novyi), Listeria (e.g., L. monocytogenes), Pseudomonas (e.g., P. aeruginosa), and Salmonella (S. typhimurium) (Toussant et al., Expert Rev Vaccines, 12: 1139-1154, 2013).

[0320] In some embodiments, the cancer vaccine comprises an antigen-presenting cell (APC) in contact with a tumor antigen, such as a synthetic peptide or recombinant protein. In some embodiments, the APC is transfected with a nucleic acid encoding the tumor antigen. In some embodiments, the APC is transfected with a nucleic acid encoding a cytokine. In some embodiments, the APC comprises a dendritic cell or a mesenchymal stem cell. In one embodiment, the cancer vaccine is PROVENGE® (Sipuleucel-T), marketed by Dendreon Corp. (Seattle, WA). PROVENGE® comprises lactated Ringer's solution (e.g., a pharma- ceutically acceptable excipient) and peripheral blood mononuclear cells (PBMCs) activated with a PAP-GM-CSF fusion protein consisting of prostatic acid phosphatase linked to granulocyte-macrophage colony-stimulating factor. PROVENGE® is approved by the Federal Drug Administration (FDA) for intravenous infusion for the treatment of asymptomatic or minimally symptomatic metastatic prostate cancer.

[0321] In some embodiments, the cancer vaccine comprises killed tumor cells. In some embodiments, the cancer vaccine comprises a tumor cell lysate. In some embodiments, the cancer vaccine comprises an APC contacted with a tumor cell lysate.

[0322]

[0317] The adjuvants of the cancer vaccine suitable for use in the methods, medicines and uses of the present disclosure include, but are not limited to, FDA approved approved formulation adjuvants.In particular, the adjuvants of the current FDA approved approved formulations include aluminum salts, monophosphoryl lipid A, oil-in-water emulsions (e.g., squalene-in-water emulsions MF59 or AS03), saponin, and CpG oligodeoxynucleotides.

[0323] Oncolytic viruses suitable for use in the methods, medicaments, and uses of the present disclosure include, but are not limited to, adenovirus, coxsackievirus, echovirus, fowlpox virus, herpes simplex virus, Maraba virus, measles virus, myxoma virus, Newcastle disease virus, parvovirus, poliovirus, retrovirus, reovirus, Seneca Valley virus, Semiliki Forest virus, vaccinia virus, and vesicular stomatitis virus (see, e.g., Russell and Peng, Chin Clin Oncol, 7: 16, 2018; and Sivanandam et al., Molecular Therapy Oncolytics, 13: 93-106).

[0324] In some embodiments, the oncolytic virus is not genetically engineered (non-recombinant virus). In some embodiments, the non-recombinant virus is an echovirus (e.g., Rigvir), Newcastle Disease Virus, Parvovirus, Reovirus, or Seneca Valley Virus.

[0325] In some embodiments, the oncolytic virus is a recombinant virus engineered to include one or more gene deletions, one or more gene insertions, or one or more gene deletions and one or more gene insertions. In some embodiments, the recombinant virus is engineered to modify host cell specificity and / or tumor cell cytotoxicity. In some embodiments, the recombinant oncolytic virus is engineered by functional deletion of one or more viral genes encoding proteins that suppress host cell responses (e.g., antiviral responses) and / or insertion of one or more transgenes encoding proteins that promote host cell responses (e.g., antitumor responses) (see, e.g., Guo et al., Frontiers in Immunology, 8: Article 555, 2017; and Lin et al., Oncology Letters, 15: 4053-4060, 2018). In some embodiments, the recombinant virus is further engineered by insertion of a transgene encoding a detectable marker, such as a fluorescent protein. The desired antitumor response includes one or both of an innate immune response and an adaptive immune response.

[0326] In some embodiments, the recombinant oncolytic virus is a recombinant herpes simplex virus (HSV), such as HSV type 1. In one embodiment, the recombinant oncolytic virus is IMLYGIC®, also known as talimogene laherparepvec or T-VEC, marketed by Amgen Inc. (Thousand Oaks, CA). IMLYGIC® is a recombinant HSV-1 that contains a functional deletion of the ICP34.5 and ICP47 genes and an insertion of a nucleic acid encoding human granulocyte-macrophage colony-stimulating factor (GM-CSF). IMLYGIC® is approved by the Federal Drug Administration (FDA) for the local treatment of unresectable cutaneous, subcutaneous, and nodal lesions in patients with recurrent melanoma by intralesional injection (intratumoral administration). In addition, IMLYGIC® has been approved by the European Medicines Agency (EMA) for the treatment of adults with locally or distantly metastatic (stage IIIB, IIIC, or IVM1a) unresectable melanoma. Specifically, the EMA-approved formulation will be administered by intralesional injection (intratumoral administration) into cutaneous, subcutaneous, and / or nodal lesions that are visible, palpable, or detectable by ultrasound guidance.

[0327] In some embodiments, the recombinant oncolytic virus is a recombinant adenovirus, such as a serotype 5 adenovirus. In one embodiment, the recombinant adenovirus is Oncorine (H101), formerly known as Onyx-015. Oncorine is a serotype 5 adenovirus engineered by inactivation (functional deletion) of the viral E1B-55k and viral E3 genes. Oncorine has been approved by the Chinese State Food and Drug Administration for the treatment of head and neck cancer in combination with chemotherapy (antineoplastic therapy).

[0328] In some embodiments, the recombinant oncolytic virus is a recombinant poxvirus. In some embodiments, the poxvirus is a vaccinia virus or a fowlpox virus. In some embodiments, the vaccinia virus is a modified vaccinia Ankara. In some embodiments, the recombinant vaccinia virus is engineered by functional deletion of one or more viral genes encoding proteins that suppress host cell responses (e.g., antiviral responses) and / or insertion of one or more transgenes encoding proteins that promote host cell responses (e.g., antitumor responses) (see, e.g., Guo et al., Journal of ImmunoTherapy of Cancer, 7: 6, 2019). In one embodiment, the recombinant vaccinia virus is Pexa-Vec, also known as pexastimogene devacirepvec and JX-594, which is a vaccinia virus engineered by inactivation (functional deletion) of the viral thymidine kinase gene and insertion of transgenes encoding human GM-CSF and β-galactosidase (Heo et al., Nat Med, 19: 329-336, 2013). In another embodiment, the recombinant vaccinia virus comprises a functional deletion of the viral thymidine kinase and vaccinia growth factor genes, and insertion of a transgene encoding the chemokine CXCL11 (see, e.g., Liu et al., OncoImmunology, 5: 3, e1091554, 2016; and Liu et al., Nature Communications, 8: 14754, 2017).

[0329] Further embodiments of the combination therapy of the present disclosure include at least one additional therapeutic agent. In some embodiments, the at least one additional therapeutic agent is selected from the group consisting of immune checkpoint inhibitors, chemotherapy (antineoplastic agents), radiation therapy, and combinations thereof.

[0330] In some embodiments, the immune checkpoint inhibitor is an antagonist of at least one inhibitory immune checkpoint molecule. In some embodiments, the at least one inhibitory immune checkpoint molecule is selected from the group consisting of PD-1 (CD279), PD-L1 (CD274), and CTLA4 (CD152). The immune checkpoint inhibitor may be a therapeutic biologic. For example, the immune checkpoint inhibitor may comprise an antibody or an antigen-binding fragment thereof. The antibody or fragment may be a monoclonal antibody (mAb), a human antibody, a humanized antibody, or a chimeric antibody and may comprise a human constant region. In some embodiments, the human constant region is selected from the group consisting of IgG1, IgG2, IgG3, and IgG4 constant regions, and in certain embodiments, the human constant region is an IgG1 or IgG4 constant region. In some embodiments, the antibody or fragment is a bispecific antibody. In some embodiments, the antigen-binding fragment comprises one of the group consisting of Fab, Fab'-SH, F(ab')2, scFv, and Fv fragments.

[0331] In some embodiments, chemotherapy includes at least one antineoplastic agent (i.e., WHO ATC code L01). In some embodiments, the at least one antineoplastic agent is selected from the group consisting of cytotoxic antibiotics, plant alkaloids, antimetabolites, and alkylating agents, other antineoplastic agents, and combinations thereof. When used in connection with chemotherapy, an antineoplastic agent is a "drug" as opposed to a "therapeutic biologic."

[0332]

[0327] In some embodiments, the radiation therapy is external beam radiation therapy. In other embodiments, the radiation therapy is internal radiation therapy. In some embodiments, the radiation therapy is ablative radiation therapy.

[0333]

[0328] As used herein, the term "biosimilar" refers to a biological product that is similar but has no clinically meaningful differences in safety and efficacy from the originator product approved by the Federal Drug Administration (FDA). For example, there may be differences between the biosimilar product and the originator product in terms of clinically inactive ingredients (e.g., different formulation excipients, slight differences in glycosylation, etc.). Clinically meaningful properties can be determined through pharmacokinetic and pharmacodynamic studies. In some embodiments, the biosimilar product is an interchangeable product as determined by the FDA. In some embodiments, the cancer vaccine is a biosimilar of an FDA-approved product.

[0334] IV. Compositions, Formulations and Routes of Administration

[0329] The present disclosure includes a pharmaceutical composition of any of the compounds disclosed herein, or a salt thereof, or a solvate thereof. Thus, the present disclosure includes a pharmaceutical composition comprising a Cbl-B inhibitor, which is a compound of formula (I), (Ia), (IA) to (IJ), (II-A) to (II-H), (II-A-1) to (II-H-1), (III-A) to (III-H), (III-A-1) to (III-H-1), (IV-A) to (IV-J), or (IV-C-1) to (IV-J-1), or any of the modifications thereof disclosed herein, or a pharma- ceutically acceptable salt or solvate thereof, or a tautomer thereof, or a stereoisomer or a mixture of stereoisomers thereof, and a pharma- ceutically acceptable excipient, such as a pharma- ceutically acceptable vehicle or a pharma-ceutically acceptable carrier. In some embodiments, the compound is a compound selected from compound numbers 1-58 in Table 1, or a pharma- ceutically acceptable salt or solvate thereof, or a tautomer thereof, or a stereoisomer or mixture of stereoisomers thereof. In one aspect, the pharma- ceutically acceptable salt is an acid addition salt, such as a salt formed with an inorganic acid or an organic acid.

[0335] The compounds and compositions disclosed herein may be administered in any suitable form and by any suitable route that will provide sufficient levels of the compound for the treatment of a disease or disorder. In some embodiments, the Cbl-b inhibitor and / or additional therapeutic agent are administered by enteral administration. In some embodiments, the enteral administration is oral administration. In other embodiments, the Cbl-b inhibitor and / or additional therapeutic agent are administered by parenteral administration. In some embodiments, the parenteral administration is intratumoral injection. In some embodiments, the parenteral administration is by a route selected from the group consisting of intravenous, intraperitoneal, and subcutaneous.

[0336] Suitable routes of administration include oral, enteral, and parenteral administration, including subcutaneous, intravenous, intraarterial, intramuscular, intrasternal, intraperitoneal, intralesional, intraarticular, intratumoral, or infusion. The compounds and compositions can also be administered sublingually, mucosally, bucally, subcutaneously, spinally, epidurally, intraventricularly, by inhalation (e.g., as a mist or spray), intranasally, intravaginally, rectally, topically, or transdermally, or by sustained or sustained release mechanisms. The compounds and compositions can be administered in unit dosage formulations containing conventional pharmacologic carriers, excipients, adjuvants, and vehicles as appropriate. The compounds and compositions can also be administered directly to specific or diseased organs or tissues. The compounds can be mixed with pharmacologic carriers, excipients, adjuvants, and vehicles to form compositions appropriate for the desired route of administration. In some embodiments, the compound may be mixed with one or both of an antigen and an adjuvant, hi some embodiments, the antigen is a cancer antigen.

[0337] In certain embodiments disclosed herein, particularly those in which the formulations are used for parenteral administration, including injection or other routes listed herein, but also any other routes of administration (oral, enteral, intragastric, etc.) as described herein, the formulations and preparations used in the methods are sterile. Sterile pharmaceutical formulations are compounded or manufactured in accordance with pharmaceutical grade sterility standards known to those skilled in the art (U.S. Pharmacopeia Chapters 797, 1072, and 1211; California Business & Professions Code Chapter 4127.7; California Code of Regulations Title 16 Chapter 1751; Code of Federal Regulations Title 21 Chapter 211). A "sterile" formulation is aseptic or free or essentially free of any viable microorganisms and their spores. Examples of methods for sterilization of pharmaceutical preparations include, but are not limited to, sterile filtration through sterile filtration membranes, irradiation with radiation such as gamma radiation, and heat sterilization.

[0338]

[0333] Oral administration is advantageous in terms of its ease of implementation and patient compliance.If a patient has difficulty swallowing, the introduction of medicine through feeding tube, feeding syringe or gastrostomy can be used to achieve enteral administration.Active compound and, if present, other co-administered drugs can be enterally administered with any other pharma- ceutically acceptable excipient suitable for the formulation for administration through feeding tube, feeding syringe or gastrostomy.

[0339]

[0334] Intravenous administration can also be advantageously used to deliver the compound or composition to the bloodstream as quickly as possible and to avoid the need for absorption from the gastrointestinal tract.

[0340] The compounds and compositions described for use herein can be administered in solid, liquid, aerosol form, or in the form of tablets, pills, caplets, capsules (such as hard gelatin capsules or soft elastic gelatin capsules), powder mixtures, granules, injections, solutions, suppositories, enemas, irrigation, emulsions, dispersions, food premixes, cachets, troches, lozenges, gums, ointments, poultices, pastes, powders, bandages, creams, patches, aerosols (e.g., intranasal sprays or inhalers), gels, suspensions (e.g., aqueous or non-aqueous liquid suspensions, oil-in-water emulsions or water-in-oil liquid emulsions), elixirs, or other forms suitable for the route of administration. The compounds and compositions can also be administered in liposomal formulations. The compounds can also be administered as prodrugs, where the prodrugs undergo conversion to a therapeutically effective form within the body of the treated subject.

[0341] In addition, pharmaceutical preparations may contain preservatives, solubilizers, stabilizers, rewetting agents, emulsifiers, sweeteners, dyes, regulators, and salts for adjusting osmotic pressure, buffers, coating agents, or antioxidants. Preparations containing the present compounds may also contain other substances that have beneficial therapeutic properties. Pharmaceutical preparations may be prepared by known pharmaceutical methods. Additional formulation and administration methods are known in the art. For suitable preparations, see, for example, Remington: The Science and Practice of Pharmacy, Lippincott Williams & Wilkins, 21st ed. (2005), which is incorporated herein by reference.

[0342]

[0337] Injectable preparations, for example, sterile injectable aqueous or oily suspensions, may be formulated according to methods known in the art using suitable dispersing or wetting agents and suspending agents. Sterile injectable preparations may also be sterile injectable solutions or suspensions in parenterally acceptable diluents or solvents, for example, as solutions in propylene glycol. Among the acceptable vehicles and solvents that may be used are water, physiological saline, Ringer's solution, and isotonic saline. In addition, sterile fixed oils are conventionally used as solvents or suspending media. For this purpose, any non-irritating fixed oils may be used, including synthetic monoglycerides or diglycerides. In addition, fatty acids such as oleic acid may be used in the preparation of injectable solutions.

[0343]

[0338] The solid dosage form for oral administration may include capsules, tablets, pills, powders, and granules. In such solid dosage forms, the active compound may be mixed with at least one inert diluent, such as sucrose, lactose, talc, or starch. Such dosage forms may also include additional excipient materials other than inert diluents, such as lubricants, such as magnesium stearate. In the case of capsules, tablets, and pills, such dosage forms may also include buffering agents. Tablets and pills may additionally be prepared with enteric coatings. Acceptable excipients for soft shell gel capsules are, for example, vegetable oils, waxes, fats, semi-solid and liquid polyols, and the like.

[0344]

[0339] The liquid dosage form for oral administration may include pharma- ceutically acceptable emulsions, solutions, suspensions, syrups, and elixirs that contain inert diluents commonly used in the art, such as water. Such compositions may also contain additional agents, such as wetting agents, emulsifying and suspending agents, cyclodextrins, and sweeteners, flavoring agents, and aromatic agents. Alternatively, the compound may also be administered in neat form, if appropriate.

[0345] The compounds and compositions can also be administered in the form of liposomes. As known in the art, liposomes are generally derived from phospholipids or other lipid substances. Liposomes are formed by mono- or multi-lamellar hydrated liquid crystals dispersed in an aqueous medium. Any physiologically acceptable and metabolizable lipid capable of forming liposomes can be used. The present composition in liposome form can contain, in addition to the compounds as disclosed herein, stabilizers, preservatives, excipients, and the like. Useful lipids include phospholipids and phosphatidylcholines (lecithins), both natural and synthetic. Methods for forming liposomes are known in the art. See, e.g., Gregoriadis, G. Ed., Liposome Technology, Third Edition: Liposome Technology: Liposome Preparation and Related Techniques, CRC Press, Boca Raton, Florida (2006); and Prescott, Ed., Methods in Cell Biology, Volume XIV, Academic Press, New York, NW, p. 33 et seq (1976).

[0346]

[0341] The amount of active ingredient that can be combined with carrier materials to make a single dosage form can vary depending on the patient to whom the active ingredient will be administered and the specific mode of administration. However, it will be understood that the specific dosage level for any particular patient will depend on a variety of factors, including the specific compound utilized; the patient's age, weight, body area, body mass index (BMI), general health, sex, and diet; the administration time and route used; excretion rate; and the drug combination, if any, used. The compound can be administered in a unit dosage formulation. The pharmaceutical unit dosage selected is manufactured and administered to provide a sufficient concentration of drug in the patient, subject, or individual.

[0347]

[0342] The compound for use as described herein may be administered as the sole medicament active agent, but it can also be used in combination with one or more other agents.When an additional active agent is used in combination with the compound for use as described herein, the additional active agent can generally be used in a therapeutic amount as indicated in Physicians'Desk Reference (PDR) 71st Edition (2017), which is incorporated herein by reference, or in such therapeutically useful amount as would be known to those skilled in the art, or as determined experimentally for each patient.

[0348] Combinations of two or more of the compounds and compositions disclosed herein may also be used. Two or more compounds or compositions may be mixed together immediately prior to administration and administered together. Two or more compounds or compositions may be administered at the same time, either by the same or different routes of administration. Two or more compounds or compositions may be administered sequentially, either by the same or different routes of administration. In one embodiment, the kit form may include two or more compounds or compositions as separate compounds or compositions, along with printed or electronic instructions for administration, either as a mixture of compounds or compositions, as separate compounds or compositions administered at the same time, or as separate compounds or compositions administered sequentially. When three or more compounds or compositions are administered, they may be administered as a mixture of compounds or compositions, as separate compounds or compositions administered at the same time, as separate compounds or compositions administered sequentially, as separate compounds or compositions where two or more are administered at the same time and the rest may be administered sequentially before or after administration at the same time, or in any other possible combination of mixed administration, administration at the same time, and administration sequentially.

[0349]

[0344] The compounds as disclosed herein may, in one aspect, be in purified form, and compositions comprising the compounds in purified form are disclosed herein. Compositions comprising the compounds as disclosed herein or salts thereof are provided, such as compositions of substantially pure compounds. In some embodiments, compositions comprising the compounds as disclosed herein or salts thereof are in substantially pure form. In one variation, "substantially pure" contemplates a composition containing no more than 35% impurities, where impurities refer to compounds other than the compound (or compounds, if a combination of compounds is used) to be administered, or salts or solvates of the compound (or compounds, if a combination is used). The weight of any added vehicle, carrier, or excipient is excluded from such calculation, and added vehicle, carrier, or excipient is not considered an impurity. For example, a composition of a substantially pure compound selected from the compounds of Table 1 refers to a composition containing no more than 35% impurities, where impurities refer to compounds other than the compound or salts or solvates of the compound. In one variation, a composition of a substantially pure compound or a salt or solvate thereof is provided, the composition containing no more than 25% impurities. In another variation, a composition of a substantially pure compound or a salt or solvate thereof is provided, the composition containing no more than 20% impurities. In yet another variation, a composition of a substantially pure compound or a salt or solvate thereof is provided, the composition containing no more than 10% impurities. In a further variation, a composition of a substantially pure compound or a salt or solvate thereof is provided, the composition containing no more than 5% impurities. In another variation, a composition of a substantially pure compound or a salt or solvate thereof is provided, the composition containing no more than 3% impurities. In yet another variation, a composition of a substantially pure compound or a salt or solvate thereof is provided, the composition containing no more than 1% impurities. In a further variation, a composition of a substantially pure compound or a salt or solvate thereof is provided, the composition containing no more than 0.5% impurities.In yet another variation, a composition of a substantially pure compound means that the composition contains no more than 15%, no more than 10%, no more than 5%, no more than 3%, or no more than 1% of an impurity. An impurity can be a compound of a different stereochemical form than the desired stereochemical form. For example, a composition of a substantially pure (S)-compound means that the composition contains no more than 15%, no more than 10%, no more than 5%, no more than 3%, or no more than 1% of an (R)-form of the compound. Alternatively, as used herein, "enantiomeric excess (ee)" refers to a dimensionless molar ratio that describes the purity of a chiral substance, for example, containing a single asymmetric center. For example, an enantiomeric excess of 0 indicates a racemate (e.g., a 50:50 mixture of enantiomers, or no excess of one enantiomer over the other). As a further example, an enantiomeric excess of 99 indicates a nearly stereochemically pure enantiomeric compound (i.e., a large excess of one enantiomer over the other). Percentage enantiomeric excess, if (R)-compound>(S)-compound, %ee=([(R)-compound]-[(S)-compound]) / ([(R)-compound]+[(S)-compound])×100; or if (S)-compound>(R)-compound, %ee=([(S)-compound]-[(R)-compound]) / ([(S)-compound]+[(R)-compound])×100. Additionally, as used herein, "diastereomeric excess (de)" refers to a dimensionless molar ratio that describes the purity of a chiral substance that contains two or more asymmetric centers. For example, a diastereomeric excess of 0 indicates an equimolar mixture of diastereoisomers. As a further example, a diastereomeric excess of 99 indicates a nearly stereochemically pure diastereomeric compound (i.e., one diastereomer is in large excess relative to the other). Diastereomeric excess may be calculated in a similar manner to ee. As one skilled in the art would understand, de is usually reported as a percentage de (%de), which may be calculated in the same way as %ee.

[0350] In some aspects, provided herein are compositions comprising cell populations containing modified immune cells, such as those described herein or made by the methods disclosed herein. In some embodiments, the compositions comprise cell populations containing modified immune cells that have been in contact or are in contact with a Cbl-b inhibitor or composition thereof described herein. In some embodiments, the modified immune cells have been in contact or are in contact with an anti-CD3 antibody alone. In some embodiments, the modified immune cells have been in contact or are in contact with an anti-CD3 antibody in combination with an anti-CD28 antibody. The provided compositions comprising cell populations containing modified immune cells, such as those described herein, may further comprise a pharma- ceutically acceptable excipient.

[0351] In some aspects, also provided herein is a cell culture composition comprising a cell population containing immune cells and a Cbl-b inhibitor as described herein. In some embodiments, the immune cells are human immune cells. In some embodiments, the immune cells are cells selected from the group consisting of hematopoietic cells, pluripotent stem cells, myeloid progenitor cells, lymphoid progenitor cells, T cells, B cells, and NK cells. In some embodiments, the cell culture composition further comprises an anti-CD3 antibody. In some embodiments, the cell culture composition further comprises an anti-CD3 antibody in combination with an anti-CD28 antibody. Methods for culturing cell compositions containing immune cells are well known in the art and are contemplated herein.

[0352] The modified immune cells or compositions as described herein, e.g., compositions or pharmaceutical compositions comprising cell populations containing modified immune cells, can be provided in a suitable container. Suitable containers include, for example, bottles, vials (e.g., dual chamber vials), syringes (e.g., single or dual chamber syringes), bags (e.g., IV bags), and tubes (e.g., test tubes). The containers may be formed of a variety of materials, such as glass or plastic.

[0353] In some embodiments, a composition (e.g., a cell culture composition) comprising a cell population containing a modified immune cell as described herein is provided in a culture vessel. Culture vessels as provided herein include, but are not limited to, tubes (e.g., test tubes), dishes (e.g., tissue culture dishes), bags, multi-well plates (e.g., 6-well tissue culture plates), and flasks (e.g., cell culture flasks).

[0354] Also provided is a composition as described herein for any of the uses described herein.In some embodiments, the composition as described herein is for preparing a medicament for treating or preventing a disease or condition associated with Cbl-b activity.In some embodiments, the composition as described herein is for preparing a medicament for treating cancer.

[0355]

[0350] Pharmaceutical compositions of any of the compounds disclosed herein, or salts or solvates thereof, for use in combination with cancer vaccines are included in this disclosure.Thus, the present disclosure includes pharmaceutical compositions comprising Cbl-b inhibitors for use in combination with cancer vaccines, where the Cbl-b inhibitor is any of the compounds of 1-719 of WO 2019 / 148005 (including their "a" and "b" variants), or any of the compounds of formula (IA), formula (I), formula (II-A), formula (II), formula (III-A), formula (III), or formula (IV) disclosed therein, or any variation thereof, or a pharma- ceutically acceptable salt or solvate thereof, or a tautomer thereof, or a stereoisomer or mixture of stereoisomers thereof.

[0356]

[0351] Additionally, pharmaceutical compositions of any of the compounds disclosed herein, or salts or solvates thereof, for use in combination with an oncolytic virus are encompassed in this disclosure. Thus, the present disclosure includes pharmaceutical compositions comprising a Cbl-b inhibitor for use in combination with an oncolytic virus, where the Cbl-b inhibitor is a compound of 1-719 of WO 2019 / 148005 (including its "a" and "b" variants), or any compound of formula (IA), formula (I), formula (II-A), formula (II), formula (III-A), formula (III), or formula (IV) disclosed therein, or any variation thereof, or a pharma- ceutically acceptable salt or solvate thereof, or a tautomer thereof, or a stereoisomer or mixture of stereoisomers thereof. The composition may further comprise a pharma- ceutically acceptable excipient, such as a pharma- ceutically acceptable vehicle or a pharma- ceutical acceptable carrier. In some embodiments, the pharmaceutical composition comprises both a small molecule Cbl-b inhibitor and a cancer vaccine. In some embodiments, the compound is a compound selected from compound 60 and / or compound 56 in Table 1, or a pharma- ceutically acceptable salt or solvate thereof, or a tautomer thereof, or a stereoisomer or mixture of stereoisomers thereof. In addition, in some embodiments, the pharmaceutical composition comprises both a small molecule Cbl-b inhibitor and an oncolytic virus. In some embodiments, the compound is a compound selected from compound 60 and / or compound 56 in Table 1, or a pharma- ceutically acceptable salt or solvate thereof, or a tautomer thereof, or a stereoisomer or mixture of stereoisomers thereof. In some embodiments, the compound is a compound selected from the Cbl-b inhibitors disclosed in the following patent applications: compounds 1-58 or compounds of formula (I) therein of U.S. Provisional Patent Application No. 62 / 849,722; compounds 1-58 or compounds of formula (I) therein of U.S. Provisional Patent Application No. 62 / 880,437; or any variation thereof, or a pharma- ceutically acceptable salt or solvate thereof, or a tautomer thereof, or a stereoisomer or mixture of stereoisomers thereof.

[0357]

[0352] In one embodiment, the pharma- ceutically acceptable salt is an acid addition salt, such as a salt formed with an inorganic acid or an organic acid.

[0358] The compounds, vaccines, and compositions disclosed herein may be administered in any suitable form and by any suitable route that will provide sufficient levels of the compounds, vaccines, or compositions to treat a disease or disorder. In some embodiments, the Cbl-b inhibitors and / or cancer vaccines are administered by enteral administration. The compounds, oncolytic viruses, and compositions disclosed herein may be administered in any suitable form and by any suitable route that will provide sufficient levels of the compounds, oncolytic viruses, or compositions to treat a disease or disorder. In some embodiments, the Cbl-b inhibitors and / or oncolytic viruses are administered by enteral administration. In some embodiments, the enteral administration is oral administration. In other embodiments, the Cbl-b inhibitors and / or cancer vaccines are administered by parenteral administration. In other embodiments, the Cbl-b inhibitors and / or oncolytic viruses are administered by parenteral administration. In some embodiments, the parenteral administration is intratumoral injection. In some embodiments, the parenteral administration is by a route selected from the group consisting of intravenous, intraperitoneal, and subcutaneous.

[0359] Suitable routes of administration include oral, enteral, and parenteral administration, including subcutaneous, intravenous, intraarterial, intramuscular, intrasternal, intraperitoneal, intralesional, intraarticular, intratumoral, or infusion techniques. The compounds, vaccines, and compositions may also be administered sublingually, mucosally, bucally, subcutaneously, spinally, epidurally, into the ventricles, by inhalation (e.g., as a mist or spray), intranasally, intravaginally, rectally, topically, or transdermally, or by sustained or sustained release mechanisms. The compounds, vaccines, and compositions may be administered in unit dosage formulations containing conventional pharmacologic carriers, excipients, adjuvants, and vehicles as appropriate. The compounds, vaccines, and compositions may also be administered directly to specific or diseased organs or tissues. The compounds and / or vaccines can be mixed with pharmaceutically acceptable carriers, excipients, adjuvants, and vehicles to form compositions suitable for the desired route of administration. The compounds, oncolytic viruses, and compositions can also be administered sublingually, mucosally, bucally, subcutaneously, spinally, epidurally, into the ventricles, by inhalation (e.g., as a mist or spray), nasally, vaginally, rectally, topically, or transdermally, or by slow or sustained release mechanisms. The compounds, oncolytic viruses, and compositions can be administered in unit dosage formulations containing conventional pharmaceutically acceptable carriers, excipients, adjuvants, and vehicles as appropriate. The compounds, oncolytic viruses, and compositions can be administered directly to specific or diseased organs or tissues. The compounds and / or oncolytic viruses can be mixed with pharmaceutically acceptable carriers, excipients, adjuvants, and vehicles to form compositions suitable for the desired route of administration.

[0360]

[0355] In certain embodiments disclosed herein, particularly those in which the formulations are used for parenteral administration, including injection or other routes listed herein, but also including any other routes of administration (oral, enteral, intragastric, etc.) as described herein, the formulations and preparations used in the method are sterile, except for the presence of the microbial vector in certain cancer vaccines. For the preparation of such formulations, all components of the formulation or preparation are prepared in a sterile manner before combination with the microbial vector. In certain embodiments disclosed herein, particularly those in which the formulations are used for parenteral administration, including injection or other routes listed herein, but also including any other routes of administration (oral, enteral, intragastric, etc.) as described herein, the formulations and preparations used in the method are sterile, except for the presence of the oncolytic virus. For the preparation of such formulations, all components of the formulation or preparation are prepared in a sterile manner before combination with the oncolytic virus. Sterile pharmaceutical formulations are compounded or manufactured in accordance with pharmaceutical grade sterilization standards known to those skilled in the art (U.S. Pharmacopeia Chapters 797, 1072, and 1211; California Business & Professions Code Chapter 4127.7; California Code of Regulations Title 16, Chapter 1751; Code of Federal Regulations Title 21, Chapter 211). A "sterile" formulation is aseptic or essentially free of any viable microorganisms and their spores. Examples of methods for sterilizing pharmaceutical formulations include, but are not limited to, sterile filtration through a sterile filtration membrane, irradiation with radiation such as gamma radiation, and heat sterilization.

[0361] Oral administration is advantageous in terms of its ease of implementation and patient compliance. If the patient has difficulty swallowing, the introduction of the drug by feeding tube, feeding syringe, or gastrostomy can be used to achieve enteral administration. The active compound, vaccine, or composition, and other co-administered drugs, if any, can be enterally administered with any other pharma- ceutically acceptable excipient suitable for formulation for administration by feeding tube, feeding syringe, or gastrostomy. The active compound, oncolytic virus, or composition, and other co-administered drugs, if any, can be enterally administered with any other pharma-ceutically acceptable excipient suitable for formulation for administration by feeding tube, feeding syringe, or gastrostomy.

[0362] Intravenous administration can also be advantageously used to deliver the compound, vaccine, or composition to the bloodstream as quickly as possible and to avoid the need for absorption from the gastrointestinal tract. Intravenous administration can also be advantageously used to deliver the compound, oncolytic virus, or composition to the bloodstream as quickly as possible and to avoid the need for absorption from the gastrointestinal tract.

[0363] The compounds, vaccines, and compositions described for use herein can be administered in solid form, liquid form, aerosol form, or in the form of tablets, pills, caplets, capsules (such as hard gelatin capsules or soft elastic gelatin capsules), powder mixtures, granules, injections, solutions, suppositories, enemas, irrigation, emulsions, dispersions, food premixes, cachets, troches, lozenges, gums, ointments, poultices, pastes, powders, bandages, creams, patches, aerosols (e.g., intranasal sprays or inhalers), gels, suspensions (e.g., aqueous or non-aqueous liquid suspensions, oil-in-water emulsions or water-in-oil liquid emulsions), elixirs, or other forms suitable for the route of administration. The compounds, vaccines, and compositions can also be administered in liposomal formulations. The compounds, oncolytic viruses, and compositions described for use herein can be administered in solid form, liquid form, aerosol form, or in the form of tablets, pills, caplets, capsules (such as hard gelatin capsules or soft elastic gelatin capsules), powder mixtures, granules, injections, solutions, suppositories, enemas, irrigation, emulsions, dispersions, food premixes, cachets, troches, lozenges, gums, ointments, poultices (compresses), pastes, powders, bandages, creams, patches, aerosols (e.g., intranasal sprays or inhalers), gels, suspensions (e.g., aqueous or non-aqueous liquid suspensions, oil-in-water emulsions or water-in-oil liquid emulsions), elixirs, or other forms suitable for the route of administration. The compounds, oncolytic viruses, and compositions can also be administered in liposomal formulations. The compounds can also be administered as prodrugs, where the prodrugs undergo conversion to a therapeutically effective form within the body of the treated subject.

[0364] In addition, pharmaceutical preparations may contain preservatives, solubilizers, stabilizers, rewetting agents, emulsifiers, sweeteners, dyes, regulators, and salts for adjusting osmotic pressure, buffers, coating agents, or antioxidants. Preparations containing the compound, vaccine, or composition may also contain other substances that have beneficial therapeutic properties. Preparations containing the compound, oncolytic virus, or composition may also contain other substances that have beneficial therapeutic properties. Pharmaceutical preparations may be prepared by known pharmaceutical methods. Additional formulation and administration methods are known in the art. For suitable preparations, see, for example, Remington: The Science and Practice of Pharmacy, Lippincott Williams & Wilkins, 21st ed. (2005), which is incorporated herein by reference.

[0365]

[0360] Injectable preparations of small molecule Cbl-b inhibitors, for example, sterile injectable aqueous or oily suspensions, may be formulated according to methods known in the art using suitable dispersing or wetting agents and suspending agents. Sterile injectable preparations may also be sterile injectable solutions or suspensions in parenterally acceptable diluents or solvents, for example, as solutions in propylene glycol. Among the acceptable vehicles and solvents that may be used are water, saline, Ringer's solution, and isotonic saline. In addition, sterile fixed oils are conventionally used as solvents or suspending media. For this purpose, any non-irritating fixed oil may be used, including synthetic mono- or diglycerides. In addition, fatty acids such as oleic acid may be used in the preparation of injectable solutions.

[0366]

[0361] The solid dosage forms for oral administration may include capsules, tablets, pills, powders, and granules. In such solid dosage forms, the active compound, vaccine, or composition may be mixed with at least one inert diluent, such as sucrose, lactose, talc, or starch. In such solid dosage forms, the active compound, oncolytic virus, or composition may be mixed with at least one inert diluent, such as sucrose, lactose, talc, or starch. Such dosage forms may also include additional excipient substances other than inert diluents, such as lubricants, such as magnesium stearate. In the case of capsules, tablets, and pills, such dosage forms may also include buffering agents. Tablets and pills may additionally be prepared with enteric coatings. Acceptable excipients for soft shell gel capsules are, for example, vegetable oils, waxes, fats, semi-solid and liquid polyols, and the like.

[0367]

[0362] The liquid dosage form for oral administration may include pharma- ceutically acceptable emulsions, solutions, suspensions, syrups, and elixirs that contain inert diluents commonly used in the art, such as water. Such compositions may also contain additional agents, such as wetting agents, emulsifying and suspending agents, cyclodextrins, and sweeteners, flavoring agents, and aromatic agents. Alternatively, the compound may also be administered in neat form, if appropriate.

[0368] The compounds, vaccines, and compositions can also be administered in the form of liposomes. The compounds, oncolytic viruses, and compositions can also be administered in the form of liposomes. As known in the art, liposomes are generally derived from phospholipids or other lipid substances. Liposomes are formed by mono- or multi-lamellar hydrated liquid crystals dispersed in an aqueous medium. Any physiologically acceptable and metabolizable lipid capable of forming liposomes can be used. The composition in liposomal form can contain stabilizers, preservatives, excipients, etc. in addition to the compounds or vaccines as disclosed herein. The composition in liposomal form can contain stabilizers, preservatives, excipients, etc. in addition to the compounds or oncolytic viruses as disclosed herein. Useful lipids include phospholipids and phosphatidylcholines (lecithins), both natural and synthetic. Methods for forming liposomes are known in the art. See, e.g., Gregoriadis, G. Ed., Liposome Technology, Third Edition: Liposome Technology: Liposome Preparation and Related Techniques, CRC Press, Boca Raton, Florida (2006); and Prescott, Ed., Methods in Cell Biology, Volume XIV, Academic Press, New York, NW, p. 33 et seq (1976).

[0369]

[0364] The amount of active ingredient that can be combined with the carrier material to produce a single dosage form can vary depending on the patient to whom the active ingredient will be administered and the particular mode of administration. However, it will be understood that the specific dose level for any particular patient will depend on a variety of factors, including the specific compound or vaccine used; the patient's age, weight, body area, body mass index (BMI), general health, sex, and diet; the administration time and route used; excretion rate; and the drug combination, if any, used. The compounds, vaccines, and compositions can be administered in unit dosage formulations. However, it will be understood that the specific dose level for any particular patient will depend on a variety of factors, including the specific compound or oncolytic virus used; the patient's age, weight, body area, body mass index (BMI), general health, sex, and diet; the administration time and route used; excretion rate; and the drug combination, if any, used. The compounds, oncolytic viruses, and compositions can be administered in unit dosage formulations. The pharmaceutical unit dosage selected is manufactured and administered to provide a sufficient concentration of drug in the patient, subject, or individual.

[0370]

[0365] The compounds, vaccines, and compositions for use as described herein may be administered as the sole pharmacoactive agent, but they can also be used in combination with one or more other agents. When an additional active agent is used in combination with the compounds, vaccines, or compositions for use as described herein, the additional active agent can generally be used in a therapeutic amount as indicated in the Physicians'Desk Reference (PDR) 71st Edition (2017), which is incorporated herein by reference, or in such therapeutically useful amount as would be known to those skilled in the art, or as empirically determined for each patient. The compounds, oncolytic viruses, and compositions for use as described herein may be administered as the sole pharmacoactive agent, but they can also be used in combination with one or more other agents. When an additional active agent is used in combination with a compound, oncolytic virus, or composition for use as described herein, the additional active agent may generally be used in a therapeutic amount as indicated in the Physicians' Desk Reference (PDR) 71st Edition (2017), which is incorporated herein by reference, or such therapeutically useful amount as would be known to one of skill in the art or as determined empirically on a patient-by-patient basis.

[0371] Combinations of two or more of the compounds, vaccines, and compositions disclosed herein can also be used. Two or more compounds, vaccines, or compositions can be mixed together just prior to administration and administered together. Two or more compounds, vaccines, or compositions can be administered at the same time, either by the same or different routes of administration. Two or more compounds, vaccines, or compositions can be administered sequentially, either by the same or different routes of administration. In one embodiment, the kit form can include two or more compounds, vaccines, or compositions as separate compounds, vaccines, or compositions, along with printed or electronic instructions for administration, either as a mixture of compounds, vaccines, or compositions, as separate compounds, vaccines, or compositions administered at the same time, or as separate compounds, vaccines, or compositions administered sequentially. When more than two compounds, vaccines or compositions are administered, they may be administered as a mixture of compounds, vaccines or compositions, as separate compounds, vaccines or compositions administered at the same time, as separate compounds, vaccines or compositions administered sequentially, as separate compounds, vaccines or compositions where two or more are administered at the same time and the rest may be administered sequentially before or after administration at that same time, or any other possible combination of mixed administration, administration at the same time, and sequential administration.

[0372] Combinations of two or more of the compounds, oncolytic viruses, and compositions disclosed herein can also be used. Two or more compounds, oncolytic viruses, or compositions can be mixed together immediately before administration and administered together. Two or more compounds, oncolytic viruses, or compositions can be administered at the same time, either by the same or different routes of administration. Two or more compounds, oncolytic viruses, or compositions can be administered sequentially, either by the same or different routes of administration. In one embodiment, the kit form can include two or more compounds, oncolytic viruses, or compositions as individual compounds, oncolytic viruses, or compositions, along with printed or electronic instructions for administration, either as a mixture of compounds, oncolytic viruses, or compositions, as separate compounds, oncolytic viruses, or compositions administered at the same time, or as separate compounds, oncolytic viruses, or compositions administered sequentially. When more than two compounds, oncolytic viruses, or compositions are administered, they can be administered as a mixture of compounds, oncolytic viruses, or compositions, as separate compounds, oncolytic viruses, or compositions administered at the same time, as separate compounds, oncolytic viruses, or compositions administered sequentially, as separate compounds, oncolytic viruses, or compositions where two or more are administered at the same time and the rest may be administered sequentially before or after administration at that same time, or any other possible combination of mixed administration, administration at the same time, and sequential administration.

[0373]

[0368] The compounds as disclosed herein for use in the pharmaceutical compositions and methods described herein may in one aspect be in purified form, and compositions comprising the compounds in purified form are disclosed herein. Compositions comprising the compounds as disclosed herein or salts thereof are provided, such as compositions of substantially pure compounds. In some embodiments, compositions comprising the compounds as disclosed herein or salts thereof are in substantially pure form. In one variation, "substantially pure" contemplates a composition containing no more than 35% impurities, where impurities refer to compounds other than the compound (or compounds, if a combination of compounds is used) to be administered, or salts or solvates of the compound (or compounds, if a combination of compounds is used) present in the composition. The weight of any added vehicle, carrier, or excipient is excluded from such calculations, and added vehicle, carrier, or excipient is not considered an impurity. For example, a composition of a substantially pure compound selected from the compounds of Table 1 refers to a composition containing 35% or less of impurities, where impurities refer to compounds other than the compound or its salts or solvates. In one variation, a composition of a substantially pure compound or its salts or solvates is provided, the composition containing 25% or less of impurities. In another variation, a composition of a substantially pure compound or its salts or solvates is provided, the composition containing 20% ​​or less of impurities. In yet another variation, a composition of a substantially pure compound or its salts or solvates is provided, the composition containing 10% or less of impurities. In a further variation, a composition of a substantially pure compound or its salts or solvates is provided, the composition containing 5% or less of impurities. In another variation, a composition of a substantially pure compound or its salts or solvates is provided, the composition containing 3% or less of impurities. In yet another variation, a composition of a substantially pure compound or its salts or solvates is provided, the composition containing 1% or less of impurities.In a further variation, a composition of a substantially pure compound or a salt or solvate thereof is provided, the composition containing no more than 0.5% of impurities. In yet another variation, a composition of a substantially pure compound means that the composition contains no more than 15%, no more than 10%, no more than 5%, no more than 3%, or no more than 1% of impurities. An impurity can be a compound of a stereochemical form different from the desired stereochemical form. For example, a composition of a substantially pure (S)-compound means that the composition contains no more than 15%, no more than 10%, no more than 5%, no more than 3%, or no more than 1% of the (R)-form of the compound.

[0374] Alternatively, as used herein, "enantiomeric excess (ee)" refers to a dimensionless molar ratio that describes the purity of, for example, a chiral substance containing a single asymmetric center. For example, an enantiomeric excess of 0 indicates a racemate (e.g., a 50:50 mixture of enantiomers, or no excess of one enantiomer over the other). As a further example, an enantiomeric excess of 99 indicates a nearly stereochemically pure enantiomeric compound (i.e., a large excess of one enantiomer over the other). Percentage enantiomeric excess, if (R)-compound>(S)-compound, %ee=([(R)-compound]-[(S)-compound]) / ([(R)-compound]+[(S)-compound])×100; or if (S)-compound>(R)-compound, %ee=([(S)-compound]-[(R)-compound]) / ([(S)-compound]+[(R)-compound])×100. Additionally, as used herein, "diastereomeric excess (de)" refers to a dimensionless molar ratio that describes the purity of a chiral substance that contains two or more asymmetric centers. For example, a diastereomeric excess of 0 indicates an equimolar mixture of diastereoisomers. As a further example, a diastereomeric excess of 99 indicates a nearly stereochemically pure diastereomeric compound (i.e., a large excess of one diastereomer over the other). Diastereomeric excess may be calculated in a similar manner to ee. As one skilled in the art would understand, de is usually reported as a percentage de (%de), which may be calculated in the same way as %ee.

[0375] The compound, vaccine, or composition as disclosed herein can be provided in a suitable container. The compound, oncolytic virus, or composition as disclosed herein can be provided in a suitable container. Suitable containers include, for example, bottles, vials (e.g., dual-chamber vials), syringes (e.g., single- or dual-chamber syringes), bags (e.g., IV bags), and tubes (e.g., test tubes). The containers can be made of various materials, such as glass or plastic.

[0376] V. Products or Kits Also provided is an article of manufacture comprising any of the compounds, pharmaceutical compositions, cells, modified immune cells, cell populations, cell compositions, cell cultures, or cell culture compositions described herein. The article of manufacture comprises a suitable container or packaging material for the compounds, pharmaceutical compositions, cells, modified immune cells, cell populations, cell compositions, cell cultures, or cell culture compositions. Examples of suitable containers include, but are not limited to, bottles, vials, syringes, IV bags, or tubes. For cells, modified immune cells, cell populations, cell compositions, cell cultures, or cell culture compositions, the suitable container may be a culture vessel, including, but not limited to, a tube, a dish, a bag, a multi-well plate, or a flask.

[0377] Also provided are kits comprising any of the compounds, pharmaceutical compositions, cells, modified immune cells, cell populations, cell compositions, cell cultures, or cell culture compositions described herein. The kits may contain the compounds, pharmaceutical compositions, cells, modified immune cells, cell populations, cell compositions, cell cultures, or cell culture compositions in a suitable container or packaging material, including but not limited to a bottle, vial, syringe, IV bag, or tube. The kits may contain the cells, modified immune cells, cell populations, cell compositions, cell cultures, or cell culture compositions in a culture vessel, including but not limited to a tube, dish, bag, multi-well plate, or flask. The kits may include the compounds, pharmaceutical compositions, cells, modified immune cells, cell populations, cell compositions, cell cultures, or cell culture compositions for administration to an individual in a single dose form or in a multiple dose form. The kits can further include instructions or labeling for administering the compound, pharmaceutical composition, cell, modified immune cell, cell population, cell composition, cell culture, or cell culture composition to an individual according to any of the methods disclosed herein. The kits can further include supplies for administering the compound, pharmaceutical composition, cell, modified immune cell, cell population, cell composition, cell culture, or cell culture composition to an individual, including but not limited to needles, syringes, tubing, or IV bags. The kits can further include instructions for making any of the compounds, pharmaceutical compositions, cells, modified immune cells, cell populations, cell compositions, cell cultures, or cell culture compositions disclosed herein.

[0378] Also provided is an article of manufacture comprising any of the compounds, vaccines, or pharmaceutical compositions described herein. The article of manufacture comprises a suitable container or packaging material for the compounds, vaccines, or pharmaceutical compositions. Also provided is an article of manufacture comprising any of the compounds, oncolytic viruses, or pharmaceutical compositions described herein. The article of manufacture comprises a suitable container or packaging material for the compounds, oncolytic viruses, or pharmaceutical compositions. Examples of suitable containers include, but are not limited to, bottles, vials, syringes, IV bags, or tubes.

[0379] Also provided are kits comprising any of the compounds, vaccines, or pharmaceutical compositions described herein. The kits may contain the compounds, vaccines, or pharmaceutical compositions in suitable containers or packaging, including but not limited to bottles, vials, syringes, IV bags, or tubing. The kits may include the compounds, vaccines, or pharmaceutical compositions for administration to an individual in single or multiple dose form. The kits may further include instructions or labeling for administering the compounds, vaccines, or pharmaceutical compositions to an individual according to any of the methods disclosed herein. The kits may further include equipment for administering the compounds, vaccines, or pharmaceutical compositions to an individual, including but not limited to needles, syringes, tubing, or IV bags. The kits may further include instructions for making any of the compounds, vaccines, or pharmaceutical compositions disclosed herein.

[0380] Also provided are kits comprising any of the compounds, oncolytic viruses, or pharmaceutical compositions described herein. The kits may contain the compounds, oncolytic viruses, or pharmaceutical compositions in suitable containers or packaging, including but not limited to bottles, vials, syringes, IV bags, or tubes. The kits may include the compounds, oncolytic viruses, or pharmaceutical compositions for administration to an individual in single or multiple dose form. The kits may further include instructions or labeling for administering the compounds, oncolytic viruses, or pharmaceutical compositions to an individual according to any of the methods disclosed herein. The kits may further include equipment for administering the compounds, oncolytic viruses, or pharmaceutical compositions to an individual, including but not limited to needles, syringes, tubing, or IV bags. The kits may further include instructions for making any of the compounds, oncolytic viruses, or pharmaceutical compositions disclosed herein.

[0381]

[0376] The present disclosure will be more fully understood by referring to the following examples. However, these examples should not be interpreted as limiting the scope of the present disclosure. The examples and embodiments described herein are for illustrative purposes only, and various modifications or changes based on them may occur to those skilled in the art, and it is understood that they are included within the spirit and scope of the present application and the scope of the appended claims. EXAMPLES

[0382] Working Example General Workup Procedure 1 The aqueous solution was extracted 2-3 times with ethyl acetate. The combined organic extracts were dried over sodium sulfate or anhydrous magnesium sulfate, or washed with brine or saturated aqueous ammonium chloride solution, then dried, filtered, and concentrated in vacuo.

[0383] Purification procedure Preparative scale chiral supercritical fluid chromatography (SFC) was performed using various CHIRALPAK columns such as CHIRALPAK AS-H, CHIRALPAK AD-H, or CHIRALPAK IG, with CO 2 / MeOH, CO 2 / EtOH or CO 2 The reaction was carried out using a solvent system such as / (MeOH+acetonitrile).

[0384] Preparative scale chiral HPLC was performed using various CHIRALPAK columns, including CHIRALPAK IA, CHIRAL ART Cellulose-SB, CHIRALPAK IF, and CHIRALPAK IG, with hexane / methanol, hexane / ethanol, (hexane+dichloromethane) / ethanol, MTBE / methanol, MTBE / ethanol, and (hexane-8 mmol / L NH 3 ) / methanol, mobile phase B: ethanol and hexane / IPA.

[0385] Preparative scale HPLC was performed using columns such as SunFire Prep C18 OBD, XBridge Prep OBD C18, and XBridge Shield RP18 OBD, with elution solvents of (water-0.1% formic acid) / acetonitrile, (water-10 mmol / L NH 4 HCO 3 ) / acetonitrile, or (water - 10mmol / L NH 4 HCO 3 ) / acetonitrile.

[0386]

[0381] Chromatography A refers to purification on silica gel, typically in a prepacked cartridge, eluting with a mixture of EtOAc in hexane or petroleum ether; Chromatography B refers to elution with a mixture of MeOH in DCM; Chromatography C refers to the use of C18 reverse phase silica gel, eluting with a mixture of acetonitrile in water; Chromatography D refers to elution with a mixture of ethanol, EtOAc, and hexane. Compounds depicted without stereochemistry in Table 1 were tested as racemic or diasteromeric mixtures in the biological examples.

[0387]

[0382] Abbreviations used in this example include the following: HATU: 1-[bis(dimethylamino)methylene]-1H-1,2,3-triazolo[4,5-b]pyridinium 3-oxide hexafluorophosphate; T3P: propylphosphonic anhydride; Xantphos: 4,5-bis(diphenylphosphino)-9,9-dimethylxanthene; NBS: N-bromosuccinimide; BPO: benzoyl peroxide; THF: tetrahydrofuran; EtOAc: ethyl acetate; DCM: dichloromethane; MeOH: methanol; DCE: 1,2-dichloroethane; TEA: triethylamine; DIPEA: N,N-diisopropylethylamine; and DMF: N,N-dimethylformamide.

[0388] Example A: Synthesis of methyl 2-(bromomethyl)-5-formyl-3-(trifluoromethyl)benzoate [ka] Step 1: Synthesis of 3-(methoxycarbonyl)-4-methyl-5-(trifluoromethyl)benzoic acid. To a degassed solution of methyl 5-bromo-2-methyl-3-(trifluoromethyl)benzoate (18.0 g, 60.8 mmol), oxalic acid (11.5 g, 91.2 mmol), acetic anhydride (9.3 g, 91.2 mmol), and DIPEA (11.8 g, 91.2 mmol) in DMF (200 mL) was added Pd(OAc) 2 (1.4 g, 6.1 mmol) and Xantphos (1.8 g, 3.0 mmol) were added. The mixture was stirred under nitrogen at 100° C. for 16 h. The reaction was quenched by adding HCl (1 M, 300 mL) until the pH was about 3, followed by General Workup Procedure 1. The residue was purified by Chromatography C to give the title compound (7.5 g, 47%).

[0389] Step 2: Synthesis of 4-(bromomethyl)-3-(methoxycarbonyl)-5-(trifluoromethyl)benzoic acid. CCl 4 To a stirred solution of 4-methyl-3-(methoxycarbonyl)-5-(trifluoromethyl)benzoic acid (8 g, 30.5 mmol) and NBS (8.2 g, 46 mmol) in (160 mL) was added BPO (2.2 g, 9 mmol). The solution was stirred at 80° C. for 16 h. The mixture was concentrated. The crude product was purified by chromatography B to give the title compound (8.0 g, 77%). MS (ESI) calculated (C 11 H 8 BrF 3 O 4 )[MH] - , 339.0;actual value, 339.1.

[0390] Step 3: Synthesis of methyl 2-(bromomethyl)-5-(hydroxymethyl)-3-(trifluoromethyl)-benzoate. To a stirred solution of 4-(bromomethyl)-3-(methoxycarbonyl)-5-(trifluoromethyl)-benzoic acid (2.65 g, 7.77 mmol) in THF (30 mL) was added borane (19.4 mL, 19.4 mmol, 1 M in THF). The solution was stirred at room temperature for 6 hours. The reaction was then quenched by adding methanol (10 mL). The mixture was concentrated. The residue was purified by chromatography A to give the title compound (1.40 g, 84%).

[0391] Step 4: Synthesis of methyl 2-(bromomethyl)-5-formyl-3-(trifluoromethyl)-benzoate. To a stirred solution of methyl 2-(bromomethyl)-5-(hydroxymethyl)-3-(trifluoromethyl)-benzoate (7.1 g, 21.71 mmol) in EtOAc (70 mL) was added 2-iodoxybenzoic acid (9.1 g, 32.5 mmol). The reaction was stirred at 70° C. for 3 h. The solids were removed by filtration and the filtrate was concentrated in vacuo. The residue was purified by Chromatography A to give the title compound (6.6 g, 94%).

[0392] Example B: Synthesis of (R)-6-((4,4-difluoro-3-methylpiperidin-1-yl)methyl)-4-(trifluoromethyl)isoindolin-1-one [ka] To a stirred solution of (3R)-4,4-difluoro-3-methylpiperidine hydrochloride (5.00 g, 29.1 mmol) in DCM (300.00 mL) was added TEA (24.2 mL, 175 mmol) and sodium triacetoxyborohydride (37.1 g, 175 mmol). The suspension was stirred for 10 min and then cooled to 0° C. before adding methyl 2-(bromomethyl)-5-formyl-3-(trifluoromethyl)benzoate (9.47 g, 29.1 mmol) in 20 mL of DCM. The mixture was stirred at room temperature for about 12 h. The reaction was quenched with saturated ammonium chloride followed by General Workup Procedure 1 using DCM. After removal of the solvent, the crude residue was dissolved in methanol (100 mL) and then ammonia (7N in methanol, 100 mL) was added to the solution. The mixture was stirred at room temperature for 12 h. The crude was concentrated and purified by chromatography B to give the title compound (7.10 g, 70.0%). ...

Claims

1. Compounds of formula (I) [Formula 1] or a tautomer, a stereoisomer, or a pharma- ceutically acceptable salt thereof, [Case 2] teeth, [C3] and Z 1 is CH or nitrogen; Z 2 is CH or nitrogen; R 1 is hydrogen, C 1 ~C 6 Alkyl, or C 1 ~C 6 haloalkyl; R 2 is hydrogen, C 1 ~C 6 Alkyl, C 1 ~C 6 Haloalkyl, or C 3 ~C 6 is cycloalkyl; R 3 is -CF 3 or cyclopropyl; R 4 is -CF 3 or cyclopropyl; X is hydrogen, C 1 ~C 6 Alkyl, C 1 ~C 6 haloalkyl, or [C4] and R 5 is hydrogen, C 1 ~C 6 Alkyl, C 1 ~C 6 Haloalkyl, C 1 ~C 6 Alkyl-OH or C 1 ~C 6 alkyl-CN; R 6 is a monocyclic C 3 ~C 6 Cycloalkyl, fused bicyclic C 4 ~C 8 Cycloalkyl, Bridged Bicyclic C 4 ~C 8 Cycloalkyl, spiro bicyclic C 5 ~C 8 cycloalkyl, or 5- or 6-membered heterocyclyl, each of which is represented by 1 to 5 R 7 is optionally substituted by a group; Or R 5 and R 6 together with the nitrogen atom to which they are attached form a 5-10 membered monocyclic, fused bicyclic, or bridged heterocyclyl, or a 5-10 membered monocyclic or bicyclic heteroaryl, each of which optionally contains 1-2 additional heteroatoms selected from the group consisting of nitrogen and oxygen, and each of which optionally contains 1-5 R 8 is optionally substituted by a group; Each R 7 are independently halo, C 1 ~C 6 Alkyl, C 1 ~C 6 Haloalkyl, C 1 ~C 6 Alkyl-OH or C 1 ~C 6 alkyl-CN; Each R 8 are independently 1 ~C 6 Alkyl, C 1 ~C 6 Haloalkyl, C 1 ~C 6 Alkyl-OH, -CN, C 1 ~C 6 Alkyl-CN, -(C 1 ~C 6 alkylene)-O-(C 1 ~C 6 alkyl), hydroxy, or halo; or two R bonded to the same carbon atom 8 groups, together with the carbon atom to which they are attached, form a spiro C 3 ~C 6 forming a cycloalkyl or spiro 5-6 membered heterocyclyl; Each R 9 are independently hydrogen, C 1 ~C 6 Alkyl, C 1 ~C 6 Haloalkyl, or C 1 ~C 6 alkyl-OH; and n is 0 or 1.

2.

5. but, [C6] or The above-mentioned formula 5 is the above-mentioned formula 6, and Z 1 is CH, or [C7] but, [C8] or The above-mentioned formula 5 is the above-mentioned formula 6, and Z 1 is nitrogen, or [C9] but, [C10] or [C11] but, [C12] or The formula 11 is the formula 12, 2 is CH, or [C13] but, [C14] or The formula 11 is the formula 12, 2 is nitrogen, or [C15] but, [C16] That is, The compound of claim 1.

3. R 1 is hydrogen, C 1 ~C 3 Alkyl or C 1 ~C 3 haloalkyl, or R 1 is hydrogen, -CH 3 , or -CF 3 That is, 3. A compound according to claim 1 or 2.

4. R 2 is hydrogen, C 1 ~C 3 Alkyl, C 1 ~C 3 Haloalkyl, or C 3 ~C 4 is cycloalkyl, or R 2 is hydrogen, -CH 3 , -CF 3 , -CHF 2 , -CH 2 F, or cyclopropyl; The compound according to any one of claims 1 to 3.

5. The compound according to any one of claims 1 to 4, wherein n is 0 or 1.

6. X is hydrogen; or X is C 1 ~C 3 Alkyl or C 1 ~C 3 haloalkyl, or X is -CH 3 Or -CF 3 or X, [C17] That is, The compound according to any one of claims 1 to 5.

7. R 5 is hydrogen, C 1 ~C 3 Alkyl or C 1 ~C 3 haloalkyl, or R 5 is hydrogen, -CH 3 , -CF 3 , -CH 2 CN or -CH 2 OH, or R 6 is a monocyclic C 3 ~C 6 Cycloalkyl, fused bicyclic C 4 ~C 8 Cycloalkyl, Bridged Bicyclic C 4 ~C 8 Cycloalkyl, spiro bicyclic C 5 ~C 8 cycloalkyl, or 5- or 6-membered heterocyclyl, each of which is represented by 1 to 5 R 7 optionally substituted by a group, or R 6 but, [C18] or R 6 The 1 to 5 R 7 group, each R 7 However, independently, halo, C 1 ~C 3 Alkyl, C 1 ~C 3 Haloalkyl, C 1 ~C 3 Alkyl-OH or C 1 ~C 3 alkyl-CN; or R 6 The 1 to 5 R 7 group, each R 7 are independently fluoro, —CH 3 , -CF 3, -CH 2 OH or -CH 2 CN, or R 5 and R 6 together with the nitrogen atom to which they are attached form a 5-10 membered monocyclic, fused bicyclic, or bridged heterocyclyl, or a 5-10 membered monocyclic or bicyclic heteroaryl, each of which optionally contains 1-2 additional heteroatoms selected from the group consisting of nitrogen and oxygen, and each of which optionally contains 1-5 R 8 optionally substituted by a group, or R 5 and R 6 together with the nitrogen atom to which they are attached, [C19] or forming a moiety selected from the group consisting of R 5 and R 6 together with the nitrogen atom to which they are attached form said heterocyclyl or said heteroaryl, each of which optionally contains 1 to 2 further heteroatoms selected from the group consisting of nitrogen and oxygen, and each of which optionally contains 1 to 5 R 8 group, each R 8 But independently, C 1 ~C 3 Alkyl, C 1 ~C 3 Haloalkyl, C 1 ~C 3 Alkyl-OH, -CN, C 1 ~C 3 Alkyl-CN, -(C 1 ~C 3 alkylene)-O-(C 1 ~C 3 alkyl), hydroxy, or halo, or two R 8 groups, together with the carbon atom to which they are attached, form a spiro C 3 ~C 4 forming a cycloalkyl or spiro 5-6 membered heterocyclyl; or R 5 and R 6 together with the nitrogen atom to which they are attached form said heterocyclyl or said heteroaryl, each of which optionally contains 1 to 2 further heteroatoms selected from the group consisting of nitrogen and oxygen, and each of which optionally contains 1 to 5 R 8 group, and each R 8 is independently -CH 3 , -CH 2 CH 3 , -CF 3 , -CH 2 OH, -CN, -CH 2 CN, -CH 2 -O-CH 3 , hydroxy, or fluorine, or two R 8 groups taken together with the carbon atom to which they are attached form a spirocyclopropyl, or Each R 9 are independently hydrogen, C 1 ~C 3 Alkyl, C 1 ~C 3 Haloalkyl, or C 1 ~C 3 alkyl-OH; or Each R 9 are independently hydrogen, -CH 3 , -CF 3 , or -CH 2 OH, The compound according to claim 6.

8. The compound according to claim 1, selected from the compounds of Example Nos. 1 to 58 in Tables 1 to 4. [Table 1] [Table 2] [Table 3] [Table 4]

9. A pharmaceutical composition comprising a compound according to any one of claims 1 to 8 and a pharma- ceutically acceptable excipient.

10. A method of modulating immune cell activity in vitro or ex vivo, comprising contacting said immune cell with an effective amount of a Cbl-b inhibitor to modulate the activity of said immune cell, said Cbl-b inhibitor being a compound according to any one of claims 1 to 8, the immune cells comprise T cells, B cells, or natural killer (NK) cells; or the immune cells have been or will be isolated from a blood sample of a mammalian subject; or the immune cell is a tumor infiltrating lymphocyte (TIL) isolated or to be isolated from a tumor in a mammalian subject having cancer; or (1) the immune cells comprise T cells, and modulating the activity of the T cells comprises one or more of increasing T cell activation, increasing T cell proliferation, decreasing T cell exhaustion, and decreasing T cell tolerance; or (2) In the case of (1), the increase in T cell activation includes an increase in cytokine production, and / or (3) In the case of (2) above, the cytokine comprises one or more selected from the group consisting of IL-2, IFN-γ, TNFα, and GM-CSF; and / or (4) In the case of (1) or (2), the increase in T cell activation includes an increase in cell surface expression of one or more T cell activation markers; and / or (5) In the case of (4), the T cell activation marker comprises one or more selected from the group consisting of CD25, CD69, and CTLA4; and / or (6) In any of (1) to (5) above, the T cells have been or are in contact with an anti-CD3 antibody alone or in combination with an anti-CD28 antibody, and / or (7) In any of (1) to (5) above, the method further comprises culturing the immune cells with IL-2 alone or in combination with an anti-CD3 antibody and / or an anti-CD28 antibody; or (8) the immune cells include NK cells, and regulating the activity of NK cells includes increasing NK cell activation; and / or (9) In the case of (8), the increase in NK cell activation includes an increase in cytokine production, and / or (10) In the case of (9) above, the cytokine comprises one or more selected from the group consisting of IFN-γ, TNFα, and MIP1β; or wherein the immune cells comprise B cells, and modulating the activity of B cells comprises increasing B cell activation, optionally wherein increasing B cell activation comprises increasing CD69 expression; and / or the immune cells are human immune cells, and / or the immune cell comprises a recombinant chimeric receptor, optionally the recombinant chimeric receptor is a chimeric antigen receptor; method.

11. 10. A method of producing a modified immune cell, comprising culturing a cell population containing an immune cell in the presence of an effective amount of a Cbl-b inhibitor to modulate an activity of the immune cell, thereby producing the modified immune cell, wherein the Cbl-b inhibitor is a compound according to any one of claims 1 to 8.

12. or further comprising culturing the immune cells with an anti-CD3 antibody alone or in combination with an anti-CD28 antibody; or further comprising culturing the immune cells with IL-2 alone or in combination with an anti-CD3 antibody and / or an anti-CD28 antibody; further comprising recovering the modified immune cells. The method of claim 11.

13. the immune cells have been or will be isolated from a blood sample of a mammalian subject, or the immune cells are tumor infiltrating lymphocytes (TILs) that have been or will be isolated from a tumor in a mammalian subject with cancer; or the immune cell is a cell selected from the group consisting of a hematopoietic cell, a pluripotent stem cell, a myeloid progenitor cell, a lymphoid progenitor cell, a T cell, a B cell, and a NK cell; or the modified immune cell is a cell selected from the group consisting of a hematopoietic cell, a pluripotent stem cell, a myeloid progenitor cell, a lymphoid progenitor cell, a T cell, a B cell, and a NK cell; or the immune cells are tumor infiltrating lymphocytes (TILs); or the immune cells are human immune cells, or the immune cell or modified immune cell comprises a recombinant chimeric receptor; or the immune cell or modified immune cell comprises a recombinant chimeric receptor, the recombinant chimeric receptor being a chimeric antigen receptor; 13. The method according to claim 11 or 12.

14. 10. Use of a Cbl-b inhibitor in the manufacture of a medicament for the treatment or prevention of a disease or condition associated with Cbl-b activity, wherein said Cbl-b inhibitor is a compound according to any one of claims 1 to 8.

15. 10. Use of a Cbl-b inhibitor in the manufacture of a medicament for treating cancer, wherein said Cbl-b inhibitor is a compound according to any one of claims 1 to 8.

16. A Cbl-b inhibitor for use in the treatment or prevention of a disease or condition associated with Cbl-b activity, the Cbl-b inhibitor being a compound according to any one of claims 1 to 8.

17. A Cbl-b inhibitor for use in the treatment of cancer, the Cbl-b inhibitor being a compound according to any one of claims 1 to 8.

18. A Cbl-b inhibitor, which is a compound according to any one of claims 1 to 8, for use in the treatment of cancer in combination with an effective amount of an additional therapeutic agent.

19. the Cbl-b inhibitor and the additional therapeutic agent are administered sequentially, in either order; or the Cbl-b inhibitor and the additional therapeutic agent are administered simultaneously; The Cbl-b inhibitor according to claim 18.

20. the additional therapeutic agent comprises an immune checkpoint inhibitor; or the additional therapeutic agent comprises an anti-neoplastic agent; The Cbl-b inhibitor according to claim 18 or 19.

21. the immune checkpoint inhibitor is an antagonist of at least one inhibitory checkpoint molecule selected from the group consisting of PD-1 (CD279), PD-L1 (CD274), CTLA-4 (CD125), LAG3 (CD223), PVR (CD155), PVRL2 (CD112), PVRL3 (CD113), TIGIT, TIM3 (CD366), and VISTA; or (i) the immune checkpoint inhibitor is an antagonist of at least one inhibitory checkpoint molecule selected from the group consisting of PD-1 (CD279), PD-L1 (CD274), and CTLA-4 (CD152); or In the case of (i), the at least one inhibitory checkpoint molecule comprises PD-1, and optionally the immune checkpoint inhibitor is selected from the group consisting of pembrolizumab, nivolumab, cemiplimab, and biosimilars thereof; or In the case of (i), the at least one inhibitory checkpoint molecule comprises PD-L1, and optionally the immune checkpoint inhibitor is selected from the group consisting of atezolizumab, avelumab, durvalumab, and biosimilars thereof; or In the case of (i), the at least one inhibitory checkpoint molecule comprises CTLA-4, and optionally the immune checkpoint inhibitor is selected from the group consisting of ipilimumab, tremelimumab, and biosimilars thereof; or the immune checkpoint inhibitor comprises an antibody or an antigen-binding fragment thereof, optionally wherein the antibody or fragment is human or humanized; or The antineoplastic agent is classified in one of the groups consisting of cytotoxic antibiotics, plant alkaloids, antimetabolites, alkylating agents, and other antineoplastic agents; or the antineoplastic agent comprises a cytotoxic antibiotic, optionally wherein the cytotoxic antibiotic is selected from the group consisting of ixabepilone, mitomycin, plicamycin, bleomycin, pixantrone, amrubicin, valrubicin, pirarubicin, mitoxantrone, idarubicin, zorubicin, aclarubicin, epirubicin, daunorubicin, doxorubicin, and dactinomycin; or the antineoplastic agent comprises a plant alkaloid, optionally wherein the plant alkaloid is selected from the group consisting of trabectedin, cabazitaxel, paclitaxel poliglumex, docetaxel, paclitaxel, demecolcine, teniposide, etoposide, vintafolide, vinflunine, vinorelbine, vindesine, vincristine, and vinblastine; or the antineoplastic agent comprises an antimetabolite, optionally the antimetabolite is a pyrimidine analog, a purine analog, or a folate analog, optionally the antimetabolite is selected from the group consisting of floxuridine, trifluridine, tegafur, fluorouracil, decitabine, azacitidine, capecitabine, gemcitabine, carmofur, tegafur, fluorouracil, cytarabine, nelarabine, clofarabine, fludarabine, cladribine, thioguanine, mercaptopurine, pralatrexate, pemetrexed, raltitrexed, and methotrexate; or the antineoplastic agent comprises an alkylating agent, optionally wherein the alkylating agent is selected from the group consisting of dacarbazine, temozolomide, pipobroman, mitobronitol, etoglucide, uracil mustard, ranimustine, nimustine, fotemustine, streptozocin, semustine, lomustine, carmustine, carboquone, triaziquone, thiotepa, mannosulfan, treosulfan, busulfan, bendamustine, prednimustine, trofosfamide, ifosfamide, mechlorethamine, melphalan, chlorambucil, and cyclophosphamide; or the anti-neoplastic agent comprises another anti-neoplastic agent selected from the group consisting of platinum compounds, protein kinase inhibitors, and other agents; or the anti-neoplastic agent comprises a platinum compound, optionally wherein the platinum compound is selected from the group consisting of cisplatin, carboplatin, oxaliplatin, satraplatin, and polyplatinone; or the anti-neoplastic agent comprises a protein kinase inhibitor; or The anti-neoplastic agent comprises another agent. The Cbl-b inhibitor according to claim 20.

22. A Cbl-b inhibitor, which is a compound according to any one of claims 1 to 8, for use in the treatment of cancer in combination with an effective amount of radiation therapy.

23. the radiation therapy is external beam radiation therapy; or The radiation therapy is an internal radiation therapy. The Cbl-b inhibitor according to claim 22.

24. said Cbl-b inhibitor is administered by enteral administration, optionally said enteral administration being oral administration; or said Cbl-b inhibitor is administered by parenteral administration, optionally said parenteral administration being intratumoral injection or said parenteral administration being by a route selected from the group consisting of intravenous, intraperitoneal, and subcutaneous; A Cbl-b inhibitor according to any one of claims 18 to 23.

25. the cancer is a hematological cancer; or the cancer is a blood cancer, the blood cancer being lymphoma, leukemia, or myeloma; or the cancer is a non-hematological cancer; or the cancer is a non-hematological cancer, the non-hematological cancer being carcinoma, sarcoma, or melanoma; A Cbl-b inhibitor according to any one of claims 18 to 24.

26. 1. A method for generating an expanded tumor infiltrating lymphocyte (TIL) population, comprising: (a) obtaining a biological sample comprising TILs from an individual treated with a Cbl-b inhibitor according to any one of claims 18 to 25; and (b) culturing the TILs in a cell culture medium containing at least one T cell growth factor to generate an expanded TIL population. The method includes:

27. 27. The method of claim 26, wherein the at least one T cell growth factor comprises IL-2.

28. the cell culture medium further comprises an anti-CD3 antibody, or both an anti-CD3 antibody and an anti-CD28 antibody; or the cell culture medium further comprises a Cbl-b inhibitor; or the cell culture medium further comprises irradiated feeder cells; 28. The method of claim 26 or 27.

29. A composition comprising the expanded TIL population produced by the method of any one of claims 26 to 28, and a physiologically acceptable buffer.

30. 1. A method for generating an expanded tumor infiltrating lymphocyte (TIL) population, comprising: (a) obtaining a biological sample comprising TILs from an individual having cancer who has received or is receiving an effective amount of a Cbl-b inhibitor, wherein the Cbl-b inhibitor is a compound according to any one of claims 1 to 8; and (b) culturing the TILs in a cell culture medium containing at least one T cell growth factor to generate an expanded TIL population. The method includes:

31. 11. The method of claim 10, wherein the cancer of the mammalian subject is a non-hematological cancer, optionally wherein the non-hematological cancer is a sarcoma, carcinoma, or melanoma, and / or the mammalian subject is a human.

32. A Cbl-b inhibitor for use in immunization comprising administering an effective amount of a vaccine and administering an effective amount of a Cbl-b inhibitor, wherein the Cbl-b inhibitor is a compound according to any one of claims 1 to 8.

33. wherein the immunizing is treating cancer, The vaccine is a therapeutic cancer vaccine. The Cbl-b inhibitor according to claim 32.

34. the Cbl-b inhibitor and the cancer vaccine are administered sequentially; or the Cbl-b inhibitor and the cancer vaccine are administered simultaneously; The Cbl-b inhibitor according to claim 33.

35. the cancer vaccine is an immunogenic composition comprising at least one tumor antigen and a pharma- ceutically acceptable excipient; Optionally, the at least one tumor antigen comprises at least one synthetic peptide or recombinant protein; or Optionally, the immunogenic composition further comprises an adjuvant; or Optionally, the adjuvant comprises one or more components from the group consisting of aluminum salts, squalene, and saponins; or Optionally, said immunogenic composition further comprises an antigen presenting cell (APC), optionally said APC is a dendritic cell, and optionally said cancer vaccine is PROVENGE; or Optionally, the cancer vaccine comprises a microbial vector, and optionally, the microbial vector is TICE-BCG; or Optionally, the microbial vector is a recombinant viral vector or a recombinant bacterial vector; or Optionally, the cancer vaccine comprises killed cancer cells or a cancer cell lysate. A Cbl-b inhibitor according to claim 33 or 34.

36. 10. A Cbl-b inhibitor for use in the treatment of cancer comprising administering an effective amount of an oncolytic virus and administering an effective amount of a Cbl-b inhibitor, wherein the Cbl-b inhibitor is a compound according to any one of claims 1 to 8.

37. the Cbl-b inhibitor and the oncolytic virus are administered sequentially; or the Cbl-b inhibitor and the oncolytic virus are administered simultaneously; The Cbl-b inhibitor according to claim 36.

38. the oncolytic virus is a virus selected from the group consisting of adenovirus, coxsackievirus, echovirus, fowlpox virus, herpes simplex virus, maraba virus, measles virus, myxoma virus, Newcastle disease virus, parvovirus, poliovirus, retrovirus, reovirus, Seneca Valley virus, Semiliki Forest virus, vaccinia virus, and vesicular stomatitis virus; or the oncolytic virus is a recombinant virus that contains one or both of a functional deletion of at least one viral gene and an insertion of at least one transgene; or Optionally, the recombinant virus comprises a functional deletion of at least one viral gene and an insertion of at least one transgene; or Optionally, the transgene encodes human granulocyte-macrophage colony-stimulating factor (GM-CSF); or the oncolytic virus is a transgenic serotype 5 adenovirus; or the oncolytic virus is a transgenic herpes simplex virus type 1 (HSV-1), optionally the transgenic HSV-1 is talimogene laherparepvec; or the oncolytic virus is a transgenic vaccinia virus, optionally the transgenic vaccinia virus is pexastimogene devacirepvec; or the oncolytic virus is a non-recombinant oncolytic virus, optionally the non-recombinant oncolytic virus is a virus selected from the group consisting of echovirus, Newcastle disease virus, parvovirus, reovirus, and Seneca Valley virus; A Cbl-b inhibitor according to claim 36 or 37.

39. the cancer is a hematological cancer; or the cancer is a blood cancer, the blood cancer being lymphoma, leukemia, or myeloma; or the cancer is a non-hematological cancer; or the cancer is a non-hematological cancer, the non-hematological cancer being carcinoma, sarcoma, or melanoma; A Cbl-b inhibitor according to any one of claims 33 to 38.

40. 10. A method for the treatment of cancer comprising administering an effective amount of a drug capable of lowering the activation threshold of immune cells and administering an effective amount of a therapeutic cancer vaccine or administering an effective amount of an oncolytic virus, said drug being a compound according to any one of claims 1 to 8.

41. the agent further has the ability to reduce the costimulatory requirement of immune cells; or the agent further has the ability to promote tumor immunosurveillance, or the agent is a small molecule Cbl-b inhibitor; The drug described in claim 40.

42. 10. A pharmaceutical composition comprising a cancer vaccine and a small molecule Cbl-b inhibitor, wherein the Cbl-b inhibitor is a compound according to any one of claims 1 to 8, and optionally further comprising a pharma- ceutical acceptable excipient.

43. 10. The pharmaceutical composition of claim 9 for use in generating a population of tumor infiltrating lymphocytes (TIL).

44. 11. Use of the immune cell of claim 10 in the manufacture of a medicament for treating or preventing a disease or condition associated with Cbl-b activity.

45. 11. Use of the immune cell of claim 10 in the manufacture of a medicament for treating cancer.

46. The immune cell of claim 10 for use in the treatment or prevention of a disease or condition associated with Cbl-b activity.

47. The immune cell of claim 10 for use in the treatment of cancer.

48. 12. Use of the modified immune cell of claim 11 in the manufacture of a medicament for treating or preventing a disease or condition associated with Cbl-b activity.

49. 12. Use of the modified immune cell of claim 11 in the manufacture of a medicament for treating cancer.

50. The modified immune cell of claim 11 for use in the treatment or prevention of a disease or condition associated with Cbl-b activity.

51. The modified immune cell of claim 11 for use in the treatment of cancer.

Citation Information

Patent Citations

  • Heterocyclic compound

    US20170015655A1

  • Inhibitors of CBL-b and methods of use thereof

    WO2019148005A1